PF-06865571 + PF-05221304 (DGAT2i + ACCi)
Protocol C3711005Final Protocol, 27 March 2020
PFIZER CONFIDENTIAL
Page 1
A PHASE 2A, 2-PART, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY 
PLACEBO-CONTROLLED, PARALLEL-GROUP (SPONSOR OPEN) STUDY TO 
ASSESS PHARMACODYNAMICS AND SAFETY OF PF-06865571 (DGAT2I) 
COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS 
WITH PRESUMED NONALCOHOLIC STEATOHEPATITIS (NASH)
Study Intervention Number: PF-06865571 (DGAT2i)
PF-05221304 (ACCi)
Study Intervention Name: N/A
US IND Number:
EudraCT Number: N/A
Protocol Number: C3711005
Phase: 2a
Short Title: Parallel-Group Study of PD and Safety of DGAT2i and ACCi Coadministered 
in Participants with Sponsor-defined Presumed NASH
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.CCI
PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes
Original protocol 27March 2020 N/A

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 3TABLE OF CONTE NTS
LIST OF TABLES ................................ ................................ ................................ ..................... 8
LIST OF FIGURES ...................................................................................................................8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................12
1.3. S chedule of Activities .............................................................................................12
2. INTR ODUCTION
...............................................................................................................15
2.1. Study  Rationale .......................................................................................................16
2.2. Background .............................................................................................................16
2.2.1. Clinical Overview .......................................................................................17
2.2.2. Nonclinical Overview .................................................................................19
2.3. Benefit/Risk Assessment
.........................................................................................19
2.3.1. Risk Assessment
.........................................................................................20
2.3.2. Benefit Assessment .....................................................................................22
2.3.3. Overall Benefit/Risk Conclusion ................................................................22
3. OBJECTI VES, EST IMANDS, AND ENDPOINT
S ...........................................................23
4. STUDY DESIGN .................................................................................................................24
4.1. Overall Design .........................................................................................................24
4.1.1. Part 1
...........................................................................................................24
4.1.2. Optional Part 2
............................................................................................25
4.2. Scientific Rationale for Study  Desig n
.....................................................................26
4.2.1. Participants of Child
-bearing Potential .......................................................29
4.2.2.
Rationale for Banked Biospecimen Collections.........................................29
4.3. Justification for Dose ..............................................................................................30
4.3.1. Part 1
...........................................................................................................30
4.3.2. Optional Part 2
............................................................................................31
4.4. End of Study  Definition ..........................................................................................31
5. STUDY POPUL ATION
................................ ................................ ................................ ......32
5.1. I nclusion Criteria .....................................................................................................32
5.2. Exclusion Criteria ....................................................................................................33

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 45.3. Randomization Criteria ...........................................................................................38
5.4. L ifesty le Con siderations ..........................................................................................39
5.4.1. Contraception ..............................................................................................39
5.4.2. Meals and Dietary  Restrictions ...................................................................39
5.4.3. Alcohol, Caffeine, and Tobacco .................................................................40
5.4.4. Activity .......................................................................................................40
5.4.5. Outpatient Visits to Site ..............................................................................41
5.4.6. Outpatient Visits to I maging/Radiology  Facility ........................................41
5.5. Screen Failures ........................................................................................................41
6. STUDY INTER VENTION ..................................................................................................42
6.1. Study  Intervention(s) Administered ........................................................................42
6.1.1. Administration ............................................................................................43
6.2. Preparation/Handling/Storage/Accountability ........................................................43
6.2.1. Preparation and Dispensing ........................................................................44
6.3. Measures to Minimize Bias: Ra ndomization and Blinding .....................................45
6.3.1. Allocation to Study Intervention ................................................................45
6.3.1.1. Part 1
.........................................................................................45
6.3.1.2. Optional Part 2
..........................................................................45
6.3.2. Breaking the Blind ......................................................................................45
6.4. Study  Intervention Complian ce...............................................................................46
6.5. Concomitant Therapy ..............................................................................................46
6.5.1. Medication for Gl ycemic Control ...............................................................47
6.5.2. L
ipid-modi fying Medications .....................................................................47
6.5.3.
Medications for Controlling Blood Pressure ..............................................48
6.5.4. Other Acceptable Concomitant Medications ..............................................48
6.5.5. Prohibited Medications
...............................................................................49
6.5.6. Rescue Medicine .........................................................................................50
6.6. Dose Modifica tion...................................................................................................51
6.7. I ntervention After the End of the Study ..................................................................51
7. DI SCONTINUATION O F STUDY INTERVENTION AND P ARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................51
7.1. Discontinuation of Study  Intervention ....................................................................51

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 57.2. Participant Discontinuation/Withdrawal from the Study ........................................51
7.2.1. Withdrawal of Consent ...............................................................................53
7.3. L ost to Follow -
up ....................................................................................................53
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................53
8.1. Efficacy  Assessments ..............................................................................................54
8.2. Safet y Assessments .................................................................................................54
8.2.1. Physical Examinations ................................................................................54
8.2.1.1. Measurement of Waist Circumference ......................................55
8.2.2. Bod y Weight ...............................................................................................55
8.2.3. Electrocardiograms
.....................................................................................56
8.2.4. Vital Signs ..................................................................................................56
8.2.5. Clinical Safety  Laboratory  Assessments ....................................................57
8.2.6. Pregnancy  Testing ......................................................................................57
8.2.7. Alcohol Intake Assessment .........................................................................58
8.2.8. Triggered Requirements and Individual Participant Stopping Rules ......... 58
8.2.8.1. Potential Cases of Hy pertrigl yceridemia ...................................58
8.2.8.2. Pot ential Cases of Thrombocy topenia
.......................................58
8.3. Adverse Events and Serious Adverse Events
..........................................................58
8.3.1. Time Period and Frequency  for Collectin g AE and SAE Information .......59
8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................59
8.3.1.2.
Recording Nonserious AEs and SAEs on the CRF...................60
8.3.2. Method of Detecting AEs and SAEs ..........................................................60
8.3.3. Follow -up of AEs and SAEs .......................................................................60
8.3.4. Regulat ory Reporting Requirements for SAEs ...........................................60
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................61
8.3.5.1. Exposure During Pregnancy ......................................................61
8.3.5.2. Exposure Duri ng Breastfeeding ................................................62
8.3.5.3. Occupational Exposure .............................................................63
8.3.6. Adverse Events of Special Interest
.............................................................63
8.3.7. Medication Errors .......................................................................................64
8.4. Tre atment of Overdose ............................................................................................64

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 68.5. Pharmacokinetics ....................................................................................................65
8.6. Pharmacod ynamics ..................................................................................................66
8.6.1. Assessment of L iver Fat Using MRI -PDFF ...............................................66
8.6.2. Assessment of L iver Fat and Stiffness –using FibroScan®.......................67
8.6.3. Assessm ent of L iver Fat and Stiffness –using Acuson Sequoia®..............67
8.7. Genetics ...................................................................................................................68
8.7.1. Specified Genetics ......................................................................................68
8.7.2. Banked Biospecimens for Genetics ............................................................69
8.8. Biomarkers ..............................................................................................................69
8.8.1. Banked Biospecimens for Bioma rkers
.......................................................70
8.9. I mmunogenicit y Assessments .................................................................................70
8.10. Health Economics .................................................................................................70
9. STATI STICAL CONSI DERATIONS
................................................................................71
9.1. Estimands and Statistical Hy potheses .....................................................................71
9.1.1. Estimands ....................................................................................................71
9.1.2. Hy pothesis Tests .........................................................................................72
9.2. Sample Size Determination .....................................................................................72
9.2.1. Part 1
...........................................................................................................72
9.2.2. Part 2
...........................................................................................................72
9.3. Analy sis Sets ...........................................................................................................72
9.3.1. Part 1
...........................................................................................................73
9.3.2. Part 2
...........................................................................................................73
9.4. Statistical Analy ses.................................................................................................73
9.4.1. P rimary  Endpoint(s) ....................................................................................73
9.4.2. Secondary  Endpoint(s) ................................ ................................ ................ 74
9.4.3. Tertiary /Exploratory  Endpoint(s) ................................ ............................... 74
9.4.4. Pharmacokinetic Analy sis..........................................................................76
9.4.5. Other Safet y Analyses ................................................................................76
9.4.5.1. Vital Signs Analy ses.................................................................76
9.4.5.2. Electrocardiogram Analy ses......................................................77
9.4.6. Other Anal yses............................................................................................77

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 79.5. I nterim Anal yses.....................................................................................................77
9.5.1. PK/PD Modeling ........................................................................................77
9.6. Data Monitoring Committee or Other Independent Oversight Committee .............77
10. SUPPORTI NG DOCUMENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................79
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversig ht Considerations ...............79
10.1.1. Regulatory and Ethical Considerations ................................ .................... 79
10.1.1.1. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................79
10.1.2. Financial Disclosure .................................................................................80
10.1.3. I nformed Consent Process ........................................................................80
10.1.4. Data Protection .........................................................................................81
10.1.5. Dissemination of Clinical Study  Data ......................................................81
10.1.6. Data
Qualit y Assurance ............................................................................83
10.1.7. Source Documents ....................................................................................84
10.1.8. Study  and Site Start and Closure ..............................................................84
10.1.9. Publication Policy
.....................................................................................85
10.1.10. Sponsor’s Qualified Medical Personnel .................................................86
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................87
10.3. Appendix 3: Adverse E vents: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ......................................................................89
10.3.1. Definition of AE .......................................................................................89
10.3.2. Definit ion of SAE .....................................................................................90
10.3.3. Recording/Reporting and Follow- up of AEs and/or SAEs .......................91
10.3.4. Reporting of SAEs
....................................................................................94
10.4. Appendix 4: Contraceptive Guidance ...................................................................95
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................95
10.4.2. Female Participant Reproductive Inclusion Criteria .................................95
10.4.3. Woman of Childbearing Potential ................................ ............................ 95
10.4.4. Contracept ion Methods ................................ ................................ ............. 96
10.5. Appendix 5: Genetics ............................................................................................98
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -up Assessments ........99

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 810.7. Appendix 7: ECG Findings of Potential Clinical Concern .................................101
10.8. Appendix 8: Strong CYP3A I nhibitors and Inducers ..........................................103
10.9. Appendix 9: 
Guidance to Investigators –Management of Individual 
Participants Gly cemic Control –including Metformin Dose Starting at Run-
In/Visit 2 ..................................................................................................................104
10.10. Appendix 10: Guidance to Investigators –Management of 
Individual 
Participants with Elevation in Fasting Serum Trigly cerides ...................................105
10.11. Appendix 11: Guidance to Investigators –Management of 
Individual 
Participants With Decrease in Platelet Count..........................................................106
10.12. Appendix 12: Abbreviations ................................ ................................ ............. 107
11. REFERENCES ................................................................................................................112
LIST OF TABLES
Table 1. Procedures for Part 1 and Optional Part 2 ................................................13
Table 2. Blood and Uri ne Collection in Part 1 and Optional Part 2 .......................14
Table 3. Planned Dosing Groups in Part 1 of Study  C3711005 .............................24
Table 4.
Double- Blind, Double- Dummy  Regimen in Part 1 of C3711005 ............43
Table 5. Additional Tertiary /Exploratory  Objectives and Endpoints .....................75
Table 6. All Plan ned Protocol Required Safet y-Related Laboratory  Tests and 
Exploratory  Biomarkers in Study  C3711005 ...........................................87
LIST OF 
FIGURES
Figure 1. Overall Study  Design ................................................................................24
Figure 2. Study  Design for Part 1 and Optional Part 2 ............................................25

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 9In this document, the two investigational products are referred to as DGAT2i (for 
PF-06865571) and ACCi (for PF-05221304).
1.PROTOCOL S UMMARY 
1.1.Synopsis 
Short Tit le:Parallel -Group Study ofPD and Safety  of DGAT2i and ACCi Coadministered 
in Participants with Sponsor -Defined P resumed NASH.
Rationale : The current study  is to evaluate the effect of coadministra tion of a range of doses 
of DGA T2iwith 1 (and pote ntially  2)doses of ACC i, on the primary  pharmaco logy (effect 
on liver steatosis) and evaluate the ability  ofa range of doses of DGAT2i to mitigate 
ACCi -
induced elevations in serum triglycerides.This is the first clinical study  specif ically 
design ed to i dentify  the lowest dos e of DGAT2i which, when co administered with ACCi , 
results in reduction in hepatic steatosis while mitigat ing the identified adverse reaction 
(ie,elevation in serum trigl ycerides) observed with administration of AC Ci alone.
This study has a 2-part design with sequential conduct of Part 1 and Part 2 with each part 
condu cted in distinct/ separate cohorts of participants. While the overall study  design, 
objectives/endpoints, eligibility  criteria for both parts a re env isioned to remain ident i cal, data 
from Part 1 will be used to det ermine whether to conduct Part2.  Observed data from Part 1 
will guide the selection of doses and dosing regimens (ie, QD vs BID) of DGAT2i + ACCi 
coadministra tionevaluat ed in 
optiona l Part2. 
Objectives , Estimands, and E
ndpoints : The primary, secondary , and key
tertiary /exploratory endpoints of focus in Pa rt 1and optional Part 2 of this study  include:
Objectives Estimands Endpoints
Prim ary: 
To evaluate effect on liver fat , 
deter mined by MRI -PDFF, of a range of 
DGAT2i doses coad ministered w ith a 
fixed d ose of ACCi compa red to 
placebo in participants with presumed 
NASH .Estimand 1: 
This estimand is intended to 
provide a population level estimate 
of the mea ntreatment effect 
(DGAT2 i + AC Cirelative t o 
placebo) on a continuous endp oint 
at Week 6 for all 
random ized/evaluabl e participants
(see details in Section 9.1.1 ).Percent change from 
baseline in liver fa t as 
assessed via M RI-PDFF, at 
Week 6 .
Secondary:
To evaluate effect on fasting serum 
triglyceride levels of a range of 
DGAT2i doses coadministered w ith a 
fixed dose of ACCi compared to 
placebo in participants with presumed 
NASHEstimand 2: 
This estima nd is intended to 
provide a population level estim ate
of the mean treatment effect 
(DGAT2i + ACCi relative to 
placebo) on a continuous endpoint, 
over time ,for all 
randomized/evaluable participants
(see details in Section 9.1.1 ).Percent change from 
baseline in fasting serum 
triglyceride levels over time.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 10Objectives Estimands Endpoints
To assess safety and tolerability with a 
range of DGAT2i doses coadministered
with fixed dose of ACCi compared to 
placebo in pa rticip ants with pre sumed 
NASH .No estimand is defi ned f or safety 
and tolerability endpoints.Proportion of participants 
with TEAEs and 
clinica lly-significant, 
abnormal clinical laboratory 
tests, vital signs, and 12 -lead
ECGs .
Tertiary/Ex ploratory: 
To evaluate effect on liver fat
determined by quantitative u ltrasound 
(FibroScan®) of a range of DGAT2i 
doses coadministered w ith fixed dose of 
ACCi, compared to placebo in 
participants with presumed NASH .This Endpoint will be an alyzed
using Estimand 1 .Percent change from
baseli ne in liver fat at 
Week 6, as asses sed by 
CAP ™via Fib roScan®.
To evaluate effect on liver fat
determined by quantitative ultrasound 
(Acuson Sequoia®) of a range of 
DGAT2i doses coadministered w ith 
fixed dose of ACCi, compared to 
placebo in partici pants wit h presumed 
NASH .This Endpoint wi ll be analyzed 
using Estimand 1 .Percent change from 
baseline in liver fat at 
Week 6, as assessed by 
UDFF ™via Acuson 
Sequoia®.
For allendpoints, baseline is defi ned as the evaluabl e result closest but priorto dosin g on Day 1 .
Overall Design : This is a mul ticenter, 2-part, sequentially  conducted, randomized, 
double -blind, double -dummy , placebo- controlled, parallel -group evaluation of 
DGAT2i +ACCi summarized 
below .
Numbe rof Par ticipants
In Part 1, approximat ely 90participants (18 per group ) with Sponsor -defined presu med 
NASH, will be randoml y assigned to the stud y intervention to ensure approximately  
75 evaluable participants (15 per group ) offer eva luable data .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 11In Par t2, it is e nvisioned that number of partic ipants on each active dose of DGAT2i + ACC i 
or placebo ma ybe adjusted. Those assigned to placebo may be reduced, giv en the intent to 
pool data from all participants receiving p
lacebo when summarizi ng end -of-studyresults. 
The d oses of DGAT 2i in Part 2 will not exceed 3 00mgBID or 300 mgQD. The doses of 
ACC i will not exceed 20 mg/day  (administered BID or QD to mirror dosin g of DGAT2i ).  A
maximum of 4active doses (plus place bo)will be evaluated in Part 2; fur thermore , the to tal 
number of participants will not exceed 90 (with no more than approximately  27 p articipants 
per each active dose) . 
Intervention Groups and D uration : In Part 1, study  interventions planned t o be 
admini stered up to 6-weeks a resummarized below . 
Group Each Dose Grou pin Part 1
DGAT2i dose ACCi dose DGAT2i:ACCi ratio
A 0 (placebo) B ID 0 (placebo) BID 0: 0
B 25 mg BID 10 mg BID 2.5: 1
C 100mg BID 10 mg BID 10: 1
D 300 mg QD* 20 m g QD* 15: 1
E 300 mg BID 10 mg BID 30: 1
*To maint ain double -blind, double -dummy design across all groups , this group will receive placebo as their 
evening dose 
In Part 2, if conducted, the doses, a s well as dosing regimens (ie, QD vs BID) evaluat ed for
DGAT2i + ACCi will be guided b y observe d data in P art1.  
Data Mon itoring Committee or Other Independent Oversi ght Committee: An 
independent Internal Review Committee (I RC) will undertake periodic unblin dedreview of 
the safet y data while the stu dy is on-going. 
Statistical M ethods: 
Natural log-transformed r elative change from basel inein fasting liver 
fat values determined using MRI -PDFF , CAP ™via FibroScan®, and UDFF ™via Acuson 
Sequoia®forDGAT2 i
+ACCirelative to placebo at Week 6 for all ra ndomiz ed/evaluabl e
participants will be analyzed using an A NCOVA with treatme nt as fixed effect and basel ine
as c
ovariate.  Natural log -transformed r elative ch anges from baseline in fasting serum 
triglycerid es for D
GAT2i + ACCi relative to placebo will be analyzed using mixed model 
repeated measures (MMRM) anal ysisincluding treatment, time, and treatment -by-time 
interaction as fixed effects, baseline a s a covar iate effect and participant as a random effect .
All saf ety data will be summarized descriptivel y through appropr iate datatabula tion, 
descriptive statistics , categorical summaries, andgraphical presentations .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 121.2.Schema
The detailed set -up ofthe study issum marized below with ident ical design for P art1 and 
optiona lPart 2 planned . Pre-Qualification (PreQ)
Run-In
(Stabilize Background Meds)
[+ ↓ Metformin dose if> 1gm/day]
Baseline 
[Single-Blind Placebo (BID)]
Randomization / Day 1
F/U #1
F/U #2Week 2
14±2 daysScreen (SCR) 
Week 4
Week 6Screening Phase Treatment Phase 
6-to 10 -weeksFollow -up
10-weeksAt least 4 -weeksVisit Window
±2 days
30±2 days post last dose14±2 days post last doseDouble -confirm ation of –
Presumed NASH
CAP ≥ 280 dB/mOn-site visit (blood draw + safety)
MRI-PDFF (to assess qu antitative liver fat)
FibroScan®(quantitativ e ultrasou nd to assess 
liver fat [v ia CAP] an d liver stiffn ess [v ia VCTE])
Acuson Sequoia® (quantitative ultrasou nd to assess 
liver fat [v ia UDFF] and liver stiffness [v ia SWE])Telephone contact 
1.3. S chedule of Activ ities
The 2Schedule of Activities (SoA) tables provide an overview of the protocol visits and
procedures.  Refer to the Section 8of the protocol for detailed information on each procedure 
and assessment required for compliance with the protocol. TheSoA tables are identical for
Part1 and optional Part2. 
The investig ator may sche dule visit s (unplanned visits )in addition t o those listed in the SoA
table s, in order to conduct evaluations or assessments required to protect the well- being of 
the part icipant .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 13Table 1. Procedures for Part 1 and Optiona lPart 2
Visit Ide ntifier
PreQ
SCR
Run-InBaseline Treat ment Phase 
[All, except Imaging procedures ,before morning 
dose of blinded study intervention]Follow -up
Study D/CWeeksaRelative to Dosing on Day 1 -4 -2 0
Day 12 4 6 8 10b
Visit # 0 1 2 3 4 5 6 7 8 9
Informed consent & demo graphy x x
(Update) Medical & Medication Infor mation x x x x x x x x x x
Liver fat and stiffness (via FibroScan®)c,dx x x x
Liver fat via MRI -PDFFc,dx x
Liver fat and stiffness (via Acuson Sequoia®)c,dx x
Physical Exam (PE)ex x x x x x x x x
Assess alcohol intake (AUDIT questionnaire) x x x x
Assess correct use of con traception, where applicable x x x x x x x xf
Counseling on diet/exercise guidelines x x
Open -ended inquiry for a dverse even ts(AEs) x x x x x x x x x x x
Singlesupine 12 -lead ECG x x x x x x
Single seat ed vitals (BP & pulse rate) and body weight x x x x x x
Registration of visit in study (via IRT) x x x x x x x x x x x
Onsiteadministration of study interventi on, with mealgx x x x x
Dispensation (via IRT) of study in tervention x x x x
Compliance check of returned study interventionhxgx x x x
a.Defined relative t o Day 1with permit ted ±2-day wind ow for each visit sta rting at Baseline/Vis it 3; for example: Week -2 = 14 ( ±2) days before Day 1; Week 4 = 28 ( ±2)days 
post Da y 1.
b.Telephone contact can be switc hed to on -site visits for follow-up of AEs a nd/or abnormal l abora tory tests; We ek 10 visit at ≥28-and ≤32 days post last dose (Day 30±2 d ays).
c.Procedure performed following ≥4-h our fast (exc ept water) , as part of on-site visit orsepara te vis it(s) to Imaging/Radiology facility; attemp ts to be made to perform Week 6 
assessment withi n ±2-h our window of time of 1stassessment (PreQ for Fibro Scan®and Baseli ne/Visit 3 for MRI- PDFF and Acuson Sequoia®).
d.Baseline assessment sperformed at or after Visit3 and before dosin g on Day 1 /Visit 4 ; We ek 6 p erformed ≤2days post last dose of blinded study interve ntion. 
e.Complete PE at PreQ and SC R and includes arm circumference (at PreQ only)and height and waist circumference (at both PreQ and SCR); otherwise, brief PEforopen 
adverse event s (AEs
)/abnormal laboratory tests , at in vestigator discre tion.
f.WOCBP parti cipants to be reminded to continue required contraception until at least 28 days post -last dose .
g.Onsite dos ing should be performed with single -blind , double -dummy placebo dispensed a t Base line/Visit 3 through 1 day prior to Day 1; double -blind, double-dummy study 
intervent ion starting on Day 1/Visit 4 .
h.Performed at on -site visits with Day 1/Day 4 reflecting complian ce with single -blind , double -dummy placebo; at subsequent visits, ref lects compliance with double -blind, 
doub le-dummy study in tervention .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 14Table 2. Blood and Urine Collection in Part 1 and Optional Part 2
Visit Identifier
PreQ
SCR
Run-InBaseline Treat ment Phase
[All procedures before morning dose ofblind ed study 
intervention , except post- dose PK samples ]Follow -up
Study D/CWeeksaRelative to Dosing on Day 1 -4 -2 0
Day 12 4 6 8 10b
Visit # 0 1 2 3 4 5 6 7 8 9
Bloo d Collection (following fast of ≥8 hours)
No blood or urine collectionSerum FSH (females only), serology (HBsAg, HCVAb [and
if positive, reflex HCV RNA] , HIV ), 1-antitrypsin, 
ceruloplasminxcxc
% CDT xcxcx x
Hematology, Chemistry (including Cystatin -C), Coagulation
(aPTT, PT, INR)xcxcxcx x x x x xdx
Pregnancy ( allfemales ) xcxcxcx x x x x xdx
Triglycerides, direct LDL -C, HDL -C, total cholesterol xcxcxcx x x x x xdx
HbA1C, Plasma Glucose xcxcxcx x x x x xdx
Direct VLDL, Serum apolipoproteins: ApoA1, ApoB total, 
ApoB 100, ApoB 48,ApoC3, ApoE ; Pro-C3, Pro -C6,and 
hs-CRPx x x x x x
Plasma PCSK9, Adiponectin, CK18-M30, CK18 -M65, 
Plasma Insulinx x x x x x
Predose PK -DGAT2i and ACCiex x x x
Post dose PK -DGAT2i and ACCifx x x
Pre-specifie d PGx andBiob anked P rep D 1(DNA) x
Biobanked Prep B1.5(plasma) andPrep B2.5 (serum) x x x
spot urine collection for –
Urine drug test xcxcxc
Urinalys is(and microscopy when appropriate) xcxcxcx x x x x xdx
On-site pregnancy test(WOCBP only) xcxcxcx x xdx
a. Defined relative to Day 1 with permitt ed±2day window for each visit starting at Baseline/Visit 3; for example: Week -2 = 14 ( ±2) days before Day 1 /Visit 4 ; 
Week 4 =28(±2) days post Day 1 /Visit 4 .
b. Telephone c ontact can be switched to on -site visits for fo llow-up of AE s and/or abnormal lab oratory tests; Week 10 visit at ≥28and ≤32 days post last dose (Day 30 ±2days) .
c. Test results to be reviewed by medically qualified site staff and deemed acceptable before pr ogress ion to next visit; for exam ple: PreQ resul ts must be r eviewed prior to 
cond uct of SCR .
d. Collections to occur only if visit is an on -site visit; collections to be skipped if visit is via telephone contact .
e. In addition to blood collection, date and time of 2 most recent doses shoul d be note din a dosing diary prior to each scheduled on -site visit plus date/tim e ofstudy intervention 
taken on -site must be captured in the eCRF .
f. Collection to occur between 0.5-1 hou r post dose on Day 1; between 2-3hours post dose at Week 2 ;and between 4-8 hours post dose at Week 4 .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 152.INTRODUCTI ON
The current study  is to evaluat e the effect of coadm inistration of a range ofdoses of DGAT2i
with 1 (and potentially  2)doses of ACCi, on the primary  pharmacology  (effect on liver 
steatosis) and evaluate the ability  of a range of doses of DGAT2i to mit igate ACCi- induced 
elevat ions in seru mtriglycerides .This is the first clini cal study specificall y designed to 
identify  the lowest d ose of DGAT2 iwhich, when coadministered with ACCi , results in 
reduction in hepatic steatosis while mitigat ing the identif ied adverse reaction (ie, elevatio
n in
serum trigl ycerides) observed with administration of ACCi alone.
DGATs cataly ze the terminal st
ep in trigly ceride sy nthesis; specifically , the esterification of 
a fatt y acid with DAG resulting in the formation of trig lyceride.1In mammals, 2 structur ally
unrelated DGAT e nzymes (DGAT1 and DGAT2 ) have be en characterized. DGAT1 is highl y 
expressed in the in testin e and play s a central role in fat absorption2whereas DGAT2 is 
highl y expressed in liver and adipose.3DGAT2i is postulated to decrease hepa tic
triglyceride 
synthes is and hepatic lipid bu rden in N AFLD and NASH. Based on observations in 
nonclinical studie s conducted, it is hy pothesized that DGAT2i will impact both phy siological 
drivers contributing to NASH via di rect inhibition of liver tri glyceridesynthesis, as wel l as 
adaptive responses leading 
to reduction in hepatic DNL. Followi ng 2 weeks of dosing i n 
participants with NAFLD, DGAT2i has been shown to reduce liver fat in a dose -responsive 
manner.
ACC is a biotin carbox ylase that cataly zes theATPdependent condensation of acet yl-CoA 
and carbona te to form malony l -CoA.4Inhibition o f ACC stimulate s fatt y acid oxidation, 
suppresses hepatic de novo lipogenesis (DNL), and reduces steatosis in animal models and in 
humans.5ACCi has been shown t o decrease hepatic DNL ( in healthy  participants followin g 
14-days of dosing), reduce liver stea tosis (in part icipan ts with NAFLD), as well as reduce 
markers of liver inflammation (ALT, AST) and markers of apoptotic activity  (CK18
-M30 
and CK18- M65), in part icipants with Sponsor - defined presumed NASH fol lowing 16 weeks 
of dosing. However, these potent ially benefi cial effects, in participants with 
NAFLD/presumed NASH, were accompanied with marked elevations in serum trigl ycerides 
and other lipid parameters which prohibit a dministrat ion of ACCi alone. 
In nonclinic al model sof NAFLD/NASH, coadministratio n of DGAT2i +ACCi has been 
shown to be more efficacious at lowering hepatic steatosis, and reducing inflammation and 
fibrosis e ndpoints, than either DGAT2i or A CC
i alone. Inaddition , coadministration of 
DGAT2i + ACCi fully  reversed the increases in circu lating fasting se rum trigl ycerides 
observed with ACCi alone –overcoming the known mechanistic consequence of hepatic 
ACCi thou ght to be a result of sterol regul atoryelement binding protein (SREBP) activation. 
Clinically , the effect of ACCi alone on fasting serum t riglycerides has been shown to be 
mitigated following 6 -week of dosing of DGAT2i + ACCi in participants with NAFLD while 
maintaining significant reduction in hepa tic stea tosis. 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 162.1.Study Rationale
The cur rent study  is an extension of a recentl y concluded s tudy (C3711001) assessing 
placebo, DGAT2i alone (300 mg BID), ACCi alone (15 mg BID), and coadministration of 
DGAT2i +ACCi for a treatment duration of up to 6 w eeks in participa nts with NAFLD.  In 
Study C37110 01, a placebo -adjusted L S mean reduction in liver fa t of ≥35% was observed in 
all active groups . In addition , on average, the increases in fasting serum triglyceride levels 
observed with ACCi alone were mitigated by coadministration with DGAT2i. Itis 
anticipated that via coadministration of DGA
T2i+ ACCi ,hepatic lipid metabolism will be 
modulated in distinct and complementary  way s, potentially  resulting in greater efficacy  than 
DGAT2i administered alone. However, whether the effect on primary  pharmacology  can be 
maintained along with mitigatio n of A CCi-induc edelevation in fasting serum trigly cerides 
via lower doses of DGAT2i as well as QD administration of both agents remains to be tested 
and forms the purpose of th e current study .  While Study  C3711001 population included 
participants with NA FLD,popula tionin the current study  is proposed as presumed NASH , 
as defined b y the S
ponsor as participants meeting allof fol lowing via double -confirmation
between the PreQ and SCR visits :
Liver fat as assessed via quantitative ultrasound parameter CAPTMof ≥280 dB/m ,
assessed using FibroScan®;
Liver stiffness as assessed via quantitative ultrasound parameter VCTETMof ≥
7kPa, 
assessed using FibroScan®;
Presence of at least 2 of the 5 concomitant medical conditions which are associated 
with NAFLD –refer to criterion # 3inSection 5; and
ALT > ULN (and ≤5 x ULN).
In the current study , a 2-part design with sequential conduct of Part 1 and Part 2 with each 
part conduct ed in distinc t/separate cohorts of participants is proposed. While the overall 
study  design, objectives/endpoints, eligibility  criteria for both parts are envisioned to remain 
identical, data from Part 1 will be used to determine whether to conduct Part
2.  Observed 
data from Part 1 will guide the selection of doses and dosing regimens (ie, QD vs BID) of 
DGAT2i + ACCi coadministration evaluated in Part 2. 
2.2.Background 
The World Health Organization lists NAFLD and NASH as the most important conditions 
contri buting to the global health burden due to liver disease s, with NASH acknowledged as a 
potentially  fatal condition leading to cirrhosis, liver failure, and HCC. NASH is diagnosed 
clinically  by liver biops y demonstrating steatosis, inflammation, and cy tologi cal ba lloon ing 
of liver hepatocy tes, often with vary ingdegrees of fibrosis. NASH progresses with 
increasing severit
y of fibrosis, with cirrhosis developing in a subset of participants6and a 
common complication of cirrhosis being HCC.7NASH is a subset of NAF LD (d efined as 
presence of ≥ 5% hepatic steatosis in the absence of other liver disease etiologies) tha t is 
associated with increased all -cause mortality , cirrhosis and end stage liver disease, increased 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 17cardiovascular mortalit y, and increased incidenc eof both liver related and non- liver related 
cancers.6
In a meta -analysis, the global prevalence of NAFLD was estimated at 25%, with the 
prevalence of NASH in the subset with biopsy -proven NAFLD assessed at 59%.8The
majority  of the population wi th NAFLD has simple steatosis which has, in general, a benign 
clinical course. A proportion of participants with NAFLD progress to having hepatocellular 
ballooning and lobular inflammation
,taking close to a decade to progress f rom 1 stage to the 
next and 30-40 years to develop cirrhosis; however, a smaller subset of participants progress 
very rapidl
y (within 10 years) to liver cirrhosis from NAFLD.8Patients with NA SH may  be 
asymptomati c or have no n-specifi c symptoms such as fatigue, despite having significant 
disease on liver biops y and associated risk for progression to cirrhosis and liver -
related 
mortality . The 5 -year (67%) and 10- year (38%) survival rates in part icipants with NASH i s 
significan
tly differ ent than in those with NAFLD. The pooled liver -specific and overall 
mortality  incidence rate estimates among those with NAFLD were calculated at 0.8 and 15.4, 
respectivel y, per 1,000 person -years. In contrast, amon gst the population with NASH, the 
incidenc e rate estimates were 11.8 (liver -specific) and 25.6 (overall) 
mortality .8  
Elevated rates of hepatic DNL have been report ed to be a distinctive characteristic of 
NAFLD.9Clinically , thosewith ele vated liver fat showed a more than 3 -fold increase in the 
rate of hepatic DNL relative to participants with normal liver fat, but no differences between 
the groups were detected in adipose FFA flux or in production of VLDL from FFAs. 
Furthermo re, as exemp lified by  other metabolic diso rders (eg, ty pe2 diabetes, dy slipidemias, 
etc), it is possible that a single drug may be insufficient to successfull y treat NASH and 
therefore, combina tion therapy  is being investigated as an earl y intervention st rateg y.  
2.2.1. Clinical Overview
As of January 2020, safety  and efficacy  of DGAT2i alone or when coadministered with 
ACCi in the target patient population (ie, those with biopsy -confirmed NASH with l iver 
fibrosis stage 2 or 3) has not been evaluated although clinical activ ity and effectiveness of 
DGAT2 i alone and when coadministered with ACCi has been assessed in participants with 
NAFLD with dosing up to 6 weeks.
Across the clinical studies completed/concluded with DGAT2i alone (n=6 studies), ACCi 
alone (n=6 s tudie s) and DG A
T2i + ACCi (n=2 studies), 736 unique participants have been 
randomized, with 120 (16%) exposed to placebo, 161 (22%) exposed to DGAT2i alone, 
407(55%) exposed to ACCi alone, 44 (6%) exposed to DGAT2i + ACCi, and 4 exposed to 
metformin alone in the DGAT2i -Metformin DDI study . DGAT2i a lone has been evaluated 
as single oral doses up to 1500 mg, repeated doses up to 1800 mg/day  (administered Q8H) 
for up t o 14 days, and repeated doses of 600 mg/day  (administered Q12H) for up to 6 weeks. 
ACCi al one h as been a dministered at single, oral dose s up to 240 mg, repeated ( ≤14- days) 
doses up to 200 mg/day  (administered QD and Q12H), and repeated ( ≤
16weeks) doses up to 
50mg/day  (administered QD). DGAT2i + ACCi has been evaluated at a single 
coadminister ed do se level of 300 mg BID (DGAT2i) + 15 mg B ID (ACCi).  

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 18DGAT2i alone or as DGAT2i + ACCi has been evaluated in six Phase 1 studies in healthy 
adults (with 132 participants randomized) and two studies (1 Phase 1 and 1 Phase 2a) in 
participants with NAFL D (wi th 148 participants randomized). ACCi alo ne has been 
evaluated in five Phase 1 studies in adults (with 151 participants randomized) and one 
Phase 2a, dose -rangin g study  in participants with NAFLD (n=305 randomized including
68% with Sponsor -defined presu med NASH). 
Administration of DGAT2i alone has been found to be well tolerated with an acceptable 
safet y profile with no special safet y concerns identified. Upon r epeated administration of 
DGAT2i, across the 20 -
fold dose range evaluated (ie, 90 to 1800 mg/day), TEAEs reported 
in ≥
7 (3%) partici pants across all groups evaluated were headache (11%), diarrhea (6%), 
fatigue (5%), pruritus (4%), abdominal pain (3%), an d nausea (3%). Upon repeated 
administration of ACCi, across a 100 -
fold dose range evaluated (ie, 2 to 200 mg/day),the
all-causalit y TEAEs reported in ≥ 1.5% of participants were headache (9%), diarrhea (7%), 
hypertrigly ceridemia (6%), and nausea (5%).
Given DGAT2i is a dose -dependent inhibitor of the transporters OCT2/MATE in kidney , as 
expected, increases in se rum cr eatinine without a change in renal fu nction (as assessed via 
eGFR determined using Cy statin -C) was noted. Dosing with ACCi alone resulted in
2identified adverse drug reactions –namely , increases in fasting serum trigly cerides, and 
decrease in p latele t count , with reversal in 1 to 2 weeks post discontinuation of ACCi alone 
observed , refer to Section 2.3.1. Based on review of pooled TEAEs, 12 -lead ECG data, 
blood pressure data, and l aborat ory data, coadministration of DGAT2i +ACC i has been 
shown to not result in worsenin
g of the safety profile relative to either agent administered 
alone.  However, coadministration of DGAT2i +ACCi at the doses tested in 
Study C3711001 (300 mg BID + 15 mg B ID) wasshown to mitigate the ACCi -induced
elevations in fasting serum trigly cerides, ApoC3, and non
-HDL. There were no clinicall y 
significant adverse effect snoted in other safet y-related assessments such as blood pressure, 
and cardiac conduction i nterva ls [assess ed on 12-lead ECGs] with DGAT2i, ACCi, and 
DGAT2i + ACCi . 
Upon repeated dosing of DGAT2i with standard meals, C maxwas achieved at 1.5-3 hours 
post dose. Steady -state plasma concentrations were achieved by  Day 4, and the mean 
terminal t ½ranged from 3.3 -6.9 hours. Dosing in the fasted st ate resulted in lower exposures 
(ie,AUC inf39% lower and C max34% lower than when a 1000 mg DGAT2i dose was 
administered with a standard meal). Following oral dosing of ACCi with a 
high-fat/high-caloric m eal, Cmaxwas a chieved at 3 -5hours post -dose, and the mean terminal 
t½ranged from 13 -18hours. There was no clinically  relevant effect on exposure with dosing 
of ACCi in the fasted versus fed state. Coadministration of DGAT2i (300 mg BID ) and 
ACCi (15mgBID) resulte din a slight decrease in the sy stemic exposure of ACCi with 
adjusted geometric mean (90% CI) of12% (2 -20%) lower (for C max) and 19% (12 -26%) 
lower (for AUC tau). There was no marked effect on the sy stemic exposure of DGAT2i , when 
coadmi nistered w ith ACCi , with adjusted geometric mean 8% hig her (for C maxand AUC tau). 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 192.2.2. Nonclinical Overview 
DGAT2i and ACCi have each individuall y been evaluated in a comprehensive nonclinical 
safet y package that included rat and cynomolgus monkey toxicity st udies up to 6 and 
9months duration, respectively , and in reproductive and developmental toxicology  studies in 
rats and rabbits, and together (ie, DGAT2i + ACCi) in combination toxicity  studies in 
monkey s up to 13 weeks in duration.  
For DGAT2i alone, n o adve rse findings w ere identified in rats or cy nomolgus monkey s. At 
the NOAEL in the 9 -month study  in cy nomolgus monkey s, exposure margins relative to a 
highest clinical dose of 300 mg BID were 4.6x and 7.3x the unbound human C maxand 
AUC 24, respectively . At the NOAEL in t he 6-month study  in rats, exposure mar gins were 
1.6/6.8x (male/female) and 1.8/7.7x (male/female) the unbound human Cmaxand AUC 24, 
respectivel y. 
For ACCi alone, all adverse findings were related to the inhibition of fatty acid biosy nthesis,
due to the pharmacology  of ACCi, and were observe d as changes in the lung, skin, 
nonglandular stomach, or Meibomian glands. At the NOAEL in the 9
-month study  in 
cynomolgus monkey s, exposure margins relative to the highest clinical dose of 20 mg/day
(with most conserva tive QD dosing and margins for Cmax) were 110x and 51x, the predicted 
human unbound Cmaxand AUC 24, respectively, and at the NOAEL in the 6 -month study  in 
rats exposure margins were 65x and 18x the predicted unbound hu man C maxand AUC 24, 
respectivel y.  
DGAT2i + ACCi were evaluated in cy nomol gus monkey toxicity  studies up to 13 weeks 
duration. All findings were attributed to ACCi and no new adverse findings were identified 
in monkey s administered DGAT2i + ACCi. Exposure margins in the 13-week stu dy in 
cynomolgus monkey s relative to a DGAT2i cl inical dose of 300 mg BID were 2.9x and 4.5x, 
the predicted human unbound Cmaxand AUC 24, respectively, and exposure margins relative 
to a ACCi clinical dose of 20 mg/day  (with most conservative QD dosin g and margins for 
Cmax) were 141x and 49x the predict ed unbound human 
Cmaxand AUC 24, respectivel y.
For review of EFD findings in studies completed with DGAT2i and separately  with ACCi 
alone, refer to Section 2.3.1 .
2.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of DGAT2i alone, DGAT2i +ACCi, and ACCi alone 
may be found in the IB 
for DGAT2i and 
separate lyforACCi, which will serve as the 2 SRSDs for this study .
A high level summary  of potential risks as well as benefits are offered in Section 2.3.1 and
Section2.3.2. 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 202.3.1. Risk Assessment
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Study Intervention –DGAT2i (as part of DGAT2i +ACCi)
Drug -drug interactions 
resulting in ch ange i n 
DGAT2i exposur e.In vitro data in dicate DGAT2i 
having low he patic clearance and 
multi -pathway metabolism with :
CYP3A –major (f m 0.68) ;
CYP2B6 –minor (f m0.16) ;
CYP2C19 –minor (f m0.16) .Study excludes participant on potent 
inhibitors or inducers of CYP3A –refer 
toSection 6.5.
Study Intervention –DGAT2i (as part of DGAT2i +ACCi)
Drug -drug interactions 
resulting in change in 
exposure of 
background/concomitant 
medic ations .Clinical data indicate that DGAT2 i at 
300 mg BID can increase pla sma 
metformin exposure by 2 -fold.Starting at Run -In (ie, a pproximately
4weeksbefore randomization ), 
participants on metformin dose 
>1gm/day must agree to metformin dose
decrease d by 1/3 or1/2 w
ith up -titration 
post randomization based on FPG results 
–refer to Section 6.5.1 and
Appendix 10.9.
In vitro data indic ate D GAT2i at 
300mg BID to be a : 
Potent BCRP inhib itor;
Inhibitor of P -gp;
Inhibitor of CYP2C9 .Use of specific medications that are 
substrates for BCRP, P -gpand/or 
CYP2C9 w ill be excluded (or restricted) 
–refer toSection6.5.
Food effect resulting in 
change in DGAT2i 
exposure .Clinical data indicate that DGAT2i 
exposures are lower in fasted state 
than in fed state .Investigati onal p roducts will be taken 
with a meal.
Fetal skeletal variations 
as a result of transient 
developmen tal delay .In embryo -fetal development 
toxicity study in rats , lower fetal 
body weight and skeletal 
anomalies observed at all doses 
with NOAEL for this 
developmental toxicity not 
identified .
In emb ryo-fetal development 
toxicity study in rabbits , no 
developme ntal toxicity observed .Risk of fetal toxicity communicated 
through theDGAT2i IB (Jan -2020) .
Enrollment of women of childbearing 
potential restricted to those using 
effective contraception – refer to 
Section 5.4.1 and Appendix 10.4.
In males who are sexually active with 
a female p artner of childbearing 
potential, use of barri er methods not
required/mandated given safety 
margins >100 -fold –refer to 
Section 5.4.1 andAppendi x 10.4.
Study Intervention – ACCi (as part of DGAT2i +ACCi)
Increase in serum 
triglycerides .Identified adverse reaction with 
inhibition of hepatic ACC; 
observed upon repeated dosing of 
ACCi alone in healthy 
participants and in those with
NAFLD /presumed NASH.
Magnitude of elevation i n Administration of A CCi alone not 
planned .
Study requires fasting serum
triglyceride ≤400 mg/dL 
(4.5mmol/L) at multiple timepoints 
prior to randomization .
Given that elevations occurred early 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 21Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
NAF LD/presumed NASH 
observed to be approximately 
2-fold higher t han in healthy 
participants –based on 
exposure :response population 
PK.post initiation of dosing, visits post 
randomization, initially, scheduled to 
be every 2 weeks.
Management of isolated and double -
confirmed elevati ons in fasting serum 
triglycerides planned –refer to 
Appendix 10.10 .
Reversal in fasting serum 
triglycerides expected (and observed) 
upon discontinuation of ACCi .
Decrease in pl atelet 
count.Identified adverse reaction with 
ACCi; observed upon repeated 
dosing of ACCi alone in healthy 
participants and those with 
NAFLD/presumed NASH .Study requires platelet count to be 
≥LLN at multiple timepoin ts prior to 
randomization .
Management of isolated and double -
confirmed declines in platelet count 
planned –refer to Appendi x 10.11.
Reversal in platelet count e xpected 
(and observed) upon discontinuation 
of ACCi .
Drug -drug interactions 
resulting in change in 
ACCi exposure .In vitro data indicate ACCi cleared 
via OATP -mediated hepatic uptake 
and metabolism (predominantly 
via3A4). Study excludes participant on potent 
inhibitors of OATP and potent inhibitors 
and inducers of CYP3A4 –refer to
Section 6.5.
Fetal external 
malformation and 
skeletal variations and 
malformations .In EFD stud y in rats, ACCi at 
highest dose, resulted in higher 
incidence of fetal skeletal 
variations (ie, structural changes 
to ribs, skull, sternebrae and 
vertebrae) plus delay in 
ossification of skull and 
sternebrae.
In EFD study in rabbits , ACCi at 
highest dose p roduce d fetal 
skeletal m alform ations including 
absent skull bones, malformed 
ribs, and malformed vertebrae; 
ACCi delayed ossification of 
thoracic vertebrae and produced 
variations in development of 
skull, ribs, and vertebrae .Risk of fetal toxicity communi cated 
through the ACC i IB (Dec -2019) .
Enrollment of women of childbearing 
potential restricted to those using 
effective contraception – refer to 
Section 5.4.1 and Appendix 10.4.
As a measure of caution, serum 
pregnancy testing to be 
undertaken in all females .
In males who are sexually active with 
a female partner of childbearing 
potential, use of barrier methods not
required/mandated g iven safety 
margins >100 -fold –refer to 
Section 5.4.1 and Appendix 10.4.
Study Procedures
Conduct of different 
imaging assessment s of 
liver fat during study 
(ie, quantitative 
ultrasound -based 
FibroScan®and Acuson 
Sequoia®as well as Procedures are relatively safe; 
potential risk for non -evaluable 
images include : 
Too much motion, for example, 
due to increased anxiety, 
claustrop hobia.
Ferric implants/devices, Perm itting pre -procedure use of 
anxiolytics to manage anxie ty (in 
case of MRI -PDFF) .
Excluding participants if they have 
contraindications for MRI , or 
quantitative ultrasound based 
assessments ( FibroScan®and 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 22Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
MRI -PDFF) . paramagnetic objects w ithin/on 
body, ferric -containing tattoos in 
area of interest (abdomen, chest, 
arms).
Minimum duration of a priori 
fast notfollowed .Acuson Sequoia®).
Clear communication via ICD of 
preparation for each visit including
duration of fast bef ore 
procedures /visits.
Other Factors Potentially Impacting Study Results
Distinction of 
drug-induced liver 
injury from 
disease -related baseline 
elevations in LFTs .Population eligible likely to have 
elevated ALT and AST (though not 
Alkaline phosphatase, total 
bilirubin) .Study requires double -confirmation of 
stable ALT, AST, alkaline 
phosphatase (ie, ≤50% variability10)
plus total bilirubin ≤ULN before
proceeding w ith screening/ baseline .
Coadministration of DGAT2i + ACCi, based on completed toxicity  studies in rats and 
monkey s, as well as completed clin ical studies, does not afford an y additional adverse 
findings above and bey ond those identified with administration of ACCi alone.  Thus, in the 
current stud y, an y adverse clinical impact of the above findings are expected to be minimized 
through : (1)theproposed frequent visits to site to permit c lose oversight of participants’ 
safet y via medical monitoring of a range of clinical assessments including safet y-related 
laboratory  tests, 12- lead ECGs, vitals, assessment of AEs; (2) inclusion of provisions fo r
management of gl ycemic control (refer to Appendix 10.9) and the 2 identified adverse 
reactions 
ie, increases in fasting serum triglycerides (refer to App endix 10.10) andreduction 
in platelet count (refer to Appendix 10.11); and(3)institution of an independent, I RC (refer 
to Section
9.5) to unde rtake u nblinded review of the safet y data while the study  is on -going.
2.3.2. Benefit Assessment
For the participants inthis study , close monitoring of their medical condition and safet y wil l 
occur as outlined in this prot ocol. In Part 1, 4 out every  5 particip ants ra ndomized will 
receive DGAT2i +ACCi and therefore, may  potentially  derive short- term benefit from the 
primary  pharmacology , namely , reduction in hepatic steatosis. Those randomiz ed to placebo 
(1 in every  5participants) are not expected to obtain a ny spec ific bene fit, bey ond close 
monitoring of their medical condition and overall close follow- up of their safet y. All 
participants will receive general, standard -of-care guidance/coun seling regarding the overall 
benefits of diet/exercise. In Part 2, if condu cted, sim ilar benefits are likely  inferred to 
participants who will be randomized.
2.3.3. Overall Benefit /Risk Conclusion
Additional details about the known and expected benefits and risks and reasonably  expected 
adverse events with administration of DGAT2 i alone , DGAT2i +ACCi, and ACCi alone 
may be found in the IB for DGAT2i and separately for ACCi, which serve as the 2 SRSDs 
for this study .Considering all available clinical and nonclinical data, the benefit :risk pro
file 
of DGAT2i and DGAT2i+ACCi supports co ntinued cli nical development as outlined in this 
protocol.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 233. OBJECTIVES , ESTIMANDS ,AND ENDPOINTS
The planned identical objectives, estima nds, and endpoints for Part 1 and optional Part2 of 
this study  are summarized below .
Objectives Estima nds Endpoints
Prim ary: 
To evaluate effect on liver fat , 
determined by MRI -PDFF, of a range 
of DGAT2i doses coadministered with 
a fixed dose of ACCi compared to 
placebo in participants with presumed 
NASH .Estimand 1: 
This estimand is in tended to provide
a population level esti mate of the 
mean treatment effect (DGAT 2i + 
ACCi relative to placebo) on a 
continuous endpoint at Week 6 for 
all randomized/evaluable participants
(see details in Section 9.1.1 ).Percent change from 
baseline in liver fat as 
assessed via MRI -PDFF, at 
Week 6. 
Secondary: 
To evaluate effect on fasting serum 
triglyceride levels of a range of 
DGAT2i doses coadministered w ith a 
fixed dose of ACCi compared to 
placebo in participants wi th presumed 
NASH .Estimand 2: 
This estimand is intended to provide 
a population level estimate of the 
mean treatment effect (DGAT 2i + 
ACCi relative t o placebo) on a 
continuous endpoint ,over time for 
all randomized/ev aluable partic ipants 
(see details in Section 9.1.1 ).Percent change from 
baseline in fasting serum 
triglyceride levels over time. 
To assess safety and tolerability with 
a range of DGAT2i dose s 
coadministered with fi xeddose of 
ACCi compared to placebo in 
participants with presumed NASH . No estimand is defined for safety and 
tolerability endpoints.  Proportion of participants 
with treatment -emergent 
adverse events (TEAEs) and 
clinically significant, 
abnormal clinic allaboratory 
tests, vital signs, and 12 -lead 
ECGs .
Tertiary/Exploratory: 
To evaluate effect on liver fat
determined by quantitative ultrasound 
(FibroScan®)of a range of DGAT2i 
doses coadministered w ith fixed dose 
of AC Ci, compared to placebo in 
partic ipants with presumed NASH . This endpoint will be analyzed using 
Estimand 1 . Percent change from 
baseline in liver fat at 
Week 6, as assessed by 
CAP ™via FibroScan®.
To evaluate effect on liver fat
determined by quantitative u ltrasound 
(Acuson Sequoia®) ofa range of 
DGAT2i doses coadministered w ith 
fixed dose of ACCi, compared to 
placebo in participants with presumed 
NASH .This endpoint will be analyzed using 
Estimand 1 . Percent change from 
baseline in liver fat at 
Week 6, as as sessed by 
UDFF™via Acuso n 
Sequoia®.
For allendpoints, baseline is defined as the evaluable result closest but prior to dosing on Day 1 .
Additional tertiary /exploratory  objectives and endpoints are listed in Section 9.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 244. STUDY DESIGN
4.1.Overall Design
This is a multicenter, 2-part, sequentiall y conducted, randomized, double -blind, 
double -dummy , placebo- controlled, parallel -group evaluation of DGAT2i + ACCi as 
summarized in Figure 1.
Figure 1.Overall Study Design
4.1.1. Part 1
Study  interventions planned are summarized in Table 3. 
Table 3. Planned Dosing Groups in Part 1 of Study C3711005
Group DGAT2i Dose ACCi Dose DGAT2i:ACCi R
atio
A 0 (placebo) BID 0 (placebo) BID 0: 0
B 25 mg BID 10 mg BID 2.5: 1
C 100 mg BID 10 mg BID 10: 1
D 300 mg QD* 20 mg QD* 15: 1 
E 300 mg BID 10 mg BID 30: 1
*In order to maintain double -blind, double- dummy design ac ross all groups , this group wi llreceive placebo 
as their evening dose .
Dosing in all groups will be accommodated via administration of 3 tablets per dose, and 
6tablets per day . The use of blister packed supplies is planned to minimiz e dosing error s and 
to enhance compliance , refer to Table 4in Section 6.1for details.
Determination of eligibility will occur via a sequential, 2 -step process starting with 
Prequ alific ation visit ( PreQ ). Participan tsidentified to be eligible at PreQ will transition to 
the main study , starting with Screening (SCR) visit .The double -confirmation (at PreQ and 
SCR) will permit progression of only  a selected subset of participants confirm ed to meet 
Sponsor -defined pres
umed NASH criteria (along with other eligibility  criteria) to the 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 25Run-In/Visit 2. At the Run -In/Visit 2, stabilization of concomitant medicines may occur , as
needed /appropriate (refer to Section 6.5). Alleligible participants must complete the 
Run-In/Visit 2, followed by  Baseline/ Visit 3. On Day 1/Visit 4, participants who meet the 
randomization criteria (Section 5.3) will be assigned to rec eive 1 of 5 double -blind, 
double -dummy  regimens (refer to Table 3) for a duration of up to 6 weeks , refer to Figure 
2. 
Figure 2.Study Design for Part 1 and Optional Part 2Pre-Qualification (PreQ)
Run-In
(Stabilize Background Meds)
[+ ↓ Metformin dose if> 1gm/day]
Baseline 
[Single-Blind Placebo (BID)]
Randomization / Day 1
F/U #1
F/U #2Week 2
14±2 daysScreen (SCR) 
Week 4
Week 6Screening Phase Treatment Phase 
6-to 10-weeksFollow -up
10-weeksAt least 4 -weeksVisit Window
±2 days
30±2 days post last dose14±2 days post last doseDouble -confirmation of –
Presumed NASH
CAP ≥ 280 dB/mOn-site visit (blood draw + safety)
MRI-PDFF (to assess quan titative liver fat)
FibroScan®(quantitativ e ultrasound to assess 
liver fat [v ia CAP] and liver stiffness [v ia VCTE])
Acuson Sequoia® (quantitative ultrasound to assess 
liver fat [via U DFF] and liver stiffness [via SWE])Teleph one contact 
Appro ximately  90 participants (18 per group ) with Sponsor -defined presumed NASH will be 
randomly  assigned to the study  intervention to ensure approximately  75evaluable 
participan ts (15 per group ) offerevaluable dat a.  
4.1.2. Optional Part 2
Part2 may  be initiatedafter unblinded review of the data from Part 1 by selected members of 
the 
Sponsor s’ study  team (the investigators/site staff as well as site -facing study team 
members willremai n blinded) ,refer to Section 9.5. T his interim analy sis will include review 
of primary  endpoint data (effect on hepatic steatosis as assessed via MRI -PDFF) as well as 
overall safety /tolerabilit y including degr ee of mitigation of ACCi -induced effect o n fast ing 
serum t riglyceride s achieved across the range of DGAT2i:ACCi dose ratios evaluated . 
Guided by these data, Part 2 may enroll up to 5 dose groups (including placebo) with intent 
toevaluat eadditional permu tations of doses of both DGAT2i and ACCi administered BID or
QD. How ever, t he doses of DGAT2i in Part 2 will not exceed 300 mgBID or 300 mgQD
and t he dose (s)of ACC i will not exceed 20 mg/day  (administered BID or QD to mirror 
dosing of DGAT2i ).Amaximum of 4active doses (plus placebo) will b e evaluated in 
Part2; furth ermore , the total number of participants will not exceed 90 (with no more than 
approximately  27 participants per each active dose). 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 26Following aspects are envisioned to remain identical between Part 1 and optional Part 2: 
Eligibility  (refer t oSection 5.1and Section 5.2)and randomiz ation (refer to
Section
5.3) criteria ;
Schedule of a ctivit ies 
including assessment of standard safety/tolerability  (via vitals, 
12-lead ECG, laboratory  tests) , refer to SoA –Table 1andSoA - Table 2; 
Overall stud y design includi ng duration of dosin g, refer to Figure 
2.
In order to enable accumulation of safet y experience in the clinica l program, mi nimize 
potential carry over effect, as well as control selection bias, partic ipants randomized and 
dosed do
uble-blind , double -dummy study  intervention in Part 1 of this study are not eligible 
for Part 2.
4.2.Scientific Rationale for Study Design
Reduction in h epatic steatosis with DGAT2i alone, ACCi alone, an d DGAT2i + ACCi have 
been s hown in participants with NAFL D with dosing of the intervention for as little as 
2weeks (DGAT2i alone) ,
6 weeks (DGAT2i alone plus DGAT2i + ACCi), and up to 
16weeks(with ACCi a lone). The current study  is an extension of a rece ntly conclu ded study 
(C3711001) assessing placebo, DGAT2i alone (300 mg BID), ACCi alone (15 mg BID), and 
coadministration of DGAT2i + ACCi, for a treatment duration of 6 weeks in participa nts
with NAFLD. The current study  is d
esigned to find the lowest dose of DGAT2i w hich will 
mitigate ACCi -
induced elevations in fasting serum trigly ceride, while maintaining 
effectiveness (as assessed via reduction in hepatic steatosis). Data from Part 1 will dictate 
conduct of, the doses , and the dosing regimen s (ie, QD vs BID) of DGA T2i+ACCi, 
potentially  evaluated in Part 2. 
In this stud y, 2 separate informed consents will be obtained: the first consent is limited to 
PreQ vis it activities on ly; and the second consent is for the main study  only (from Screening 
through participan t co
mpletion/E arly Termination) in those deeme d to meet eligibility  
criteria based on non -invasive procedures completed at PreQ. Between the PreQ a nd SCR 
visits, m any of the non -invasive procedures and clinical labora tory tests assessed are 
iden
tical. Thi s ismotivate d by the intent to confirm that t he population progressed to 
Run-In/Visit 2 is consistently  characterized as Sponsor -defined presu med NASH. As a 
measure of additional diligence and as an attempt to remove variability  due to laboratory -to-
labor atory differ ences, the clinical laboratory  tests assessed at PreQ and SCR are proposed to 
be anal yzed by the Sponsor -identified central labor atory. Theassess ments to narrow the 
population ultimately  progressed to Run -In/Visit 2 consist of doubl e
-confirmat ionbetween
assessment at PreQ and SCR of: (a) blood
-based markers of liver function (i e, ALT, AST, 
alkaline phosphatase, total bilirubin) and ensuring partic ipants have stable results (defined b y 
≤50% variability  in ALT/AST/alkaline phosphata se10plus total bilirubin ≤ U LN, unless 
Gilbert’s sy
ndrome); and (b) a constellation of clinical and liver imaging characteristics 
which are highl y suggestive of a NASH diagnosis (in the absence of a liver biopsy )referred 
to asSponsor -defined presum ed NASH.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 27ACCi alone is not planned for evaluation in this study  given the previousl y described 
undesirable changes in fasting serum trigl ycerides encountered with liver-targeted ACC
inhibitors and their potential implications for lon g term cardiom etabolic health. 
In this stud y, based on a combination of thorough medical history (including assessment of 
ethanol intake and administration of the interview -version of the AUDIT -10 -item 
questionnaire11),and cli nical laboratory  tests ( ie, %CDT), medica lly qualifi ed site -staff will 
be required to rule out alcohol based as well as and/or other causes of hepatic 
steatosis/inflammation/fibrosis12, and ensure that the population enrolled is con
firmed, as 
best as pos sible, to have Sponsor -defin ed presumed NA SH. Thes e assessme nts (AUDIT and 
%CDT) will be re -assessed prior to randomization and at end of dosing to confirm that while 
in the study  alcohol intake remained in moderation. Participants with previously  confirme d 
genetic pol ymorphisms, for example, P NPLA3 carr iers, are e ligible given that these 
polymorphisms are known to modify /increase risk for steatohepatitis but do not by  
themselves cause steatohepatitis.
An explicit intent in this study is to exclude those wi th severe hepatic impairment
(eg., ascites,hepat ic encephal opathy , cirrhosis, and HC C) and severe renal impairment 
(ie,eGFR using CKD -EPI-Cystatin -
C13≤30mL/min) via specific eligibility  criteria (refer to
Section 5.1 andSection 5.2). This is in line with the clinical data to date showi ng ≤ 3-fold 
increase in plasma exposure in severe hepatic impairment as defined b y Child -Pugh 
classification for ACCi and preliminary , partial PK data from 2 (of planned 6) participants 
with mild, 3 (of planned 6) participants with moderate plus 5 (of plann
ed6) participants with 
severe hepatic impairment in the on-going Phase 1 S tudy (C2541009) with DGAT2i in 
participants with vary ing degrees of hepatic impairment compared to historical data in 
healthy  participants in Study C2541001; as well as renal e limin ation confirmed to represent 
<2% of unchanged drug for both DGAT2i and ACCi. The major clearance mechanism for 
DGAT2i and ACCi is predicted to be multi -pathway . Thus, the inclusion/ex clusion criteria 
have been defined to help limit pharmacokinetic variab ility while also capturing a population 
that is characteristic of the intended target population. Plasma samples (both pre -and 
post-
dose) to permit population- pharmacokinetic anal ysiswill be collected to further 
examine the effect of demographics on pha rmacokinetic variability  and to explore the 
relationship of PK to PD endpoints. 
The current study  also undertakes assessment for potential improvement of safet y
-related, 
metabolic m arkers and selected biomarkers. The parameters include markers of liver
function tests (ALT, AST, Alkaline phosphatase, GGT, t otal bilirubin), NASH -related 
biomarkers14(CK18- M30 and CK18- M65, markers of apoptotic activity ; ProC3 , a marker of 
fibrinogenesis; ProC6, a marker of fibrinoly sis), gly cemic parameters (HbA1C, FPG,FPI, 
HOMA-IR, adiponectin), and fasting lipid parameters/markers of target engagement (total 
cholesterol, trigly cerides, direct LDL -C, HDL -C, direct VLDL, apolipoprotein A1, B total, 
B100, B48, C3, and E plus PCSK9, hs -CRP). In addition, banking of plasma (Prep B1.5) and 
serum (Prep B2.5) collections are planned to enable retrospective anal ysis of (y et to be 
identified) sensitive/specific biomarkers of disease diagnosis, and/or treatment ef fect. 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 28For the assessment of liver fat (via MRI -PDFF, CAP™using FibroScan®, and UDFF™via 
Acuson Sequoia®)and liver stiffness (via VCTE™using FibroScan®, and SWE™via Acuson 
Sequoia®), participants will be required to fast (water permitted) for ≥4hours given the 
ability  of food to potentially impact the seresul ts. As an additional measure to limit 
variability , attempts will be made to standardize the nominal time of these assessments. The 
clock time of day  when these assessments are made should fall within a practical window 
(
±2hours) relative to clock time at the time of 1stassessment in this study  (ie, PreQ for 
FibroScan®;Baseline for MRI -PDFF and Acuson Sequoia®).
In this study , while exploratory  comparison of observed effect on liver fa t is planned, 
comparing MRI -PDFF, CAP™using FibroScan®, and UDFF™via Acuson Sequoia®, a 
comparison of treatment effect on liver stiffness (via VCTE™using FibroScan®, and SWE™
via Acuson Sequoia®), is not planned especially  considering the short durati onof dosing 
(ie,6 weeks). However, 1 of the exploratory  objective s included in this study  (refer to 
Table 5) is comparison of the performance of the two quantitative ultrasound technologies 
(FibroScan®and Acuson Sequoia®)in the ir ability  to assess liver stiffness (via VCTE™and 
SWE™), respectivel y.
In this stud y, measures to ensure participant safety include: (a) frequent (every  2weeks),
outpatient visits up to Week 6/Visit 7, with provisions for unplanned visits for follow -up of 
AEs; (b) off stud y intervention observation via an on -site follow -up visit 14±2 day s post -last 
dose and a telephone contact ≥28 and 
≤32days post- last dose; (c) as much as practically 
doable , the use of same -day shipment of safety- related blood/urine samples to 
Sponsor -identified central laboratory  with rapid turn -around of safety -related results ; 
(d)standardized management of metformin dose as well as overall gl ycemic control in those 
with T2DM ±managed via metformin (Appendix 10.9) ; (e ) standardization of blinded
management of the two identified adverse drug reactions with administration of 
ACCi -namely  increases in fas ting serum trigl ycerides (refer to Ap pendix 10.10) and 
reductions in platelet count (refer to Appendix 10.11); ( f) esta blishment of IRC (refer to 
Section
9.5to undertake unblinded review of safety data while the stud y is on -going; and 
(g)monthly  blinded review of safet y by the Sponsor’s clinical team members to assess for 
potential trigger for additional unblinded review(s) of cumulating safet y data while the study  
is on- going. 
Plasma exposure of ACCi following a high fat/high caloric breakfast was similar relative to 
administration of ACCi following an overnight fast; however, plasma exposure of DGAT2i 
is reduced b y 39% (AUC inf) and 35% (C max) when administered following an ove rnight fast 
versus with standard meal. Therefore, administration of the study  interventions in this study  
will be requested to occur with the morning (and evening) meals –given the importance of 
regular meals to the s
tandard of care diet counselling for t he planned population.
For all participants deemed eligible after SCR visit, transition to Run -In/Visit 2 is 
mandatory for stabilizing background medications (including simply compliance) and 
accompan ying monitoring pa ram
eters in order to minimize placebo response post 
randomization. In addition, a fixed, single -blind, 2 week baseline period from

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 29Baseline/Visit 3 to one day  prior to Day 1/Visit 4 is included in this study  with the explicit 
purpose of familiarizing the p articipants with the dosing instructio ns for the study  
intervention (refer to SoA -Table 1), and to exclude participants who are notcompliant with 
the single -blind placebo prior to randomization in an attempt to minimize medications e rrors 
post randomization.
4.2.1. Participants of C hild-bearing Potential
Human reproductive safety  data are not available for DGAT2i +ACCi. 
In the completed, nonclinical embry o-fetal developmental studies with DGAT2i alone and 
ACC i alone (and hence DGAT2i +
ACC i in this study ) findings have been noted, refer to 
Section
2.3.1. Therefore, the use of a highly effective method of contraception is required
by females of child
bearing potential , refer to Section 5.4.1 and Appendix 10.4 for additional 
details.
The potential risk of exposure, via ejaculate, to DGAT2i +ACCi in a fem alesexual partner 
of childbearing potential of a male participant in this study  is low. As such , use of barrier 
methods of contraception is notrequired/mandated in the male participants. The calculated 
safet y margin is >100- fold be tween the estimated pa rtnerexposure due to seminal transfer 
and the NOAEL for serious manifestations of developmental toxicity  in nonclinical studies. 
The safet y margin of >100 -fold is based on appl ying a 10 -fold safet y factor for interspecies 
extrapolati on and a 10- fold saf ety factor for susceptible populations.15
4.2.2. Rationale for Banked Biospecimen Collections
Banked Biospecimens will be collected and stored for further anal yses which may , for 
example, provide greater understanding of the study  intervention . Comparing the DNA ,
RNA, protein, and metabolite variation patterns of participants who respond well and those 
who res pond poorl y to treatment may  help to better define the most appropriate group of 
participants in which to target a given treatment. Colle cting biospecimens for exploratory  
pharmacogenomic/genomic /biomarker analy ses and retaining them in the BBS make it 
possible to better understand the investigational product’s mechanism of action and to seek 
explanations for differences in, for example, e
xposure, tolerabili ty, safety, and/or efficacy not 
anticipated prior to the beginning of the stud y. Banked biospecimens retained in the BBS 
also can be used in research for NAFLD/NASH. Refer to Section 8.8.1 foraddit ional details. 
Providing these biospecimens is a required stud y activity  for study  sites and participants, 
unless prohibited by  local regulations or EC decision.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 304.3.Justification for Do se
4.3.1. Part 1 
In Part 1, a range of doses of DGAT2i wi ll be coadminist eredwith fixed dose of ACCi 
(20mg/day ).Doses selected 
(refer to Table 3) were based on the observe d effect on liver fat 
following 2 weeks of dosing with DGAT2i in Study  C2541005, 6 weeks of dosing of 
DGAT2i alone , ACCi alone, a nd coa dmin istration in Study C3711001, as well as 16 weeks 
of dosing with ACCi alone in Study C1171002.
In Stud y C3711001, admi nistration of DGAT2i 300 mg BID and ACCi 15 mg BID alone and 
when coadminist ered over 6 weeks inparticipants with NAFLD, a place bo-adjustedLS mean 
reduction 
in liver fat of ≥35% was observed in all groups . In addition , on average, fasting 
serum trigl yceride increases observed with ACCi alone were mitigated by coadministration 
with DGAT2i.  In the current study , coadministration of DGAT2i + ACCi (at a ratio of 20:1) 
wasselected as the highest dose; it contains the same DGAT2i dose assessed in 
Study C3711001 (DGAT2i 300 mg BID + ACCi 15 mg BID ; at a ratio of 30:1 ) though a 
slightly  lower ACCi dose (10 mg BID) is proposed in the current study  acknowledging that 
while mitiga tionof ACCi -induced effect on fasting serum trigl ycerides with coadministration 
of DGAT2i was seen, 
this response had an upper 90% CI  of an increase of 28% in 
placebo-adjusted change from baseline for DGAT2i + ACCi ,in Study  C3711001. 
The lower doses of 50 mg/ dayand 200 mg /day of DGAT2i , administered BID
(ie,25mgBID and 100 mg BID)
, in this study  are proposed in order to assess the 
dose-response 
for mitigation of ACCi -induced elevations in fasting serum trigl ycerides, as 
well as to assess the effect of thes e coadministered doses on liver steatosis.  Given that 
DGAT2i dec reases PCSK9 with an ED 50of 7mgBID and that PCSK9 is a marker of SREBP 
activity  (mechanism postulated to be responsible for the DGAT2i- mediated mitigation of 
ACCi -induced ele vations in fasting serum trigl ycerides), it is possible that doses significantl y 
lower than 300 mg BID may  mitigate ACCi -mediated lipid changes.  Spacing of the DGAT2i 
doses by  3-4 fold allow for covering a 12- fold range of DGAT2i doses (ie, 50 to 600, 
mg/day).
Inaddition to a range of BID doses, a QD group is included where 300 mg DG AT2i will be 
coadministered with 20 mg ACCi.  As 300 mg dose of DGAT2i represents the highest 
currentl y feasible QD dose, the purpose of this group is to assess the effect of a QDdosing 
regime n on hepatic steatosis as well as the potential to evaluate wheth er DGAT2i dose to 
mitigate ACCi -mediated elevations in fasting serum trigly cerides can be administered QD
.  
Depending on the observed profile with this QD dosing regimen in P art1,additional dose 
ranging with QD doses may  be considered in Part 2 of this study .
The DGAT2i and ACCi doses selected have been demonstrated to be safe and well -tolerated 
in previous clinical studies and are supported b y the safet y margins from the noncl inical, 
chroni c toxicity  studies completed in rats and monkey s for each o
f the agents alone and up to 
13-week combination toxicity  stud ies completed in monkey s. In the current study , the 
highest DGAT2i dose (300 mg BID) and ACCi dose (10 mg BID) propos ed are3 times (f or 
DGAT2i) and 10 times (for ACCi) lower than the highest repeated dose evaluated for each

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 31agent in previous clinical studies (refer to Section 2.2.1) as well as afford adequate safety
marg ins compared to completed nonclinical chronic toxicity  studies (refer to Section 2.2.2).
The overall selection of doses of DGAT2i and ACCi were also influenced by the aim to 
evaluate t he study objectiv es using the tablet strengths available (ie, 25, 50, and 150 mg for 
DGAT2i; 10 mg and 20 mg for ACCi) as efficiently  as possible.
As proposed, the 
dose-range planned in Part 1 will necessitate e ach participant to self -administer 
3tablets/dose ,twicedaily, in order to maintain the double -blind, double -dummy  design of 
the study . To aid compliance b y the participants, study  intervention will be packaged and 
dispensed as blister cards (not bottles) with each card permitting 7 days of dosing , refer to
Section
6.1. 
4.3.2. Optional Part 2
The planned dose range for DGAT2i +
ACCi (both BID and QD) in Part 1 are envisioned to 
permit selection of dose(s) to be evaluate d in P art 2.
Based on observed da tain Part 1 (refer to Section 9.5), doses and/or dosing regimen selected 
in Part 2 will be in accordance with the following considerations: 
Total daily doses of DGAT 2i, adminis tered QD, will ra nge from 25mg(lowest) to 
300mg(highest);
Total daily doses of DGAT2i, administered BID
, will range from 50 mg (lowest) to 
600mg(highest);
With DGAT2i doses projected to be sufficientl y separated based on plasma expos
ure;
Coadminister ed with ACCi dose of 10 mg/day  or20 mg/day  with frequency  
mirroring DGAT2i dosing regimen –BID or QD;
DGAT2i + ACCi dose(s) evaluated in Part 1 may  be repeated to permit better 
characterization of effectiveness of DGAT2i to mitigate ACCi -induc ed elevatio n in 
fasting serumtriglycerides;
And each dose will be limited to ≤4 tablets (ie, up to 8 tablets per day )with drug 
packaged and dispensed as blister cards (not bottles) with each card permitting 7 days 
of dosing.
While data from Part 1 (via an interim anal ysis) will be used to guide dose groups evaluated 
in Part 2, dat a for any dose groups repeated in Part 1 and Part 2 (at a minimum placebo), will 
be pooled for purposes of reporting in the clinical study
 report. 
4.4.End of Study Definition
End of the study  is defined as the date of conduct of the very  last 2ndFollow -up vi sit in a 
participant randomized into this trial, globally . 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 325.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participants are enrolled. The 
following eligibility  criteria are designed to select participants for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol.
Prospective approval of protocol deviatio ns to recr uitment and enrollment criteria, also 
known as protocol waivers or exemptions, is 
notpermitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if allof the following criteria appl y:
Age and Sex:
1.Male or female par ticipants between the ages of 18 and 75 years, inclusive, at PreQ 
andSCR.
Refer to Appendix 10.4 for reproductive criteria for male ( Appendix 10.4.1 ) and 
female (Appendix 10.4.2) participants .
Type of Participant and Disease Characteristics:
2. At PreQ andSCR, meet the following criteria, based on assessment via FibroScan®, 
with a single repeat permitt ed,on a separate da y,to assess eligibility , if needed, at 
each of these 2 visits : 
CAP ™ ≥280 dB/m;
VCTE™ ≥7.0 kPa.
3.At PreQ andSCR, meet ≥2of the following criteria [ for laboratory parameters, 
results must be as assessed by the S ponsor -identified centr allaboratory , with a single 
repeat permitted to assess eligibility , if needed, at each of these 2 visits]:
Fasting Plasma Glucose (FPG) ≥100 mg/dL (5.6 mmol/L), oron pharmacological 
agents with explicit purpose of improving glycemic contr ol (refer to Section 6.5.1
for acceptable versus prohibited medications);
Fasting serum HDL -C <40 mg/dL (1 mmol/L) for males and <50 mg/dL 
(1.3mmol/L ) for females, or on pharmacol ogical agents with explicit purpo seto 
increase HDL- C (refer to Section 6.5.2 for acceptable versus prohibited 
medications);

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 33Fasting serum trigl yceride ≥150 mg/dL (1.7 mmol /L), oron pharmacological 
agents with explicit purpose to decrease serum trigl ycerides (refer to Section 6.5.2
for acceptable versus prohibited medications);
Seated blood pre ssure (BP) ≥130 / 85mm Hg, or on pharmacological agents with 
explicit purpose for BP control (refer to Section 6.5.3 for acceptable versus 
prohibited medications);
Waist circumference ≥40inches (102 cm) for males and ≥35 inches (89 cm) for 
females.
4.Participants who are willing and able to compl y with all sc heduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures .
Weight:
5. B MI≥25 kg/m2with upper lim it of 40kg/m2(inclusive) at PreQ and SCR with a 
single repeat assessment of body  weight and/or BMI  permitted on a different day to 
assess eligibility, if needed, at each of these 2 visits .
6.Body weight must be stable (not vary b y ≥5% for at least 12 weeks before SCR ), as 
reported b y the partici pant.
Informed Consent:
7.Participants are capable of giving signed informed consent as described in
Appendix 10.1 which includes compliance with the requirements and restrictions 
listed in the I CDs and in this protocol at PreQ and SCR.
For participants who qualify  based on PreQ procedures, at SCR, evidence of a 
separate personall y signed and dated informed consent do cument indicating that 
the participant has been informed of all pertinent aspects of the main study , is 
required.
5.2. Exclusion Criteria
Participants are excluded from the study  if any of the following criteria apply :
Medical Conditions:
1.Current significant alcohol consumption at PreQ and SCR defined a sany one of 
these parameters –with a single repeat assessment of laboratory -related parameters 
permitted using the S ponsor -identified central laboratory , to assess eligibility , if 
needed, at each of these 2 visits
: 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 34>14 drinks/week (men) and >7 drinks/w eek (women) where 1 drink = 5 ounces 
(150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard 
liquor;
% CDT (carboh ydrate deficient transferrin) ≥1.5x ULN ;  
Total score of ≥ 8 on the AUDIT questionnaire .
2.Evidence of other causes of live rdisease at PreQ orSCR, with a single repeat 
assessment of laboratory -related parameters permitted using the S ponsor -identified 
central laboratory , to assess elig ibility , if needed, at each of these 2 visits –including: 
Alcoholic steatohepatitis;
Compensated and decompensated cirrhosis;
A
ctive viral hepatitis B – defined b y presence of HBsAg;
Active viral hepatitis C –defined as presence of HCVAb;
HIV infection defined as presence of HIV antibody ;
Hepatocellular carcinoma or other t ypes of liver ca ncer;  
Wilson’s disease, defined as ceruloplasmin level <0.1 g/L; 
A1AT deficiency , defined as A1AT level <LLN; 
Upper gastrointestinal bleed due to esophageal varices , liver transplant, or curr ent 
MEL D-Nascore16>12; 
Evidence of presumptive cirrhosis ba sed on assessments performed as part of this 
study .
3.History  of pancreatitis orT1DM , at PreQ .
4.Any condition possibly  affecting drug absorption (eg, prior bariatric surge ry, 
gastrectom y, ileal resection) ,at PreQ :
Participants who have undergone cholecy stectomy a nd/or appendectom y are 
eligible for this study  so long as the surgery  occurred >6 months prior to PreQ.
5. Diagnosis of T2DM which requires management with >3 oral medications within 
12 weeks prior to SCR ormanagement with excluded agents for gly cemic control , 
refer to Section 6.5.1 .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 356.Dyslipidemia which requires management with > 3 lipid-modify ing agents within
12weeks prior to SCR oruse of excluded agents for lipid management: 
In additi on, specific r estrictions need to be satisfied at SCR in order to progress
to randomization;
Those on gemfibrozil will need to agree to be switched to another agent once 
deemed eligible (at ini tiation of Run -In) and for duration of study ; 
Those on statins w ill be permitted base d on re view of the total daily  dose ,
refer to Section 6.5.2 .
7.At PreQ orSCR, those with severe h ypertension defined as seated s ystolic BP 
≥180 mmHg and diastolic BP ≥105 mm Hgwith a single repeat permitted, if needed, 
to assess eligibility  at each of these 2 visits; and/or managed with >3 agents to 
control BP within 12 weeks prior to SCR (refer to Section 6.5.3 for acceptable 
medications) :
BP must be assessed using a blood pressure cuff size available at individual sites 
and compatible with the arm circumference of the participant, refer to 
Section 8.2.4;
Participants with seated BP ≥160/100 mmHg at PreQ 
orSCR to use the Run- In 
period to revise/adjust medications to improve BP control;
In those with hypertensio n, BP must be well-controlled in order to progress 
with randomization , refer to Section 5.3.
8.Cardiovascular event within 12 
months prior to PreQ :
A history  of m yocardial infarction, stroke, transient ischemic attack or 
revascularization procedure to prevent an y of these events;
Ahistory  of congestive heart failure (NYHA class III or IV) or unstable angina. 
9.Recent (within 5 years of PreQ) systemicall y administered treatment sfor malignancy
including (but not limited to) the use of chemotherapy , radiotherap y, or
immunotherapy .
Orany other active malignancy (within 3 years of PreQ), except for adequately  
treated basal cell or squamous cell skin cancer, or carcinoma in situ .
10.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may increase the risk 
of study  participatio n or, in the investigator’s judgment, make the participant 
inappropriate for the study .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 36Prior/Concomitant Therapy:
11.At SCR, on any  prohibited concomitant medication(s) or those unwilling/unable to 
switch to permit ted concomitant medication(s), refer to Section 6.5.5 .
Prior/Concurrent Clinical Study Experience:
12. Known prior participation in a trial involving DGAT2i orACCi (ie, randomize d and 
received a t least 1 dose of study  intervention, including placebo).
13.Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or5half-lives preceding the first dose of study  intervention 
in this study  (whicheve r islonger). 
Diagnostic Assessments:
14.Results as reported b y Sponsor -identified central laboratory, at PreQ andSCR, as 
below with a single repeat of anyof these parameters permitted to assess eligibility , if 
needed, at each of these 2 vi sits:
ALT <ULN or>5x UL N;
AST >5x UL N;
Alkaline phosphatase (ALP) >2x ULN ; 
Total bilirubin >UL N and direct bilirubin >ULN; 
Note: Participants with a history  of Gilbert sy ndrome would be eligible for 
this study  provided direct bilirubin level is ≤ ULN, and hemoglobin and 
reticulocy te count are within the reference range of the Sponsor -identified 
central laboratory ;
Note: If there is a >50% variability  between the PreQ (orPreQ repeat, if 
performed) and SCR results for ALT, AST, oralkaline phospha tase ortotal 
bilirubin is > ULN, these LFTs must be repeated 1 additional time, ≥2weeks 
after SCR, with the variability  between the PreQ ( orPreQ repeat, if 
performed) and the 1 additional measurement confirmed to be ≤ 50% for ALT, 
AST, and alkaline phosphatase, and total bilirubin ≤ULN, andwithin the 
parameters above to confirm eligibility , as reported by the Sponsor -identified 
central labora tory,prior to progressing to the Run- In/Visit 2;
HbA1C >9% (75 mmol/mol), as assessed using NGSP certified method and 
standardized to DCCT assay ;
Fasting Plasma Glucose >270 mg/dL (15 mmol/L) ;

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 37Fasting serum trigl ycerides >400 mg/dL (4.5mmol/L );
Platelet count < LLN ;
INR ≥1.3;
Albumin <LLN ;
eGFR (using CKD -EPI-Cystatin -C) of 
<30 ml/min/1.73 m2;
A positive urine drug test for illicit drugs (with this 1 assessment not permitted to 
be repeated at each visit to confirm eligibility ).
15.At PreQ orSCR, supine 12- lead ECG demonstra ting QTc interval >480 msec orQRS 
interval >120 msec ;
If QTc interval exceeds 480 msec or Q RSinterval exceed 120 msec, the 12 -lead 
ECG should be repeated twice (on the same or different day ) and the average of 
three QTc/QRS intervals used to determine eligibility ;
Note:if uncorrected QT interval is >480 msec, this interval must be 
rate-correct edusing the Fridericia method, with the resulting QTcF used for 
decision making and reporting.
Other Exclusions:
16. Participa nts meeting criteria for contraindicati on to undergoing imaging assessments 
at PreQ andSCR. 
Active placement of medical devices in/ onthoracic cavit y –such as pacemakers, 
defibrillators [as these interfere with use of ultrasound based imaging modalities ,
and MRI ];
History /evidence of anyof the following :
Contraindication to MRI  such as ferric implant ;
History  of severe claustrophob iaimpacting ability  to perform MRI during the 
study  even despite mild sedation/treatment with an anxioly tic; 
Inability  to lie still within the closed environment of the MRI  scanner or
maintain a breath hold for the required period to acquire images even despite
mild sedation/treatment with an anxioly tic.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 3817.Investigator site staff or Pfizer employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised b y the investigator, and their respective family 
members.
5.3. Randomization Criteria
A computer -generated randomization code using the method of rand om permuted blocks will 
be utilized to randomize participants equall y balanced across the stud y interventions on 
Day 1/Visit 4 prior to the first dose of the double -blind, double -dummy  study  i ntervention 
provided participants satisfy  allthe following crit eria:
1.Eligibility  criteria outlined in Section 5.1 and Section 5.2;
2. A ne gative urine drug test for illicit drugs for sample collected at Baseline/Visit 3, as 
reported b y Sponsor -identified central laboratory (with repeat assessme nt not
permitted for this visit) ;
3.Fasting ( ≥8 hours overnight, with water permitted) serum trigly ceride result of 
≤400 mg/dL (4.5mmol/L), for sample collected at Baseline/ Visit 3, as reported by
Sponsor -identified central laboratory ;
A single repeat assessment permitted using Sponsor -identified central laboratory , 
though results of this repeat, whe n done, must be available ahead of 
randomization;
4.Fasting ( ≥
8 hours overnight, with water permitted) plasma glucose result of 
≤270 mg/dL (15mmol/L), for sample coll ected at Baseline/ Visit 3,as reported by  
Sponsor -identified central laboratory ;
A single r epe
at assessment permitted using S ponsor -identified central laboratory , 
though results of this repeat, when done, must be available ahead of
randomization, refer to Appendix 10.10.
5.In females ,a negative 
serum pregnancy  test result for sample collected at
Baseline/ Visit 3,as reported by Sponsor -identified central laboratory ;
Plus, in females of childbearing potential, urine pregnancy  test on Day 1/Visit 4,
as reported on -site using supplies of
fered b y Sponsor -identified central laboratory , 
must be 
negative for pregnancy , refer to Section 8.2.6;
6.
In those with hy pertension, BP controlled via adjustment of concomitant medications 
forBP c ontrolduring the Run -In period with seated BP on Day 1/Visit 4of 
<160/100 mmHg;
7.Compliance of ≥90% and 
≤110% with doses of single -blind placebo administered
(base d on tablet count) from Baseline/ Visit 3 to 1 day  before Day 1/Visit 4, inclusive , 
refer to Section 6.4; 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 398.Total score of <8 on the AUDIT questionnaire, as assessed on Day 1/Visit 4;
9.
An evaluable MRI- PDFF, as assessed b y Sponsor -identified central imaging vendor, 
collected between B aseline/Visit 3 and prior to dosing with study  intervention on 
Day 1/Visit 4 .
5.4.Lifestyle Conside rations
After confirmation of eligibility at PreQ and SCR , at Run -In/Visit 2, participants will be 
instructed to maintain the guidelines described below for the duration of their participation in 
the study . These guidelines must be reitera ted on Day 1/Visit 4.
5.4.1. Contraception
The investigator or his or her designee, in consultation with the participant of childbearing 
potential , will confirm that the participant has selected an appropriate method of 
contraception for the individual participan t from the permi ttedlist of contraception methods 
(see Appendix 10.4) and will confirm that the participant has been instructed in its consistent 
and correct use. At time points indicated in the SoA – Table 1, the investigator or designe e 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant’s affirmation in the participant’s 
chart (participants need toaffirm their consistent and correct use of at least 1 of the selected 
methods of contraception). In addition, the investigator or designee will instruct the 
participant to call immediately  if the selected contraception method is dis
continued or if 
pregnancy  is known or suspected in the parti cipant or partner.
5.4.2. Meals and Dietary Restrictions
1.Participants must abstain from all food and drink (except water) for ≥8hours prior to 
anyblood sample collections for clinical laboratory  tests, pre-dose PK ,and 
explorat ory biomarker related collections : 
Note: Water may  be consumed as desired (ad libitum) . 
2.Participants must abstain from all food and drink (though water is permitted) for 
≥4hours prior to conduct of any of the imaging assessments –ie, MRI -PDFF, 
FibroScan®and Acuson Sequoia®.
3.Blinded study  intervention must be administered twice daily with: 
Morning dose at approximately  08:00 AM (± 2 hours), local time with 
breakfast/meal ;
Second dose, at approximately  ≥8 and ≤12 hours after the morning dose, with th e 
evening meal . 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 404.At scheduled outpatient visits to the site, in the morning, from Baseline/Visit 3 
through Week 6/Visit 7, participants must be instructed to arrive without having 
consumed the morning meal/breakfast and without taking th e mor ning dose of t he 
blinded study  intervention andconcomitant medications for management of gl ycemic 
control ( Section 6.5.1 ), lipid control ( Section6.5.2), and blood pressure 
(Section
6.5.3) : 
At Baseline/Visit 3 through Week 6/Visit 7, inclusive, following completion of all 
pr
e-dose procedures, the mor ning meal will be consumed with above- mentioned 
medications at the site ;
The morning meal during site visits will be either provided b y the site, orthe 
participant provided a voucher [or similar] by  the site to purchase the meal before 
arriving at the sit e for each visit.
5.Participants will be counseled on appropriate dietary  and lifest yle guidelines
: 
Counseling on dietary  guidelines should be individualized in accordance with 
local medical standards of care for these participant s andappropriate f or the 
concomitant medical condition(s) of each participant
;
Participants will be asked to maintain these guidelines throughout the study 
(ie,up to the Follow -up/Visit 8). 
5.4.3. Alcohol, Caffeine, and Tobacco
Intake of alcohol is permitted in mo deration, refer to exclusion criterion 1in
Section 5.2 for limits on amount of alcohol consumption;
Consumption of caffeinated drin ks and nicoti ne-containing products is permitted 
during participation in the study , except:
There may be a need for brief interruption while at the site and/or imaging 
facility , depending on local policy ;
Consumption is prohibited for at least 1 hour prio
rto any  vital sign measurement.
5.4.4. Activi ty
Participants will notbe permitted to engage in ph ysically s trenuous exercise (for example: 
heav y lifting, weight training, calisthenics, and aerobics) : 
Within 48hours before each blood sample collection for clini cal laborat ory tests for 
the duration of participation in the study ;
Physical activity  at an individ ual participant’s normal pace is permitted.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 415.4.5. Outpatient Visits to Site 
For each participant, every outpatient visit to the site is envisioned to occur with the 
partici pant a rriving at the site between approximately  6AM and 10 AM local time 
with each visit lasting approximately  2hours.
At selected visits, to permit collection of post dose blood samples for PK, participants 
may either extend their stay  on-site after dosing or leave and return la ter the 
same day, refer to Section 8.5for details. 
5.4.6. Outpatient Visits to Imaging/Radiology Facility 
Quantitative ultrasound -based a ssessment svia FibroS can®andAcuso n Sequ oia®will 
occur either at the site or the imaging facilit y, depending on where these devices are
located;
Thelocation of the sedevice smust be kept consistent at individual sites 
throughout stud y execution ie, either both devices reside at the sit e orboth
devices reside a t the imaging facility  –for the dura tion of the study ; 
For each participant , the a ssessment of MRI -PDFF and quantitative u ltrasound ( via 
FibroScan®and Acuson Sequoia®) must occur at the same time of day  (±2hours)
relative to 1sttime o f assessment while in study , as much as practically possible , 
refer to Section 8.6 for additional detai ls. 
5.5.Screen Failures
Screen failures are defined as participants w ho co nsent to pa rticip ate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention/entered in the study . A 
minimal set of screen failure information is required to ensure transparen t reporting of screen 
failure participants t
omeet the CONSOR T publish ing requirements and to respond to queries 
from regulatory  authorities. Minimal information includes demograph y, screen failure 
details, and an y SAE.
In this stud y, participants who scre en fail in Part 1 may  be considered for Par t 2. Inaddition , 
in rare cases, participants may  be re -screened if due to logistical/administrative constraints, 
the maximum period between PreQ and Day 1/Visit 4, of 10 weeks, is exceeded . In both of 
these 
cases , 
Individual circumstances must be review ed with a member of the Sponsor’s Clinical 
team 
before the given participant is re- consented ;
All PreQ and SCR procedures must be repeated under a new 8 -digit SSI D number ;
Participants must be deemed to meet allthe eligibility  criteria including double 
confirmati on of Sponsor- defined presumed NASH stat usunder the new 8 -digit SSI D 
number .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 426.STUDY INTERVENTION
Study  intervention is defined as anyinvestigational intervention(s), marketed product(s ), 
placebo, medical d evice(s), or study  procedure(s) intended tobe adm inistered t o astudy 
participant according to the study  protocol.
For the purposes of this protocol, the term investigational product (ie, IP) may be used 
synony mously  with study  interv ention and refers to all of the following:
Placebo matching D GAT 2i;
Placebo matchi ng ACCi ;
DGAT2i;
ACCi.
6.1.Study Intervention(s) Administered
The following tablet strengths will be provided centrally  by the 
Sponsor for use as stud y 
intervention s in this stud y:
For DGAT2i – 25 mg, 50 mg and 150 mg PF -06865571 tablet s and matchi ng 
placebo
;
For AC Ci –10 mg and 20 mg PF -05221304 tablets and matching placebo.
The study  intervention s above, will be packaged together in blinded blister cards, according 
to the trea tment groups as noted in Table 4, and will be di spensed by  theIRT sy stem in 
sufficient quantities to enable dosing during the intervals between visits outlined in the
SoA -Table 1. One extra blister card wi ll be dispensed at each dispensation visit to suppor t 
the flexibility  provided by  the visit windows. Each blinded blister card supports oral dosing 
for 7days and will be labeled according to individual country  regulatory  requirements. 
In Part 1, across t he 5treatment groups , double -blind, double -dumm y administ ration of 
study intervention will be maintained as outlined in Table 4. Each dose will consist of 
3tablets, ie, 2 large tablets (DGAT2i/matching placebo) plus 1 small tablet (ACCi/matching 
placebo).

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 43Table 4. Double -Blind, Double -Dumm y Regimen in Part 1 of C3711005
Regim en # of DGAT2i Tablets
(mg strength)# of ACCi Tablets
(mg strength)
placebo 25 50 150 placebo 10 20
A Placebo, BID AM 2 - - - 1 - -
PM 2 - - - 1 - -
B DGAT2i 25 mg BID 
+ AC Ci 10 m gBIDAM 1 1 - - - 1 -
PM 1 1 - - - 1 -
C DGAT2i 100 mg BID 
+ ACCi 10 mg BIDAM - - 2 - 1
PM - - 2 - 1
D DGAT2i 300 mg QD 
+ ACCi 20 mg QDAM - - - 2 - - 1
PM 2* - - - 1* - -
E DGAT2i 3 00 mg BID 
+ ACCi 10 mg BIDAM - - - 2 - 1 -
PM - - - 2 - 1 -
*To ma intain dou ble-blind, double -dummy design across all groups , this group will receive placebo as evening dose .
For Part 2, u pdated dosing details will be offered via Investigational Product (I P) Manual 
for the site and separately for the parti cipants via Dosing Diary Instructions once the data 
from Part 1 are reviewed and doses for Part 2 are identified. 
6.1.1. Administration
Participants will either self -administer on -site(during scheduled v isits) orat home /outpatient
with meals – twicedaily. Participants wil l swallow th e study  intervention whole and will not 
manipulate or chew the study  intervention prior to swallowing. Each day , the participants 
will be instructed to consume orally , the 3 tablets with the morning meal an d 3 tablets w ith 
the ev ening meal asoutlined i n Table 4.
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maint ained during transit for all study interventions rec eived and an y 
discr epancies are reported and resolved before use of the study  intervention . 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized sit e staff may supply or administer stud y interventi on. All study 
interventions must be stored in a se cure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage
conditions with access limited t o the invest igator and authorized site staff. Ata 
minimum, daily  minimum and maximum t
emperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must 
indicate the min imum and maximum temperatures s ince previousl y documente d for 
all site storage l ocations upon return to business.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 443.Any excursions fr om the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with an y actions taken. The site should 
activel y pursu e options for returning the stud y interv ention to the storage conditions 
described in the labeling, as soon as possible.  Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer p rovides permission 
to use the study intervent ion.  Speci fic details reg arding th e definition of an excursion 
and informa tion the si te should report for each excursion will be provided to the site 
in the IP manual.
4.Any storage conditions stated in the SRSD will be superseded b y the stora ge 
conditions stated on t he label.
5.Study interven tions should be stored in their original containers .
6.Site staff will instruct participants on the proper storage requirements for take -home 
study intervention.
7.The investiga tor,instituti on, or the head of the medical inst itution (where applicable) 
is responsibl e for stud
y intervention accountability, reco nciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition reco rds), such as the 
IPAL or Sponsor -approved equiv alent.  All study  inter ventions will be accounted for 
using a stud y intervention accountabilit y form/record. Allstudy intervention that is 
taken home for outpatient dosing by the participant, both used and unused, must be 
returned to th e investigator b ythe parti cipant.  Return ed study intervention must not
be re dispense d to the participants.
8. Further guidance and infor mation for the final disposition of unused study  
interventions are provided in the IP manua l. All destruction must be a dequa tely 
document ed. If des truction is aut horize d to take place at the investigator sit e, the 
investigator must ensure that the materi als are destroy ed in compliance with 
applicable environmental regulations, institutional poli cy, and any  special instruc tions
provided b y Pfizer.
Upon identificatio n of a product complaint, notify the Sponsor within 1 business day  of 
discovery  as described in the I P manual .
6.2.1. Preparation and Dispensing
The investigational product will be dispensed u sing the IRT s ystem at vis
its id entified in the 
SoA 
–Table 1.  A qualified staff member will dispense the study  intervention via unique 
container numbers on the blister cards provided, in quantities appropriate for the visit 
schedu le. A second staff m embe r will verify  the dispensing. 
The participant should be instructed to maintain the product in the blister cards provided 
throughout the course of dosing and return all blister cards, both used and unused to the site 
at the next study  visit.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 456.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocat ion to Study Intervention
6.3.1.1. Part 1
Approximately  90 participants will be randomized in a bal anced ratio to receive either 
double -blind, double -dummy  placebo, or 1 of 4doses of DGAT2i + ACCi(with 3 entaili ng 
B
ID dosi ng of DGAT2i + ACCi and1 dose -level of Q D do sing but with blind maintained 
via dosing of placebo as the 2nddose each day ). A com puter -generated randomization code 
using the method of random permuted blocks will be utilized t o assign participant s to any  
1of the 5 dosing groups on Day 1/Visit 4.
Allocation of participants to treatment groups will proceed through the use of an IRT s ystem 
(IWR). The site personnel (study  coordinator or specified designee) will be required to enter
or select infor mati
on includi ng but not limited to the user’s ID and p assword, the protocol 
number, and the unique 8 -digit participant number. The site per sonnel will then be provided 
with a treatment assignment, randomization number, and DU or container number(s) from 
the IRT system. The IRT system will provide a confirmati on report containing the 
participant number, randomization number, and DU or contain er number(s) assigned. The 
confirmation report must be stored in the site’s files. 
The investigation al product will be dispensed a t the s tudy visits summarized in the 
SoA -Table 1; returned study  intervention should notbe re dis pensed to the participants.
The study  specific IRT reference manual and IP manual will provide the co ntact informa tion 
and further details on the use of the IRT s ystem.
6.3.1.2. Optional Part 2
The allocation of treatment in Part 2 , will be in accordance to options described in 
Section 4.3.2, after the revi ew of data from Part 1 .
6.3.2. Breaking t he Blind 
The blind should only be broken in emergency  situations for reasons of participant safet y and
when knowing t he specific investigational product that the participant received alters the 
course of medical manageme nt. 
The IRT will be programmed wit h blind breaking instructions. In case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety  must alway s be the firstconside ration 
in making s
uch a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every  effort to contact the Sponsor prior to unblinding a 
participant’s treatment assignment unless this could delay further management of the 
participant. If a participant’s treatment ass ignment is unblinded, the Sponsor must be 
notified within 24 hours after bre aking the blind. The date and reason that the blind was 
broken must be recorded in the source documentation andCRF.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 46The study -specific IRT reference manual and IP manual will provide the contact informat ion
and further details on the use of the IRT s ystem.
6.4. S tudy Intervention Compliance 
Compliance with investigational produ ct will be assessed at each on -site visit starting on 
Day 1/Visit 4 and continuing until Week 6/Visit 7 , refer to SoA -Table 1.Complianc e (as 
asses sed b y cou nting returned blister cards and/or tablets) will be defined as self -
administrati on, by  the participants, of :
Baseline period (Visit 3 to 1 day  prior to Day 1/Visit 4, inclusive ): ≥90% and 
≤110% compliance with single -blind, double -dummy , placebo based on the num ber 
of doses consumed for the specific duration of dosing ; for example ;
Ifduration of dosing was 12 days, participant can miss a maximum of 2doses
(ortake a maximum o f 2extra doses) andstill qualify  for randomization;
Ifduration of dosing was 16days, participant can miss a maximum of 3doses
(ortake a maximum of 3 extra doses) andstill qualify  for randomization;
Day 1/Visit 4 to last day  of dosing orWeek 6/Visit 7, inclusive : ≥80% compliance 
with self -administration of the study  intervention is expected;
Investigators must closely monitor non -compliant participants in order to enhance 
participants’ adherence to the study  intervention; 
Post randomization , at each dispensation visit (refer to SoA -Table 1), 
participants who are <80% compliant, based on tablet count plus review of 
dosing diary  performed, must be re -educated by the site staff on the 
importance of daily  self-administration of study  inter vention;
Overall aim : maintain ≥80% compliance over the duration of dosing with 
double -blind, double -dummy  study  intervention.
6.5.Concomitant Therapy
Given the relativel y short duration of the double -blind, double -dummy  dosing in this study , 
whenever possible , attempts must be m ade to 
notalter the doses and regimens of the 
background /concomitant medic ations after randomization, Day  1/Visit 4 and until the
required on-site Follow -up(ie, Visit 8). 
All concomitant medications taken during the study must be recorded with indicatio n of use. 
In addition, agents used for gl ycemic control, lipid control, and blood pressure control, dail y 
dose, start and stop dates of administration must be captured. All p articipants must be 
questioned about concomitant medication at each outpatient v isit to the site. 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 47Medications started before Day 1/Visit 4 will be documented as prior medications. 
Medications started after dosing of double -blind , double -dummy investigatio nal product on 
Day 1/Visit 4 anduntil the required on-site Follow -up(ie, Visi t 8), inclusive, will be 
documented as concomitant medications.
6.5.1. Medication for Glycemic Control
The use of the following class esof agents is not permitted within 8 weeks prior to SCR 
visit and until the required on- site Follow -up(ie, Visit 8 ), inclusive :
TZDs such as pioglitazone and rosiglitazone; 
Subcutaneously  administered agents for gl ycemic control (e g, insulin, exenatide, 
liraglutide, pramlintide).
Participants are per mitted to be on stable doses of up to a maximum of 3 oral agents for 
glycemic co ntrol,starting at ≥12weeks prior to SCR and until the required on- site 
Follow -up (ie, Visit 8) , inclusive, across the country -specific, approved classes of agents 
including (but not limited to) the following:
Biguanide such as metformin , refer to Appendix 10.9 for protocol -required 
dose-adjustment in participants on metformin dose > 1gm/day; 
Sulphony lureas such as acetohexamide, chlorpropamide, tolazamide, tolbutami de, 
glimepiride, glipizide, gly buride;
Meglitini de analogues such as repaglinide, nateglinide;
Dipeptidy l peptidase
-IV inhibitors (DPP- IVi) such as sitagliptin, saxagliptin, 
vildagliptin;
  -glucosidase inhibitors such as acarbose, miglitol;
Sodium -glucose cotransporter 2 inhibitors such as canag liflozin , dapagliflozin, 
empagliflozin.
6.5.2. Lipid -modifying Medications
The use of an y injectable agent (eg, those which inhibit monoclonal antibodies inhibiting 
proprotein c onvertase subtilisin/kexin ty pe 9 (PCSK9) such as alirocumab, evolocumab , or 
inclisi ran)is notpermitted within 12 weeks prior to SCR and until the required on- site 
Follow -up (ie, Visit 8 ), inclusive . 
Participants are permitted up to a maximum of 3 lipid -modifying oral agents if they  are on 
stable doses, starting from ≥ 12weeks prior to SCR and until the required on- site Follow -up
(ie,Visit 8), inclusive, across the country -specific, approved classes of agents including (but 
not limited to) the following:

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 48Those on selected statins which are BCRP substrates will only bepermitted if on: 
Rosuvastatin doses up to 10 mg/day ;
Atorvastatin doses up to 40 mg/day ;
Simvastatin or Fluvastatin doses up to half- maximum in -country  approved dose;
Note : pravastatin and p itavastatin are permitted at doses up t o the maximum 
approved, in-country dose;
Bile acid sequestrants such as cholest yramine, colestipol, or colesevalam;
Fenofibrate, a fibric acid derivative;
Nicotinic acid/niacin;
Ezetimibe.
Note: Use of gemfibrozil, an OATP inhibitor, is notpermitted start ing at Run- In/Visit 2and
until the required on -site Follow -up (ie, Visit 8) – participants on this agent , at SCR, will 
need to agree to be switched to another acceptable agent starting at Run -In/Visit 2, with 
stable dose of the acceptable agent achieved f or ≥4weeks before Day  1/Visit 4 , in order to 
continue to randomization in this study .
6.5.3. Medications for Controlling Blood Pressure
Across the man y classes of agents for management of hy pertension, 
partici pants are 
permitted to be on stable doses of up to a maximum of 3 agents, starting at ≥ 12weeks prior 
to SCR visit and until the required on -site 
Follow -up (ie, Visit 8), across the man y approved 
classes of agents .
Note: Starting at 
Run-In/Visit 2, medications ± doses of medications for BP control can be 
adjust ed to a maximum of 3 agents inorder to meet BP criteria needed to progress to 
randomization [refer to Section 5.3].
6.5.4. Other Acceptable Concomitant Medications
As much as possible, participants on the following list of medicati ons must be on stable 
doses (i e, ≥12 weeks prior to SCR and until the required on- site Follow -up/Visit 8), 
inclusive ]:
Use of multi -vitamins is permitted though those on Vitamin E must be on stable dose 
for ≥24weeks before SCR;
Use of aspirin at doses of ≤325 mg/day ;

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 49Use of oral agents that alter stomach pH – eg, antacids, histamine -2 receptor 
antagonists, proton- pump inhibitors;
Use of inhaled and topical corticosteroids ;
Note : Intercurrent treatment with sy stemic steroids, during participation in the study , 
may be permitted if treatme nt does/will not exceed 7 days;
Thyroidreplacement therapy ;
Postmenopausal hormone therap y;
Hormonal contraceptives that meet require ments of this study  are allowed to be used 
in participants who are WOCBP (see Appendix 10.4);
Antipsy chotic medications such as olanzapine, risperidone;
Antidepressant medications such as tricy clic agents, selective serotonin reuptake 
inhibitors and seroton
in/norepinephrine reuptake inhibitors;
Selected ( herbal )supplements (orapproved agents), below, in countries where they  
are part of standard of care to lower LFTs ( based on limited/weak scientific evidence );
Glutathione;
Glycyrrhizic acid;
Polyene phospha tidylcholine;
Silymarin;
Ursodeox ycholi c acid;
Chronic and i ntermittent use of NSAIDs (such as ibuprofen, ketoprofen, diclofenac, 
naproxen, indomethacin, meloxicam; and celecoxib) is permitted;
Intermittent use of acetaminophen/paracetamol at doses up to 2 grams per day  
(forexample: for short -term pain management ) is deemed acceptable.
6.5.5. Prohibited Medications
Certain medications for glycemic control, lipid -modification, and BP control are not
permitted as per restrictions in Section 6.5.1, Section 6.5.2, orSection 6.5.3.
Use of drugs historicall y associated with fatt y liver are prohibited within any
≥4 weeks interval in the previous 12 -months prior to SCR and until the required 
on-site Follow -up(ie, Visit 8 ), inclusive ;

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 50Examples include amiodarone, methotrexate, systemic glucocorticoids (such as 
prednisone, dexamethasone, triamcinolone, budesonide, betamethasone), anabolic 
steroids, t etracy clines, tamoxifen, estrogens at doses greater than those used for 
hormone replacement, valproic acid, other known hepatotoxins . 
Use of the following medications within 12 weeks prior to SCR and until the 
required on
-site Follow -up(ie, Visit 8), inc lusive, is prohibited :
Chronic use of immunosuppressants such as cy closporine and tacrolimus;
Pharmacological agents with approved indication for weight loss such as orlistat 
and sibutramine;
Over-the-counter appetite - simulant or appetite- suppressant, as advertised;
P-gp substrates with narrow TI (eg, digoxin) ;
Potent inducers and inhibitors of CYP3A (refer to Appendix 10.8) includin g but 
not limited to the following
:
Inducers –eg, rifampi n,pheny toin, carbamazepine, St John’s w ort, 
phenobarbital;
Inhibitors 
–eg, ketoconazole/itraconazole, clarithromy cin, man y protease 
inhibitors;
CYP2C9 substrates with narrow TI (eg, warfarin o r phe nytoin); 
Blood thinner(s) – eg, apixaban, dabigatran, rivaroxaban, edoxaban, 
fondaparinux, heparin, as well as Vitam in K antagonists (eg, warfarin);
Clinically  significant OATP inhibitors –eg, cy
closporine, gemfibrozil, rifampin.
6.5.6. Rescue Medicine
There is no rescue therapy  to reverse the AEs (including identi fied adverse drug reactions) 
observed with an y of the study  interventions; standard medical supportive care must be 
provided to manage the AEs. 
Participant with T2DM with repeated fasting plasma gluco se values >270 mg/dL 
(15mmol/L ) as reported by  the Sponsor- identified central laboratory , at 2 sequential visits 
(eg,a combination of 2 consecutive scheduled visits or1 scheduled visit followed by  an 
unplanned visit to confirm the eleva ted result) ,post randomization , must either :
Have the 
dose of background metformin for gl ycemic control optimized , refer to 
Section
6.5.1 and Appendix 10.9;

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 51Orbe withdrawn from the study  ( if noton metform inprior to randomization) for loss 
of glycemic control.
For the identified adverse drug reactions , guidance to investigators is offered (refer to
Appendix 10.10 and Appendix 10.11) on the basis that reversal of effect towards base line 
expected/observed in previous studies with ACCi upon discontinuation of study intervention . 
6.6.Dose Modification 
Dose modification of doub l
e-blind , double -dummy study  intervention in individual 
participants in this study  is not permitted to be modified.
The decision to pause orstop dosing at a stud y
-level, for 1 or more active dose (s) of 
DGAT2i + ACCi may  be considered based on recommendati on from the IRC ba sed ontheir 
review of unblinded, study-level emerging, observed safet y data , refer to Section 9.6. 
6.7.Intervention 
After the End of the Study
This is the first study to evalua te a range of doses of DGAT2i + ACCi. As such, multiple 
active groups are 
being included, to enable identification of efficacious dose(s) upon its’ 
completion (not at start of study ).In add ition, considering du ration of treatment period 
(ie,6weeks ), benefit of the doses being studied cannot be claimed simply  on the results from 
this study .  Hence, study  intervention will notbe provided to participants at the end of the 
study .
7.DISCONTINUAT ION OF STUDY INTERVEN TION AND PARTICIPANT
DISCONTINUATION/WI THDRAWAL
7.1.Discontinuation of Study Intervention
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation). Reasons for def initiv e discontinuati on of study  
intervention include advers eevents or some other ( a
dministrative) reason. 
If study  intervention is definitively  discontinued, the participant will not remain in the study  
for further evaluation. See SoA -Table 1and SoA - Table 2for data to be collected at the 
time of discontinuation of study  intervention.  
7.2.Participant Disconti nuation/Withdrawal f rom the St udy 
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further follow- up;
Lost to follow -up;
Death ;

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 52Study  terminated by  Sponsor ;
Discretion of the Investi
gator or S ponsor for safet yor behavioral reasons, or the 
inability of the participant to comply with the protocol -required schedule of study
visits or procedures at a given stud ysite. 
As soon as practically  possible afterthe decision to withdraw from t he study , an on -site visit 
should be considered :
Participants
should be questioned regarding their reason for withdrawal;
See SoA – Table 1and SoA -Table 2–for assessment s to be collected at the time of 
study  discontinuation and follow -up for an y further evaluations that need to be 
completed. 
In this study ,anyparticipant who discontinues participation after th ePreQvisit but prior to 
randomization and administration o fthe 1stdose of double -blind, double -dummy study 
intervention will have no additional procedures completed.
The early  discontinuation visit applies only  to participant s who are randomized and t hen are 
prematurel y withdrawn from the study .  Participants s hould be questioned regarding their 
reason for withdrawal.
The participant will be permanently discontinued both from the study interve ntion and from 
the study  at that time.
If aparticipant wit hdrawsfrom the study , he/she may  request destruction of any remaining 
samples taken and not tested, andthe investigator must document any  such requests in the 
site study  records and notify  the Sponsor accordingl y.
If the participant withdraws from the st udy and also withdraw s consent (see Section 7.2.1)
for disclosure of future information, no further evaluations shoul d be performed and no 
additional data should be collected.  The Sponsor may  retain and c ontinue to use an y data 
collected before suc hwithdrawal of cons
ent.
Lack of com pletion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant’s safet y was preserved.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 537.2.1. Withdrawal of Consent 
Participants who request to disconti nue receipt of studyintervention w ill remain in the study  
and must continue to be followed for protocol -specified follow -up procedures. The onl y 
exception to this is when a particip ant specificall y withdraws consent for any  further contact 
with him or he r or persons previo usly authorized by the participant to provide this 
information. Participants should notify  the investigator in writing of the decision to 
withdraw consent from fut
ure follow -up, whenever possib le. The withdrawal of consent 
should be e xplained in det ail in the medical re cords by  the investigator, as to whether the 
withdrawal is only  from further receipt of study  intervention or also from study  procedures 
and/or post treatment study  follow -up, and entered on the appropriate CRF page. In t
he event 
that vital status (whether the participant is alive or dead) is being measured, publicly  
available information should be used to determine vital status only  as appropriately  directed 
in accordance with loca l law.
7.3.Lost to Follow -up 
A participant will be conside red lost to follow -upif he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken i fa participant fails to return to the site for a required 
study  visit:
The site must a ttempt tocontact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit sch edule and ascertain whether or not the participant wishes to and/or 
shoul d continue in the st udy;
Before a p articipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact w ith the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participa nt’s last known maili ng
address or l ocal equivalent methods). These contact attempts should be documented 
in the participant’s medical record;
Shou ld the participant continue to be un
reachable, he/she will be considered to have 
withdrawn from the study. 
8. STUDY ASSESSMENTS AND PROCEDURES
Theinvestigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures at PreQ. In addition , a separate 
signed/dated ICD must be obtained b efore performin g any study-specific procedures at SCR. 
Study  procedures and their timing are summarized in the SoA – Table 1and SoA-Table 2.
Protocol waivers or exemptions are not allowed. Safety  issue sshould be dis cussed with the 
Spons or immediately  upon occurrence or awareness to determine whether the participant 
should continue or discontinue study  intervention. Adherence to th estudy design 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 54requir ements, including those specified in the SoA –Table 1and SoA -Table 2-is essential 
and required for stud y conduct. All screening evaluations must be completed and reviewed 
to conf irm that potential participants meet all eligibility  criteria.  The inve stigator will 
maintai n a screening log to record det ails of all participants screened and to confirm 
eligibility  or record reasons for screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
c
ompleted as des cribed .  However, it is anticipated t hat from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigat or must take all steps necessary  toensure t he saf ety and 
well-being of the participant.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y correcti ve and preventive 
actions that he or she has taken to ensure that requir ed proces ses ar e adhe red to as soon 
as 
possible.  The study  team must be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, p rocessing, storage, and 
shipment inst ructions and contact information wi ll be provided to the investigator site prior 
to ini tiation of the study .
The total blood sampling volume for individual participants in Part 1 of this study will be 
approximately  325 mL. Blood volume collected in Part 2 is envisioned to be the same as in
Part1 given i ntent to maintain the same design – refer to Section 4.1.2.
Additional blood samples may  be taken for saf etyassessments at times specified b y Pfi zer, 
provided the total volume tak en during the s
tudy does not exceed 550mL during anyperiod 
of 60 consecutive day s.  
8.1.Efficacy Assessments
No efficacy  assessments a re being undertaken in this study . 
8.2.
Safety Asses sments
Planned time points for all safety assessments are provided in the SoA –Table 1and
SoA -Table
2.Unscheduled clinical laboratory  measurements may  be obtained at any time 
during the stud y to asses s any perc eived safet y issues.
8.2.1. Physical Examinations
In this stud y,physicalexaminations are to be performed at nominal time points specified in
theSoA 
–Table 1.
A complete physical exa mination will include, at a minimum, assessment s of the 
cardiovasc ular, respiratory , gastrointestinal, and neurological s ystems.  
A brief physical examination will include, at a minimum, assessments of the skin, 
lungs, cardiovascul ar sy stem, and abdomen ( liver and spleen).

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 55Investigators should pay special attention to cl inical signs r elated to previous se rious 
illnesses.  
8.2.1.1. Measurement of Waist Circumference 
Waist circumference will be measured at the nominal time points specified i n SoA -Table 1
using a flexible anthropom etric tape and ideall y,reporting the measur ement in centim eters 
with accuracy  to the nearest 0.1 centimeter ( or1/16thinch).
Measurement will be undertaken as fo llows:
While participant is in a standing position with arms resting comfortabl y at the side;
Atthe end of a normal expiration (when lun gs are at their residual capacity ) ;
And the measurement will consid er the following anatomical features as benchmarks:
Circumference ofthenarrowest partofthetorso asviewed from the anterior 
aspect or;
Ifthe n arrowest partofthe torso cannot beidentified, themeasurement must be
made of the smallest horizontal cir cumference in the area between the ribs and the 
iliac crest.
8.2.2. Body Weight
In this stud y, assessment of body  weight will occur at the nominal time points specified in
SoA
-Table 1per the following specifications:
Weight will be recorded using a scale place d on a stable, flat surface in a 
(semi) -private area;
Same scale, as much as practicall y possible, will be used wit h the scale reporting 
weigh tin kilograms or pou nds, and accuracy to the nearest 0.1 kg [or 0.2 pounds]
-ie,the device used for this study  must be able to distinguish a difference between 
68.4 kg and 68.3 kg;
Measure ment must be undertaken anddocumented to 1decimal place;
Assessm ent performed a t appr oximately  the s ame time of the day  at each nominal 
time point , as much as practically possible ;
Under standard conditions (eg, participants must wear light clothing with content of
their pockets emptied or hospit al gown and not be wear ing shoes or bulky layersof 
clothin g/jackets).

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 568.2.3. Electrocardiograms
Standard single 12-lead ECGs utilizing limb leads (wit h a 10 second rh ythm strip) should be 
collected at times specified in SoA – Table 1using an ECG machine that automatically  
calcula testhe RR interval (o r heart rate) andmeasures PR, QT, and QTc intervals and QRS 
complex. Alternative lead placement methodology using torso leads (eg, Mason -Likar) is 
notrecommended given the potential risk of discrepancies with E CGs acquired us ing 
standa rd limb lead placement. 
All scheduled 12- lead ECGs should be performed after the participant has rested 
quietly  for ≥10minutes in a supine position;
Starting at 
Day 1/Visit 4, if a machine -read QTc value is prolonged, as defined in
Appendix 10.7, repeat mea surements may not be necessary  if a qualified phy sician’s 
interpretation de termines that the QTc values are in the acceptable range;
Assessment of whether prolonged QTc interval meets criteria as defined in
Appendix 10.7, must assess QTc interval using only the Fridericia’s correction 
(ie,QTcF) either as reported by  the 12 -lead ECG machine orQTcF derived using 
Sponsor -provided tool and reported QT and RR intervals;
In some cases, it may  be appro priate to rep eatabnormal 12 -lead ECGs to rule out 
improper lead placement as contributing to the ECG abnormality ;as much as 
practically, possible, it is important that leads beplaced in the same positions 
each time in or der to achieve precise ECG record ings.
Additio nalECG values of potential clinical concern are listed in Appendix 10.7.
8.2.4. Vital Signs
In this stud y, assessment of vital signs (including seated bloo d pressure, and pulse rate) will
occur at the 
nominal time points specified in SoA – Table 1per the following specifications:
At the 
PreQ visit, the participants’ arm circumference should be measured (usi ng a 
flexible anthropometric tape) at the midpoint of the l ength of the upper ar mandthe
appropriate cuffselected andused throughout the study to measure BP/pulse rate vi a
an automated device using an oscillometric method ( notauscultation);
Participant s with arm circumference greater than the largest cuff size available at
each si te are not eligible ;
Single seated blood pressure/ pulse ratewillbemeasured with thepartic ipant’s arm
supported at the level of the heart, and recorded to the nearest mm Hg, following a
rest of ≥5minutes .
Same arm (preferabl y the d ominant arm) will be used for blood pressure/pulse rate
assessment throughout the study .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 578.2.5. Clinical Safety Laboratory Assessments 
See Appendix 10.2 for the li st of clinical saf ety laboratory  tests to be perfor med a nd 
SoA -Table 2for the timing and frequency .  All protocol -required laboratory  assessments, as 
defined in Appendix 10.2, must be conducted in accor dance with the laboratory  manual and 
SoA
-Table 2.  Unscheduled clinical laboratory  measurements may be obtained at any  time 
during the stud
y to assess any perceived safet y issues.  
The investigator must review th e laboratory  repo rt, documen t this review, and record a ny 
clinically relevant changes occurring during the study in the AE section of the CRF.  
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disea se, unless judged by the inv estigator to be more severe than expecte d for 
the participa nt's condition.
All laboratory  tests with values co nsidered clinically  significantl y abnormal during 
participation in the study  or within 28days after the last dose of study interventio nshould 
berepeated until the values return to nor malor baseline or are no longer considered clinicall y 
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged re asonable by  
the investigator , the etiology  should be identified, andthe Sponsor notifi ed.
See Appendix 10.6 for suggested actions and follow -up assessments in the event of potential 
drug-induced liver injury.
8.2.6. Pregnancy Testing
Pregn ancy  tests may  be urine or serum tests but must h ave asensitivity  of at least 
25mIU/mL and perform ed using supplies offered by  the 
Sponsor -identified central 
laboratory . Serum (all females) and urine pregnancy  tests (in WOCBP) will be perfor med at 
the times listed in SoA
-Table 2. Following a negative pregnancy  test result at screening, 
appropriate contraception must be commenced (or continued) and a second negative 
pregnancy  test result wil l be required at the baseli
nevisit prior the particip ant’s receiving the 
study interventio n
(ie, single -blind , double -dummy placebo starting at Baseline/Visit 3 and
double -blind , double -dummy  study  intervention starting at Day  1/Visit 4). Pregnancy  tests 
will also be done whenever 1menstrual cy cle is misse d during the active treatm ent period (or 
when poten
tial pregnancy is otherwise suspected) and at the end of the study . Pregnancy  
tests may  also be repeated if requested b y IRBs/ECs or if required b y loc al regulations. If a 
urine test cannot be confirmed as negative (eg, an ambiguo us result) ,a serum preg nancy  test 
is required. In such cases, the participant must be discontinued if the serum pregnancy  result 
is positive.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 588.2.7. Alcohol Intake Assessment
In this study , the interview -basedAUDIT questionnaire11will be co mpleted by  thesite staff 
based on responses offered by  the participants –at the visits outlined in SoA –Table 1. 
Training for the site staff c
ompleting this questionnaire will be offered b y theSponsor as part 
of the protocol -
specific training ahead of the initiation of the study .
8.2.8. Triggered 
Requir ements and Individual Participant Stopping R ules
8.2.8.1. Potential Cases of Hypertriglyceridemia
In the curr ent study , fasting se rum trigl ycerides as report ed by the S ponsor -identified central 
laboratory , with or without any  accompany ing signs/sy mptoms, will be as sessed versus the 
threshold outlined in Appendix 10.10 . 
Individual participants with c onsistently  increasing fasting serum triglycerides over time (or
double -confirmed result) ultimately  reaching the threshold of ≥800 mg/dL ( ≥9mmol/L) as 
outlined in Appendix 10.10 should stop dos ing with study  intervention and an AE of 
hypertrigly ceridemia captured.
NOTE: dose(s) of background agent(s) for lipid control (refer to Section 6.5.2 ) must not be 
adjusted while in this study  as it compromises ability  to evaluate effectiveness of 
DGAT2i +ACCi to mitigate ACCi -induced elevations in serum trigly cerides.
8.2.8.2. Potential Cases of Thrombocytopenia
In the current study , platelet count as r eported b y the S ponsor -identified central laborato ry,
with or without any  accompany ing signs/sy mptoms, will be assessed versus th e threshold 
outlined in Appendix 10.11 .
In participants observed to have platelet count b elow the LLN should have an
unplanned visit occur as soon as practically possible to:
Inquire about adverse events via open -ended inquiry ; 
Andcollect b lood sample to permit safety- related laboratory  assessments included 
hematolog y panel assessment by  the Sponsor -identified centra l laboratory .
Participants observed to have a consistent decline over time (ordouble -confirmed result) 
ultimately  reaching the threshold of <75,000/mm3in platelet count as outlined in
Appendix 10.11 should stop dosing with study  intervention and an AE of thrombocy topenia 
captured.
8.3.Adverse Events and Serious Adverse Even ts
The definitions of an AE and an SAE can be found in Appen dix10.3.
AEs will be repo rted b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representativ e). 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 59The investigator and an y qualified designees are respons ible for detecting, documenting, and 
recording even
ts that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and t oassess whether the 
event meets the criteria for classific ation as an SAE or caused the participant t o disconti nue 
the study  intervention 
–(see Section 7.1). 
Each participant will be question ed about the occurrence of AEs in a nonleading manne r.
In ad dition, the investigator may be requested by Pfizer S afety to obtain specific follow -up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs a nd SAEs (“active collection 
period”) for each part icipant beg ins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving stud y intervention), through and including a 
minimum of 28 calendar days , except as indicated below, after the last administration of the 
study  intervention or until study  completion or withdrawal, wh ichever is longer. 
Follow -up by  the investigator continues th roughout and after the active collection period and
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator and Pfizer concurs with that assessment.
Forparticipants who are screen failures, the active c ollectio n period ends when screen failure 
status i s determine d.
If the partic ipant withdraws from the study  and also withdraws consent for the collection of 
future information, the active collection perio d
ends when consent is withdrawn.
If a participant d efinitivel y discontinues or temporarily discontinu es study  intervention 
becau se of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek AEs or SAEs after the par ticipant has 
concluded stud y participation .However, if the investig ator learns of any  SAE, including a 
death, at an y time after a participant has completed the study, and he/she considers the ev ent 
to be reasonably  related to the study  interventio n, the i nvestigator must promptly  report the 
SAE 
to Pfizer us ing the CT SAE Report Form.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as describ ed in 
Section 8.3.1 are reported to Pfiz er Safety on the CT SAE Rep ort Form i mmediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in
Appendix 10.3. The in vestigator will submit any  updated SAE data to the Sponsor within 
24hours of it bein
g available.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 608.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the act ive collection period as 
described in Section 8.3are recorded on t he CRF. AEs and SAEs that begin after obtaining 
informed consent but before the start of stud y interv ention will be recorded on the Medical 
History /Current Medical Conditio ns section of the CRF, not the AE section. AEs and SA Es
that begin after the start of study  intervention are recorded on the AE section of the CRF. 
The investigator is to record on the CRF all directly  observ ed and all spontaneously  reported 
AEs and SAEs re ported by  the participant.
8.3.2. Method of Detecting AEs an d SAEs
The method of record ing, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are pro vided in Append ix10.3.
Care will be ta ken not to introduce bias when detecting AEs and /or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurren c
es.
8.3.3. Follow -up of AEs and SAE s
After the initial AE/SAE report, the investigator i s required to proact ively follow each 
participa nt at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolutio n, stabilization, the event is otherwise explained, 
or the participant is lost to f ollow -up (as define d inSection 7.3).
In general, foll ow
-up information will include a description of the event in sufficient detail to 
allow fo r a complete medical assessment of the case and ind ependent determina tion of 
possible causality .Any information relevant to the event, such as concomitant medication s 
and illnesses, must be provided. In the case of a par ticipant death, a summary  of avai lable 
autopsy  findings must be submitted as soon as possible to Pfize r Safety . 
Further informat ion on follow -up procedures is given in Appendix 10.3.
8.3.4. Regulatory Reporting Requireme nts for SAEs
Prompt notification by  the investigator to the Sponsor
of an SAE is essential so that leg al 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The Sponsor ha s a legal responsibility  to notify  both the local r egulatory  authority  and other 
regul atory  agencies about the sa fety of a stud y intervention under clinical investigation. The 
Sponsor will comply  with country -specific regulatory  requiremen ts relating to safety 
reporting to the regulatory  authorit y, IRBs/EC s, and investigators.
Investigator safety  reports must be pre pared for SUSARs according to local regulatory  
requirements and Sponsor policy  and forwarded to investigators as necessary .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 61An investigator who receives SUSARs or other specific safet y informatio n (eg, summary  or 
listin g of SAEs) from the Sponsor will revi ew and then file it along with the SRSD(s) for the 
study  and will notify  the IRB/EC, if appropriate according to local requireme nts.
8.3.5. Exposure Du ring Pregnancy or Breastfeeding, and Occupational E xposure
Exposure to the study  intervention under stud y during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness .
8.3.5.1. Exposure Duri ngPregnancy
An EDP occurs if: 
A female participant is found to be pregnant while rece iving or after discontinuin g 
study  intervention.
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental e xposure. Below are examples of 
environmental exposure during pregnancy : 
A female fami ly member or healthcare pro vider reports that she is pregnant after 
having been exposed to the study  intervention by  inhalation or skin contact.
A male fa mily member or he althcare provider who has been exposed to the study
intervention by  inhalat ion or ski
n contact then exposes his female partner prior to 
or around the time of conception.
The investigator must report EDP to Pfizer Safety within 24 hours of t he investigator’ s 
awareness, irrespective of whether an SAE has occ urred. The initial infor mation su bmitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant o r a participant’ s partner, the investigator must report 
this informat ion to Pfizer Safety on the CT SA E Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of stud yintervention an d until at least 
28days after the last dose of study intervention .
If EDP occurs in the setting of environmenta l exposure, the investigator must report 
information to Pfizer Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure i
nformation does not pertain to the participant enrolled in 
the study , the informat ion is not recorded on a CR F; however, a cop y of the 
completed CT SAE Report Form is maintained in the investigator site file.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 62Follow -up is conducted to obtain general info rmation on the pregnancy  and its outcome for 
all EDP r eports with an unknown outcome . The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP Sup plemental Form. In the case of a live birth, the struc tural 
integrity of the neona te can be assessed at the t ime of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by  gross visual inspection (unless 
preprocedure test findings a re conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregna ncy meets 
the criteria for an SAE (ie, ectopic pregna ncy, spontaneous abortion, intrauterine fetal 
demise, 
neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal deat h, the investigator sh ould follow the procedures 
for reporting SAEs. Additi onal information about pre gnancy  outcomes that are re ported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causalit y, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the s
tudy intervention. 
Addi tional information regarding the EDP may  be requested by the S ponsor. Further
follow -up of birth outcome s will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregn ant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pr egnant Partner Rel ease of Information Form t o provide to his 
partner.
8.3.5.2. Exposure During Breastfeedi ng
An exposure during 
breastfeeding occurs if:
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention.
A female is found to be breastfeeding while bei ngexposed or having been exposed to 
study  interventi on (ie, environmental exposure). An example of e nvironmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that sh e is breastfeeding after having been exposed t o the study  intervention 
by inhalation or skin cont act. 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 63The investigato r must report exposure duri ng breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an S AE has occurred. The 
information must be rep orted using the CT SAE Report Form. When exposure dur ing 
breastfeeding o ccurs in the setting of env ironmental exposure, the exposure information does 
not pertain to the participant enrolled in the study, so the i nformation is not recorded on a 
CRF. However , a cop y of the completed CT SAE Report Form is maint ained in the 
inves tigator site file.
An expos ure during breastfeeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding w omen (eg, vit amins) is administered in accor d with 
authorized use. However, if the infant experie nces an SAE assoc iated with such a drug, the
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
An occupational exposure oc curs when a p erson receives unplanned direct contact with the 
study  intervention, which may  or ma y not lead to the occurrence of an AE. Such persons 
may include healthcare providers, famil y members, and other roles that are involved in the 
trial participant’s care.
The investigator must report occup ational exposure to Pfizer Safet y within 24 hours of the 
investigator ’s awareness, regardless of whether there is an associated SAE. The information 
must be reported using the CT SAE Report Form. Since the inform ation doe snot pertain to a 
participant enro lled in the study , the information is not recorded on a CRF; howeve r, a cop y 
of the completed CT SAE Report Form is maintained in the investigator site file.
8.3.6. Adverse Events of Special Interest
In this stud y, adve rse event of special interest are the identi fied adverse reactions with 
administration of ACCi :
Increase in fa sting serum trigl yceride re sult of ≥ 800 mg/dL ( 9 mmol/L) –refer to 
Appendix 10.10 ideally  via double -confirmation provided pa rticipant is 
asymptomatic;
Reduction in platelet count to <75,000/mm3– refer to Appendix 10.11 ideally  via 
double -confirmation provided participant is as ymptomatic.
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.3.1 through Section 8.3.4. An AESI  is to be recorded as an AE or SAE on the 
CRF. I n addition, an AESI  that is also an SAE must be 
reported using the CT SAE Report 
Form.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 648.3.7. Medic ation Errors
Medication err ors may result fr om the administration or consumption of the study  
intervention by  the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention un der stud y may occur in clinic al trial settings, such as 
medicat ion errors .
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 
24Hours of Awar eness
Medication errors All (regardless of whether 
associated with an AE )Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention;
Potential medication errors or uses outside o f what is foreseen in the protocol that do 
or do not involve the study  participant.
Such medication err ors occurring to a study  partici
pant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the S ponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, a sdetermined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF. 
Medicati on errors should be reporte d to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this st udy, an y dose of DGAT2i greater than 1800 mg, orany dose of ACCi greater than 
200mg, within a 24 hour time period will be consid ered an overdose.
Sponsor does not recommend specific treatment for an overdose. However, in the event of 
an overdose, the inv estigator should:
1.Contact the medical monitor immediately .
2.Closely  monito r the participant for an y AEs/SAEs and laboratory abnorm alities until
the study  intervention can no longer be detected sy stemicall y (at least 5days).

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 653.Obtain a blood sample for PK an alysis as soon as practicall y possible .
4.Document the quantit y of the exce ss doses as well as the durat ion of the overdose in 
the CRF.
5.Overdose is reportable to Safety  only when associated with an SAE .
Decisions regarding dose interruptions or modifications
will be made by  the investigator in 
consultatio n with the medical monitor based on the clinical evaluation of the participant. 
8.5.Pharmac okinetics 
In this stud y, blood samples ( 4mL each) to provide sufficient plasma for pharmacokinetic 
analysis of PF-
06865571 and PF- 05221304 will be collected into sepa rate, appropriatel y 
labeled tubes containing K 2-EDTA, at times defined in the SoA -Table 2. The date and tim e 
of 2 most recent doses should be noted in a dosing di ary (or simila r) by the participants prior 
to each scheduled, on -site visit; plus date/time of double -blind, double -
dummy study 
intervention ta ken on -site,must be captured in the eCRF.
The PK sample smust be processed and shipped as indicated in the study -specific 
laboratory  manual provided to the site, prior to initiation of study , to maintain sample 
integrit y:
Any deviations from the PK sample handli ng procedure (eg, sample collection 
and processin gsteps, interim storage or shipping conditions), includi ng an y 
actions taken, must be documented and reported to the Sponsor. On a 
case-by-case basis, the S ponsor may  make a determination as to whet her sam ple
integrit y has been compromised. Any deviation from the specified sample 
handling procedure resulting in compromised sample integrit y will be considered 
a protocol deviation .
Anyof the following errors in scheduled collection of blood samples f or PK ( referto
SoA -Table 2) will be captur ed as protocol deviations even if results are deemed to 
be evaluable : 
Predose collection (ie, C trough) obtained post dose;
Post dose PK sample notcollected w ithin collection window fol lowing morning 
dose;
PK sample (pre -or post -dose) notcollected.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 66Aspart of understanding the pharmacokinetics of the study  intervention, samples may  
be used for metabolite identification and/or evaluation of the bioanaly tical method, as 
well a s for ot her inter nalexploratory  purposes including endogenous biomarkers for 
drug metabolizing enzy mes and/or drug transpor ters. These data will not be included 
in the clinical report .
Samples will be analy zed for DGAT2i and ACCi using a validated anal ytical meth od 
in co
mpliance with Pfizer standard operating procedures.
8.6.Pharmacodyn amics
This study  will assess effectiveness of DGAT2i + ACCi for reducing hepatic steatosis as 
assessed via MRI -PDFF.  This evaluation however is labeled as a p harmacody namic 
assessment ( and notefficacy) in line with the evaluation being that of pharmacolo gical 
activity .
8.6.1. Assessment of Liver Fat Using MRI -PDFF 
At scheduled visits (refer to the SoA -Table 1), liver fat (via MRI -PDFF) and total liver 
volume (via MR volume acquisition protocol) will be assessed. 
Transportation of the participants to the I maging facility  does no tneed to be supervi sed b y 
the site staff. Each assessment will require the participants to be in a supine positi on in the 
confined space of the MR I scanner for approximately  25 minutes with the image acquisition 
undertaken following a fast (except water) of ≥4hours, and as much as practically 
possible , at the same time ( ±2hours) of the day  relative to assessment at Baseline 
(ie,between Ba seline/ Visit 3 and prior to 1stdose on Day  1/Visit 4).
Across the stud y sites , the S ponsor -identified central imaging v endor wi ll train the staff at the 
imaging facility  on the MRI  acquisition protocols, on just -in-time review of the acquired 
images for a ssessme nt of images being deemed evaluable, and on transfer (preferabl y 
electronically ) of the images to the S ponsor -identified central imaging vendor for analy sis 
and quantification of liver fat. Only the staff members at the i maging facility who are 
trained by theSponsor -identified central imaging vendor are permitted to acquire 
images , however in rare/limited situations , except ions may  be granted with written approval 
of the S ponsor. Complete details on the MRI -PDFF acquisit ion protocol, determination of 
qualityof images, and transmission of data to Sponsor - identified central imaging vendor will 
be provided in an Imagin g Manual provided to the sites prior to the start of the study .
At the selected visits (refer to the SoA – Table 1) when liver fat is assessed via MRI -PDFF , 
additional MR sequen ces may  be acquired for expl oratory  purposes including liver volume. 
These additional MR sequences and an y additional MR endpoints, if analy zed, will notbe 
included in the clinical study report but w ill be summarized via a standalone report.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 67Management of Incidental Findings
An inci dental finding is one unkn own to the participant that has potential health or 
reproductive importance, which is discovered unexpecte dly in the course of a rese arch st udy 
but is unrelated to the purpose and bey ond the aims of the study .
The images will be r eviewed b y a Sponsor -ident ified central review facility . The purpose of 
this review is to evaluate images for the amount of fat in the liver. Central image r eview i s 
not a complete medical review of the participant. If, during t he central review process, a n 
unexpected observation i s identified and this finding could, in the opinion of the central 
reviewer, have a significant health or reproductive consequence , this find
ing may  be shared 
with the study  Sponsor for disclosure to th e PI. All follow -up testing and final diagnosis will 
be left to the discretion of the medical professionals at the site or those with an existing 
physician -participant relationship. The PI  will be responsible for reporting any  AEs 
identified from incidenta l findings as described in t he AE reporting section. Identification of 
such incidental findings during the central review process should not be expected, and the 
site maintains resp onsibil ity for performing a general safet y review of all images as per site
protocols.
8.6.2.
Assessment of Li ver Fat and Stiffness –using FibroScan®
In this stud y, assessments of liver fat and stiffness using FibroScan®will occur at scheduled 
visits outlined in the SoA –Table 1. Each assessment will require the participants to be in a 
supine positio
n for approximately  15minutes with the image acquisition undertaken 
following a fast (except water) of ≥
4hours, and as much as practically possible , at the 
same time ( ±2hours) of the day  relative to assessment at PreQ visit. The results for liver fat 
(viaCAP™) in dB/m and liver stiffness (via VCTE™) in kPa to determine whether an 
individual participant qualifies at PreQ to progress to SCR will be display ed on the 
FibroScan®device at t he end of each assessment. Acquisition results do not need 
independen
t over -reading, but steps to ensure that acquisition was complete and accurate are 
required . Training is to be offered to at least 2 site staff (who may be sonographers or
compar able) by  EchoSens andcertified as operators based on this training by  EchoS ens, at 
the start of the stud y. As much as practical ly possible , attempts will be made to ensure each 
individual participants’ assessment is performed by the sam e site staf f throu ghout the study .
The summary  of numerical results (including quality -related outputs) must be printed and 
saved b y the stud y site (or imaging facility , as applicable) as par t of each participant’s source 
documents. In addition, all images and outpu t repor ts acquire d must be saved by  the study  
site until the conclusion of the study .
8.6.3. Assessment of Liver Fat and Stiffness – using Acuson Sequoia®
The assessment of liver fat (UDFF™in%) and liver stiffness (via SWE™in kPa) using 
Acuson Sequoia®will o ccur at scheduled visits outlined in the 
SoA – Table 1.  Each 
assessment will require the participants to be in a supine positio n for approximately  
15minu teswith the image acquisition undertaken following a fast (except water) of 
≥4hours, and as much as practically possible , at the same time ( ±2hours) of the day  

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 68relative to assessment at Baseline (ie, between Ba seline/ Visit3 and prior to 1stdose on 
Day 1/Visit 4).
The results will be display ed on the Acuson Sequoia®device at the end of each assessment. 
Acquisition results do not need independent over -reading, but steps to ensure that acquis ition 
was complete and accurate are required . Training is to be offered to at least 2 site staff (who 
may be so nographers or compar able) by Siemens andcertified as operators based on this 
training b y Siemens , at the start of the study . As much as practically pos sible , attempts will 
be made to ensure each individual participants’ assessment is performed b y the same site 
staff throughout the study .
The summary  of numerical results (including quality -related outputs) must be printed and 
saved by the study  site (or i maging facility , as applicable) as part of each participant’s source 
documents. In addition, all images and output reports acquir ed must be saved by  the study  
site until the conclusion of the study .The SWE endpoints, if analy zed, will no t be included 
inthe clinical study  report but will be summarized via a standalone report.
Complete details regarding acqu isitions using Fi broScan®to assess CAP™and VCTE™as 
well as use of Acuson Sequoia®to assess liver fat (UDFF™in %) and liver stiffn
ess (via 
SWE™inkPa) will be provided in a study -specific manual supplied by  the Sponsor before 
initiat ion of this study .
Post-Hoc Analys es
As a means to understand the effects on liver fat, the Sponsor may  undertake retrospective 
analyses of the partic ipant- level, coded data acquired using 3 imaging modalities -
ie,MRI -PDFF, FibroScan®and Acuson Sequoia®.Similarly , retrospective anal yses of th e 
participant -level, coded data may be undertaken to understand the performance of liver 
stiffness, a s asses sed using FibroSc an®and Acuson Sequoia®.  An ysuch analy ses will not
be included in the clinical study report; a separate supplemental rep ortwillbe written to 
capture this work, if undertaken . 
8.7.Genetics
8.7.1. Specified Genetics
A 4mLblood sample for DNA iso lation , for pre -specified PGx, will be collected into plastic 
K2-EDTA tubes, as defined in SoA - Table 2. The DNA samples will be analy zed for the 
purpose of assessing the impact of allelic variants of SL CO1B1 (encodes for OATP1B1 ), 
SLCO1B3 (encode s for OATP1B3), SLCO2B1 (encodes for OATP2B1), SL C10A1 (encodes 
for NTCP), ABCG2 (encodes for BCRP), PNPL A3, and H SD17b13. As par t of these 
analyses, genome -wide markers may  be used to control for ethnic -based genetic associations .
Addi tionally , these sa mples may  also be used for retrospective evaluation of ad ditional 
genetic variants associated with variation in PK, bioma rker response, or to explore AEs 
should these be observed. Samples will be retained for a period of up to 3 years af ter 
regulatory app roval .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 69See Appendix 10.5 for information regarding genet ic research. Details on processes for 
collection and shipment of these samples can be found in Sponsor -identified study -specific 
central l aboratory  manual.
This pre-specified PGx sample must be pro cessed and shipped as indicated in the 
instructions provide d to the investigator site, to maintain sample integrity . Any deviations 
from the PGx processing steps, includin g any actions taken, must be documented and 
reported to the Sponsor. On a case-by-case basis, the 
Sponsor may  make a determination as 
to whether sample in tegrity  has been compromised. Any sample deemed outside of 
established stability , or of questionable integr ity, will be consi dered a protocol deviation.
As part of further understanding t he biological response to study  intervention, samples may  
be used fo r evaluation of other related genot yping as well as development and validation of 
bioanaly tical metho ds.
Any data outside of t he SLCO 1B1/1B3/2B1, SL C10A1, ABCG2, PN PLA3 and HSD17b13 
genot yping will be used for internal exploratory  purposes and wi llnot be included in the 
clinical study  report. 
8.7.2. Banked Biospecimens for Genetics
A 4mLblood sample optimiz ed for DNA isolation (Prep D1) will be collected as local 
regula tions and IRBs/ECs allo
w –refer to SoA - Table 2.
Banked Biospec imens may  be used for research related to the study  intervention(s) and 
NAFLD/ NASH . Genes and other analy tes (eg, proteins, RNA, nondrug metabolites) may  be 
studied using the banked sampl es.
See Appendix 10.5 for inform ation regarding genetic research . Details on processes for 
collection and shipment of thes e sample scan be found in Sponsor -identified study - specific 
central laboratory  manual.
8.8.Bioma rkers
Blood, serum , and plasma samples for exploratory biomarker s (refer to Table6) including 
NAFLD/ NASH -related biomarker s,potent ial mechanism -related parameters, metabolic 
parameters, and aide in understanding the study  intervent ions, w ill be collected a t the
nominal time po ints defined in the SoA - Table 2.
Collection of these samples for explorat
ory biom arker research is part of this study ;
These samples must be processed and shipped as indicated in the study -specific 
laboratory manual provided b y the Sponsor to the site, prior to initiation of study , to 
maintain sample integrit y:

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 70Any deviations from the sample handling procedure (eg, sample collection and 
processing steps, interim storage or shipping co ndition s), including an y actions 
taken, must bedocumented as protocol deviation and reported to the Sponsor. On 
a case -by-case basis, the S ponsor m ay mak e a determination as to whether sample 
integrit y has bee n compromised;
Any scheduled collection prior to nex t dose of blinded study  intervention, if
undertaken postdose, will be captured as a protocol deviation even if results are 
deemed evaluable ;
Samples will be analy zed using a validated anal ytical method (w hich need notmeet 
GLP standards, especially  for the se exploratory  endp oints) but in all c ases, the 
method will be in compliance with Pfizer standard operating procedures.
In addition, as par t of further understanding the biological response to study  inter vention, 
samples may  be used for evaluation o f other related biomarkers as well as developme nt and 
validation of bioanal ytical methods. These data will be used for internal exploratory  
purpo sesand w ill notbe included in the clinical study  report. 
8.8.1. Banked Biospecimens for Biomarkers
Additional Banked Bios pecimens in this st udy are as follows a nd collected at the time points 
outlined in the SoA 
-Table 2:
4 mL Prep B1.5 blood collection tube (for plasma); 
6mLPrep B2.5 blood collection tube (for serum). 
Banked Biospecimens will be collected as local regulations and IRB/ECs allow. 
Banked Biospecimens may  be used for research related to the study  inter
ventio n(s)and 
NAFLD/ NASH. Genes and other analy tes (eg, proteins, RNA, nondrug metabolites) may  be 
studied using the banked samples. 
Collecti on of these samples for exp loratory  biomarker research is part of this study .  
See Appendix10.5 forinformation regarding genetic research. Details on processes for 
collection and shipment of these s amples can be found in Sponsor -
identified study-specific 
central laboratory  manual. 
8.9.Immu nogenicity Assessm ents
Immunogenicit y assessments arenot include din this study .
8.10. Health Economics
Health economics/medical resource utilization and health econ omics parameters are not 
evaluated in this study .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 719.STA TISTICAL CONSIDERATI ONS
Detailed methodolog y for summary  and statistical anal yses of the data collected in t his study  
is outlined in this section of the protocol and further detailed in a SAP, which will be 
maintained by  the S
ponsor.  The SAP may  modify  what is outlined in the protocol where 
approp riate; however, an y majo
r modifications of the pri mary endpoint d efinitions or their 
analyses will also be ref lected in a protocol amendment.
9.1.Estimands and Stat istical Hypotheses
9.1.1. Estiman ds
Two estimands are define d for this study .Estimand 1 will be used in Part 1 and Part 2 to 
support objectives related toimaging ass essments for continuous endpoints assessed at 
Week 6.Estimand 2will be used in Part 1 and Pa rt 2 to support all other objectives for 
continuous 
endpoints assessed over time.
Estimand 1: For a given endpoint, the es timand will be the estim ated population based 
average treatment effect on natural log -transformed relative change from baseline for 
DGAT2i + ACCi relative to pl acebo at Week 6for all r andomized/evaluable participant s.
Intercurrent Events: 
Non eval uable baseline – All data colle cted post -rando mization will be excluded.
Withdrawal from study  intervention after randomization –All data co llected after a 
participan t stops taking study  intervention will be excluded. 
Prohi bited medications –All assessmen
ts aft er a partici pant receives prohibited 
medications that would modulate the primary endpoint will be omitted from the 
analysis. Thelist of concomitant medications would be reviewed prior to database 
lock to determine wh ich would be classed as “prohibit ed” fo r this esti mand.
Inadequate complianc e –All randomized/evaluable p articipants with compliance 
<80% , over the entire duration of dosing with double -blind, doubl e-dummy  study  
interventio n,will nothave their endpoint measurement used as recorded in t he 
analysis.  
Population level summary: 
The population level summary  will be the mean difference in natural log -transformed 
relative change from baseline between DG AT2i + ACCi groups and pl acebo groups 
for the endpoint of interest at Week6.
Estimand 2: For a givenendpoint, the estimand will be t he estimated population based 
average treatment effect on natural log -trans formed relative chan ge from baseline for 
DGAT2i + AC Ci relative to place bo over time for all randomized/e valuable participants.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 72Intercurrent E vents:
Non evaluable baseline – All d ata collected post -randomization will be excluded.
Withdrawal from study  interventi on after randomization –All data collected a fter a 
participant stops taking study  intervention willbe included.
Prohibited medica tions –All assessments after a participan treceives prohibited 
medications that would modulate the endpoin t will be omitted fr om the analy sis. The 
list of concomitant med ications would be reviewed prior to database lock to 
determine which would be cla ssed as “p rohibited” for t his estimand.
Inadequate compliance –All randomized/evaluable p articipants , regardl ess of the 
level of compliance ,will have their endpoint measurem ent used as recorded in the 
analysis.
9.1.2. Hypothesis Test s
No formal h ypothesis tests are planned for Part 1 or Part 2.
9.2.Sample Siz eDetermination
9.2.1. Part 1
The proposed sample size for this study  isapprox imately  90 pa rticipants randomized 
(18participants per group ) to ensure at least 75 participants (15 participant s per group ) offer 
evaluable data .  With a sam ple size of 15 completers per group and with natural 
log-transformed SD of 0.221 for liv
er fat (assessed via MRI -PDFF), a 25% placebo- adjusted 
liver fat decrease can be dete cted at a significance level of 5% 1- sided with a powe r >90%.
9.2.2. Part 2
In Part 2, it i s envisioned that number of participants randomized to each active dose of 
DGAT2 i +ACC i or placebo may be adjusted .  Those assigned to placebo may be reduced, 
given intent to pool data from all participants receiving placebo when summarizing 
end-of-study  results. And while a maximum of 4active doses (plus placebo) will be 
evaluated in Par t 2,the total number of par ticipants will not exceed 90 (with no more t han 
approxima tely 27participants per each active dose). 
9.3.Analysis 
Sets
Data for an y dose gr oups r epeated in Part 1 and P art2 (at a minimum placebo), will be 
pooled for purpose s of summarizing end -of-study  resul ts and reporting these data in the 
clinical study report.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 739.3.1. Part 1
For purposes of analy sis, the following anal ysissets are defined:
Participants Analysis 
SetDescri ption
Enrolled All participants who sign the preQ ICD.
Randomly assigned to 
invest igational productAll participants randomly assigned toIP rega rdless of whether or not study 
intervention was administered.
Evaluable All part icipan ts randomly assigned to IP and w ho take at least 1 dose of IP.  
Partici pants w ill be analyzed according to the randomized intervention.
Safety All participant s randomly assigned to IP and w ho take at least 1 dose of IP.  
Participants will be analyze d acco rding to the product they actually received.
Defined Population for 
AnalysisDescription
Estimand Set 1 All evaluable participants randomly assigned to stud y interven tion and who take 
at least 1 dose of study inter vention (ie Placebo /DGAT2i +ACCi).  
PK Concentration Set All participants randomly assigned to study interv ention and who take at least 
1dose of DGAT2i +ACCi and in whom at least 1 concentra tion value is
reported .
9.3.2. Part 2
Analy sis set for Part 2 is envisioned to be identical to Pa rt 1.
9.4. Statistical Analyses
TheSAP will be developed and finalized before any  analyses of Part 1 (eg,interim analy sis) 
are performed and will describe the anal yses and procedure s for accounting for missing, 
unused, and spurio us data. This section is a summ ary ofthe planned statisti cal anal yses of 
the primary  and secondary  endpoints for Pa rt 1 and optional Part 2 of the study .
9.4.1. Primary Endpoint(s)
Endpoint Statistical Analysis Me thods
Percent change from 
baseline in liver f atas 
assessed via MRI- PDFF at 
Week 6An ANCOVA analys is will be performed on the natural log -transfor med
relative change from bas eline in fasting liver fat values at Weeks 6 from 
the Estimand Set 1 to estimate the treatment effect related t o the 
Estimand 1.
The model will include treatment as fixed eff ect, b aseline as a covariat e 
effect. 
No adjust ments w ill be made for multiplicity .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 749.4.2. Secondary Endpoint(s)
Endpoint Statistical Analysis Methods
Percent change f rom 
baseline in fasting serum 
triglyceride levels over 
timeA mixed model repeated measures (MMRM) analy sis will be fitted to 
natural log -transform ed relative change from baseline in fasting serum 
triglycerides at Weeks 2, 4, 6, and Follow -Up from  the Esti mand Se t2 to 
estimate the tre atment effect related to the E stimand 2.
The MMRM w ill include treat ment, time,and treatment -by-time interact ion 
as fixed effects, baseline as a covariate effect and participant as a random 
effect.  An unstructured correlatio n matri x wil l be used, and the
Kenward -Roger approximation w ill be used for estimating degrees of 
freedo m forthe model parameters.
Missing values will be imputed as part of t he MMRM model assumptions.
No adjustments will be made for multiplicity.
9.4.3. Tertiar y/Exp lorator y Endpoint(s)
Endp oints Statistical Analysis Methods
Refer to Table 5 Will be described in the SAP fin alized before any analyses of Part 1 (eg interim 
analysis) .
Beyond the objectives, estimands, and endpo ints outline d in Section 3 this stud y will also 
evaluate th eobjectives/endpoints summarize d in Table 5.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 75Table 5. Additional Tertiary/Exploratory Objectives a nd Endpoints
Objectives Endpoi nts
To evaluate concordance between effect on liver fat 
of a range of DGAT2i doses coadministered with 
fixed dose of ACCi, compared to placebo , determined 
by MRI -PDFF, versus 2 different quantitative 
ultrasound techniques (CA P™by FibroScan®, and 
UDFF ™ by Acuson Sequoia®) in participants with 
presu med NASHPercent change from basel ine at Week 6 in :
MRI -PDFF
CAP ™
UDFF™
To evaluate concordance between liver stiffness
determined by 2 different quantitative ultras ound 
techniques (VCTE™ by FibroScan®,and SWE by 
Acuson Sequoia®) in participants with presumed 
NASHValues at baseline and Week 6 in:
VCTE™
SWE ™
To eva luate effect on liver functi on tests of a range 
of DGAT2i doses coadministered with fixed dose of 
ACCi, compared to p lacebo in participants with 
presumed NASHPercent change from baseline , over time,in: 
ALT
AST
Alkaline Pho sphatase
Total Bilirubin and
GGT
To evaluate effect on metabolic parameters of a 
range of DGAT2i doses coadministered with fixed 
dose o f ACCi, comp ared to placebo in par ticipants 
with presumed NASHPercent change from basel ine, over time, in:
Total chole sterol
Direct LDL
HDL -C
Direct VLDL
Apolipoprotein A1, B total, B100, B48, C3, and E 
Change from baseline, overtime, in:
HbA1C
FPG
FPI
HOMA -IR
To evaluate the effect on mechanism/disease -related
biomarkers of a range of DGAT 2i doses 
coadministered with fix ed dose of ACCi, compar ed to 
placebo in participants with presumed NASH Percent change over time in: 
CK 18 -M30, -M65
Pro-C3, and Pro -C6
PCSK9
Adip onectin
hsCRP
To summ arize plasma PK of DGAT2i and ACCi , 
across the active d oses of DGAT2i +ACCi evaluated
in participants with pr esumed NASHPredose DGAT2i and ACC i plasma concentrations (ie, C trough) 
To enable the exploratory research th rough collec tion 
of banked biospec imens, unless prohibited by local 
regulations or ethic s comm ittee decisionBiobanking of blood -based specimens (inclu ding Prep D1, 
B1.5, and B2.5 collections to permit retrospective analysis of 
yet-to-be identified biomark ers) 
These results may or may not begenerated in the context of 
the present study
Forallendpoints, baseline is defi ned as the evaluable res ult clo sest prior to dosing on Day 1.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 769.4.4. Pharmacokinetic Analysis
All pharmacokinetic analy ses will be performed on the PK concentrati on set. 
Plasm a concentration data for DGAT2i and ACCi will be list ed and summarized (C trough
only) by treatment . 
In additi on, as permitted by  data and determ ined by  the Sponsor, exposure -response 
relationships between plasma concentr ations of DGA T2i and/ or ACCi and ef fect on primary , 
secondary  and tertiary  endpoints may becharacterized using a populati on PK/PD approach. 
Theobject ives of such an anal ysis, if conducted, would aim to chara cterize 
exposure -response relationships and exp lore potenti al covar iates (eg, age , race, gender, and 
body  weight, etc.) influencing the obser ved PK and/or response to DGAT2i and/or ACCi. 
Thepopula
tion PK and/or PK/PD analy ses, if conducted, will be report ed separately  from the 
main clinical study  repo rt. 
9.4.5. Other Safety A nalyses
All sa fety anal yses will be performed on the safet y populatio n.
Thesafet y data will be summ arized in accordance with Pfize r Data Standards.  All 
participants who receive study  inter vention (safet y population) will be included in the safet y
analyses.  All safety data will be summarized descriptively  through appropri atedata 
tabulation, descriptiv e
statistics, categorica l summa ries, and graphical presenta tions.
Endpoint Statistical Analysis Methods
Secondary
(refer to 
Section 3 )The secondary endpoint will be analyzed i n accordance w ithPfizer Data Standards as 
above.
The primary analyses w illbe on the incidence and severity of all treatment emerg ent 
adverse events (TEAE), t hat wi ll be reported by treatment group .  The number of 
participants and percent will be presented.
The MedDRA dic tionary will be used to classify  allAEs with respe ct to system organ class 
and preferred term. Summaries of AEs will include treatment- emerge nt AEs acc ording to 
treatment group. 
9.4.5.1. Vital Signs Analyses
Changes from basel ine in sy stolic bloo d pressure, dia stoli
c blood pressure and pulse rate will 
be summariz ed by treatment and time. The number (%) of participants with maximum 
increases from basel ine will be tabulated b y treatment as defined in the SAP. Numbers and 
percenta ges of participant
s meeting the c ategorical criteria will be provided and individual 
values listed in the study  report. No formal inferential statistics will be applied to the vita l 
signs data.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 779.4.5.2. Electrocardiogram Analyses
Changes from baseline for the ECG p arameters QT inte rval, heart rat e, QTcF interval, PR 
interval, and QRS interval will be summarized by  treatment and time. QTcF will be derived
using Fridericia’s heart rate co rrection formula. The number (%) of participants with 
maximum increases from base line will be ta bulated by  treatment as defined in the SAP. 
Numbers and percentages of pa rticipants meeting the categorical criteria will be provided and 
individual values li stedinthe study report. No formal inferential statistics will be applied to 
the E CG data.
9.4.6. Other Analyses
Pharm acog enomic or biomarker data from Banke d Biospecimens may  be collected during or 
after the trial and retained for future anal yses; the results of suchanalyses are not planne d to 
be included in the CSR.
9.5.Interim Analyses
Interim anal yses willbe performed aftercompletion of Part 1 (referto Figure 1) to determine 
whether to conduct Part 2 and if so, guide selection of doses o f DGAT 2i and/or ACCi to 
evaluate in Part2.  Interim analy sis results may  be used to conduct a sample size 
r
e-estimation (eg, observed var iability  in Part 1 is higher than assumed for derivation of 
sample size for Part 1), facilitate PK/PD modeling, an d internalbusiness decisions regarding 
planning of future trial s with DGAT2i and/or DGAT2i+ACCi.  Before the inte rimanalysis is 
instigate d, the details of the objectives, decision criteria, dissemination plan, and method of 
maintaining the stud y blind as perS
ponsor’s SOPs will be documented and approved in an 
interim analy sis SAP or final SAP.
9.5.1. PK/PD Modeling 
A limited number of individuals not on the study  team will be unbli nded according to 
Sponsor SOPs with the purpo se of composi ng PK/PD analy sis sets and conducting PK/PD 
analysi
s. Data draws are expec tedatapproximately  50%, and 100% of total st udydata from
Part1. These data ar e expected to include the primary endpoi nt (M RI-PDFF), plasma PKfor 
DGAT2i and ACCi , fasting serum lipid parameters includin g fasted serum trigl yceri des (and 
fasted serum ap olipoproteins, if available) .  Other data outlined in Table 5, may  also be 
considered
.The PK/PD analysis output at the completion of Part 1 (ie, achieveme nt of 
LPLV in Part 1) will be shared as part of the planned Interim Anal ysis withselected 
members of the Sponsors’ study  team to enab le decision to conduct Part2 and if so, the 
dose(s) an d dosin g regi men(s) of DGAT2i + ACCi evaluated in Part 2.
9.6.Data Mon itoring Committee or Other Independent Oversight C ommittee
This study  will use an IRC. The IRC will underta ke periodic unblinded revi ew of t he safe ty 
data while the stud y is on -going. These reviews are envisioned, at a minimum, after 
approximately 33%, and 66%, of planned total sample size in Part 1 (and separately if 
conducted, Part 2), has been randomized .The IRC is independent of t he study  team and 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 78includes 3 senior S ponsor colleagues members with no direct involvement in the conduct o f 
the study . The IRCcharter describes t he role of the I RC in more detail.
Across the IRC mem bers, there will be at least 1 medically -qualified individual, and 
1statistician.
The IRC will be responsible for ongoing monitoring of th e safet y of participan ts in 
the study  according to the c harter. The recommendations made by  the IRC to alter 
the conduct of the study will be forwarded to the a ppropri ate Pfizer personnel for 
final decisi on.  P fizer will forward such decisions, which may  include summaries of 
aggregate anal yses of safety  data, to regul atory  authorities, as appropriate.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 7910.SUPPORTING DOCUME NTATION AND OPERATIONAL CONSIDERAT IONS
10.1. Appen dix 1: Regu latory, Ethical, and Study Oversi ghtConsiderations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protoc ol and with the following:
Consensus ethical principl es derived fro m international guidelines inc luding the 
Declaration of Helsinki and CI OMS International Ethical Guidelines;
Applicable ICH GCP guidelines;
Applica ble laws and reg ulations , including applic able privacy  laws .
The protocol, protocol amendments, ICD, SRSD( s),and other relevant documents 
(eg,advertisements) must be reviewed and ap provedby the Sponsor and 
submitted to an 
IRB/EC by  the investigator and reviewed and app roved by  the IRB/EC before the study  is 
initiated.
Any amendments to the protoc ol will req uire IRB/EC approval before imple mentati on of
c
hanges made to the study  desig n, except for changes necessary  to eliminate an immediate 
hazard to study participants.
The investigator will be re sponsible for the following:
Providing written summar ies of the status of the study  to the IRB/EC annual ly or
more frequently  in accordance w ith
the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the I RB/EC of SAEs or other sig nificant safet y findings as required by 
IRB/EC proced ures;
Provi ding oversight of the conduct of the study  at the site and adherence to 
requi rements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/20 14 
for clinical studies (if applicable), and all other applicable local regulations.
10.1.1.1. Reporting of Safety Issu es and Serious Brea ches of the Protoc ol or ICH GCP
In the event of an y pro hibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
informati on that mig ht influence the evaluation of the benef its a nd risks of the study  
interventi on,Pfizer should be informed immediately . 
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to prot
ect the study  participants against an y immed iate ha zard , and 
of an y serious breaches of this pro tocol or of ICH GCP that the investi gator becomes aware 
of.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 8010.1.2. Finan cial Disclosure
Investigators and sub- investigators will provide the Sponsor with sufficient, ac curate 
financi al information as requested to allow theSponsor to submit complete and ac curate
financial certification or disclosure statements to the appropria te regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 year after completion of the study .
10.1.3. I nformed Consent Process
The investigator or his/her representative will explain the nature of the study  to the 
participant and answer all questions regarding the study .  The par ticipant should be given 
sufficie nt time andopportunity  to ask questions and t o deci dewhether or not to participate in 
the trial.
Participants must 
be informed that their participation is vo luntary .Participants will be 
required to sign a state ment of i nformed consent that meets the re quireme nts of 21 CFR 50, 
local regulations, IC H guidelines, HI PAA requirements, where appl icable, and the IRB/EC 
or study center.
The investigator must ensure that each study  participant is fully  informed about the nature 
a
nd objectives of the study , the s haring of datarelated to the study ,and possi blerisks 
associated with participation, inc luding the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that h is/her pe rsonal study -related data will be used b y the
Sponsor in accordance with local data p rotection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined b y Clinica l 
Quality Assurance auditors or other au thorized personnel appointed by  the S ponsor, by
appropriate IRB/EC members , and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed a bout his or 
her right to access and correc t his o r her personal data and to withdraw con sent forthe 
processing of his or h er personal data.
The medical record must include a statement that written inf ormed consent was obtained 
before the participant was e nrolled i n thestudy  and the date the writ ten con sentwas obtained.
The authorized pers on obt aining the informed consent m ust also sign the ICD.
Participants must be reconsented to the most current ve rsion of the IC D(s) during their 
participation in the s tudy.
A copy of the IC D(s) must be provide d to th e participant.   Participants who are re screen ed
are required to sign new I CD(s).

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 81Unless prohibited by  local re quirements or IRB/EC decision, t he ICD wil l contain a separate 
section that addresses the use of samples f or optional additional research. The op tional 
additional research does not req uire thecollection of an y further samples.  The investigator 
or author ized designee will explain to each participant the objectives of the additional
research. Partic ipants wi ll betold that they  are free to refuse to participate and may  
withdraw their c onsentat any  time and for any  reason during the storage period.
A sep arate signature will be required to docume nt a participant's agreement to allow 
specimens to be u sed for additional research. Participants who de clin
e to participate in this 
optional addi tional research will not provide this separate signature .
10.1.4. Data Prote ction
All parties will comply  with all app licable laws, including laws regarding the implementation 
of org anizational and techn ical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper
form and will be password protected or secured in a locked room to ensur e that on ly 
authorized study  s taff have ac cess.  The study site will implement appropria te tec hnical and 
organizational measures to ensure that the personal da ta can be recovered in the event of 
disast er.  In the event of a potential personal data breach, the study sitewillbe responsible 
for det erminin g wh ether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required b y law.
To protect the rights and freedoms of participants with regard to the processing of person al 
data, part icipants w ill be assigned a single, part icipant-specific numerical code. Any 
participant records or data sets that are transferred to the S ponsor will contain the numerical 
code; particip ant names will not be transferred. All other identifia ble data transferred to the 
Sponsor will be ident ified by this single, participant- speci ficcode. The study  site will 
maintain a confidential list of participant s who participated in the study , linkin g each 
participant ’s numerical code to his or her actua l identit yandmedical record identificati on. In
case
of data transfer, the Sponsor wil l protect the confidentiality  of participant s’ personal 
data consistent with the c linical study agreement and app licable privacy  laws.
10.1.5. Dissemination of Clinical Study D
ata
Pfize r fulfills its commitment to publicly  disclos e clinical study  results through post ingthe 
results of studies on www.clinicaltrials.gov (ClinicalTrials .gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applica ble local
laws/regulati ons.  In addition, Pfizer repo rtsstudy  results outside of the re quirements of local 
laws/regulations pursuant to its SOPs.
In all cases , study  results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner a nd are re ported regardl ess of the outcome of the stud y or the country  in 
which the study was conducted.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 82www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer -sponsored interventional 
studies (conducted in patients) that eva luatethe safety  and/or efficacy  of a pr oduc t, 
regardless of the geographical l ocation in which the study  is conducted.  These r esults are 
submitted f or posting in accordance with the format a nd timelines set forth by  US law.
EudraCT
Pfizer posts clinical trial results on EudraCT for Pfiz er-sponsore d interventional studies in 
accorda ncewith the format and timelines set forth by  EU requirements.
www.pfi zer.com
Pfizer posts public disclosure s ynopses (CSR sy nopses in which any  data that could be used 
to identify individual participants have been r emov ed)on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/ submissio ns
Pfizer complies with the Europ ean Uni on Policy  0070, the proactive publicati on of clinical 
data to the EMA website.  Clinical data, under Phase 1 o f this policy , includes clinical 
overview s, clinical summaries, CSRs, and appendices containing t he protoc ol and protocol 
amendments, sampl
e CRFs, andstatistical methods.  Clinical data, under Phase 2 of this 
policy , includes the publishing of individual 
participant data.  Policy  0070 applies to new 
marketing authorization applications submitted via the centr alized procedure since 
01January 2015 a nd applications for line extensions and for new indications submitted via 
the centralized procedure since 01 J uly 2015.
Data Sharing
Pfizer provides re searchers secure access to patient -level data or full CS Rs for the pu rposes 
of “bona -fide scientif ic rese arch” t hat contribute sto the scientifi c understanding of the 
disease, target, or compound class. Pfizer will make available data from these trials 
24months after study  completion.  Patient -level data will be anon ymize din accordance with 
applicable privacy  laws and regulations.   CSRs will ha ve personall y identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Researchteams must include a biosta tistici an. Data will not 
be provided to appli cants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 8310.1.6. Data Quality Assurance
All participa nt data r elating to the stud y will be recorded on printed or electronic CRF unless 
trans mit
tedto the S ponsor or designee electronically  (eg, laboratory  data). The investigator 
is responsible for veri fying that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
The in
vestigator must maintain accurate docum entation (source data) that supports the 
information entered in the CRF .
The investigator must ensure that the CR Fs are securel y stored at the study site in encry pted 
electronic and/or paper form and are passwo rd protecte d or secured in a locked room to 
prevent access by unauthorized third parties.
The investigator must permit study -related mon itoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct ac cess to source data documents.   This 
verificati
on may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available during the monitor ing visits and possible audits or 
inspections and that sufficien t time is devoted to the process.
Monito ringdetails describing strategy (eg, r isk-based initiatives in operations and quality  
such as risk management and mitigation strategies and a nalytical r isk-based monitoring), 
methods, responsibilities ,and requireme nts,including handling of noncom pliance issues and 
monitoring techniques (cent ral, remote, or on- site monitoring) ,are provided in thestudy 
monitori ng plan. 
The Sponsor or designee is resp onsible for the data management of this study ,inc
ludin g 
quality checking of the data.
Study  moni tors wi ll perform ongoing source data verifica tion to confirm that data entered 
into the CRF by  authorized site perso nnel are accurate, complete, and verifiabl e from source 
documents; that the safety and right s of participa nts are being protected; and that the st udy is 
being conducted in accordance wi th the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable regulatory  require ments.
Records and documents, including signed IC Ds, pertaining to t he conduct of this study  must
be ret ained
by the investigator for 15years after study  completion unless local regulations or 
institutional polici es require a longer retention period. No records may  be destroy ed during 
the retention peri od wi thout the written approval of the Sponsor. No re cords may be 
transferred to another loc ation or part y without written notification to the Sponsor .The 
invest igator must ensure that the records contin ue to be stored securel y for aslong as they  are 
mainta ined.
Whe n par ticipant data are to be dele ted, th e inves tigator will ensure that all cop iesofsuch 
data are promptly  and irrevocabl y deleted from all systems.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 84The investigator(s) will notify theSpons or or its agents immediatel y of an y regulatory 
inspecti on notifi cation in relation to the study . Furthe rmor e , the investigator will cooperate 
wit
h the Sponsor or its agents to prepare the investigator site for the inspection and will allow 
the 
Sponsor or its agent, whenever feasible, to be present during the inspectio n.  The 
investigator site and inv
estigat or willpromptly  resolve any  discrepanc iesthat are identified 
between the stud y data and the participant 's me dical records.  The investigator will prom ptly 
provide copies of the inspection findings to the S ponsor or itsagent.  Before response 
subm ission to t he regulatory  authorities, the inve stigator will provide the S ponsor or its 
agents with an opportunity to review and comment on responses to an y suc h findings.
10.1.7. Source Documents
Source documents provide e vidence f or the existence of the participa nt and substantiate the 
integrit y of the data col lected. Source document s are filed at the investigator site.
Data r eported on the CRF or entered in the eCRF that are from source document s must be 
consistent with the sourc e documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
The investi gator must maintain accura te docum entat ion (source data) that suppo rts the
information entered in the CRF.
Definit ionofwhat constitutes source data can be found in the c linical monit oring plan.
Description of the use of compu terized sy stem is documented in the Data Management 
Plan.
10.1.8. Study and Site Start and Closure
The s tudy start date is the date on which the clinic al stu dy will be open for recruitment of 
participants.
The first act o f recruitment is the date of the f irst part icipant’s first visit and will be the study  
start date.
The Sponsor designee reserves the right to clos e the study site or terminate the study  at an y
time for an y reason at the sole discretion of the Sponsor. Study sites will be closed upon 
study completi on. A study  site is considered closed when all require d docume nts and study  
supplies have been collect ed an da stud y
-site closure visit has be en performed.
The investigator may  initiate study -site closure at any  time upon notification to the Sponsor if 
requested to do so b y the responsible IRB/EC or if such terminat ion is required to protect the 
health of s tudy participants.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 85Reasons for the earl y closure of a stud y site b y the Sponsor may  include but are not limi ted 
to:
Failure of the investigato r to compl y with the protocol, the requirements of the 
IRB/EC or local h ealth authorities, the Sponsor's procedu res, o rGCP guidelines ;
Inadequate recrui tmentof participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the Sponsor s hall pr omptly inform the 
investigators, the ECs /IRBs, the regulatory  authorities, and an y CRO(s) used in the study  of 
the reason for termination or suspensio n, as specified by  the applicable regulatory
requirements. The investigator shall promptly  inform the par ticipa nt and should assure 
approp riate 
partici pant therapy  and/or follow - up.
Study termination is also provided for in the clinical study  agreement.  If there is an y conflict 
between the contrac t and this protocol , the contract will control as to terminati on rig hts.
10.1.9. Publication Policy
Theresult s from Part1and Part 2 are envisioned t o be presented as a single pooled dataset at 
the end of the trial at a scientific meeting.  Bey ond this, the results of this study  may  be 
published or presented at scie ntific meetin gs by the investigator afte r publi cation of the 
overall study
 results or 1 year after the end of the study  (or stud y termination), whichever 
comes first. 
The investigator agree s to refer to the primary  publication in any  subsequent publicati ons 
such as s econdary  manuscripts, and s ubmits all ma nuscripts or abstracts to the Spons or 
30
days before submission. This allows the Sponsor to protect pro prietary  information and to 
provide comments and the investigator will, on request, remove an y prev iously  undisc losed 
confidential informat ion bef ore di s
closure, except for any  study -or Pfizer
intervention- related information necessary  for the appropriate scientific presentation or 
underst anding of the study  results.
For all publications relating to the stud y, the investigator will compl y with reco gnized ethical 
standards concerning publi cations and authorship, including those established by  the 
Internatio nal Committee of Medical Journal Ed itors.
The Sponsor will comply with the requirements for publica tion of the overall study  results 
coveri ng all invest i g ator sites. In accordance with s tandar d editorial and ethical practice, the 
Sponsor will support publ ication of multicenter studies only  in their entirety  and not as 
individual site data. I n this case , a coo
rdinat ing investigator will be de signate d by mutual 
agreement. Authorship of pub
licationsfor the overall study  results will be determined by  
mutual agreement and in line with I nternatio nal Com mittee of Medical Journal Editors 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 86authorship requiremen ts. Ifpubli cation is addressed in the clinica l stud yagreement, the 
publication policy set out inthis section will not apply .
10.1.10.
Sponsor’s Qualified Medical Personnel
The contact information for the Sponsor's appropriately  qualified medical personnel for the 
study is d ocumented in the study  cont act list located inthesupporting study  documen tation.
To facilitate access to appropriatel y qualified medical pers onnel on study -related medical 
questions or problems, participant s are provided with a contact card at the time of informed 
consent .  The c ontact card c ontains, at a minimum, protocol and studyi ntervention
identifiers, participant numbers, contact informa tion for the investigator site, and contact 
details for a contact center in the event that the inve stigato r site staff cannot be reached to
provide advi ceon a medical question or problem originating from another healthcare 
professional not involved in the participant ’s participation in the study .  The contact number 
can also be used b y investigator sta ff if t hey are
seeking advice on medical questi ons or
problems; however, it should be us ed only in the event that the established communication 
pathway s betw een the investi gator site and the study  team are not available.  I t is therefore 
intended to augmen t, but not re place, the established comm unicati on pat hways between the 
investigator site and thestudy  team for advice on medical questions or problems that may 
arise durin g the stud y.  The contact num ber is not intended for use b y the participant directl y
, 
and i f a participant calls that number , he or she w ill be directed back to the investi gator site.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 8710.2. Appendix 2: Clinical Laboratory Tests
Table6 delineates the protocol mandat ed safety related laboratory tests and exploratory 
biom arkers to be collected following an overnight f ast of ≥8hours .The required blood and 
urine collections will be performed at times defined in SoA -Table 2. Additional laboratory  
results may be reported on these samples as a result of the method of anal ysis or the ty pe of 
analyzerused by the cli nical laboratory , or as der ived from calculated values.  These 
additional t ests would not require additional collection of blood.  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perce ived safet y issu es.
Investigators must docu ment their review of each laboratory  safet y repo rt.
Laboratory/anal yte results that could unblind the study  will notbe reported to investigator 
sites or other blinded personnel until the study  has been unblinded.
Table 6. All Plann ed Protocol Required Safety -Related Laboratory T ests a nd 
Exploratory Biomarkers in Study C3711005
Hem atology Chemistry Urinalysis
Hem oglobin
Hem atocrit
RBC count
Reticulocyte count (Abs)
MCV
MCH
MCHC
Platelet cou nt
WBC cou nt
Total neutrophils (Abs)
Eosino phils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymp hocytes (Abs)BUN
Creatinine
Cystatin -C (and eGFR using 
CKD -Epi-Cystatin -C)
Plasma Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST (SGOT)
ALT (SGPT)
Total bilirubin
Alkaline ph osphatase
GGT
Direct (conjugated) bilirubin
Indirect (unconjugated) bilirubin
Total bile acids
Creatine Kinase
Uric acid
Albumin
Total protein−pH
−Glucose (qual)
−Protein (qual)
−Blood (qual)
−Ketones
−Nitrites
−Leukocyte estera se
−Urobilinogen
−Urine bil irubin
−Microscopya

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 88Other 
HbA1C
Coagulation (Plasma aPTT, PT, INR)
Serum FSHb
Serum and urine pregnancy test (refer to Section 8.2.6 )
Urine drug testc
  1-antitrypsind
ceruloplasmind
Serology :dHBsAg, HCVAb (and if p ositive, refl ex HCV RNA), HIV
%CDTe
Fasting serum L ipid Panelf
Additional exploratory bioma rker
asses smentsginclude:
Seru m apolipoproteins A1,Btotal, B100, B48,
C3,E,and direct VLDL
−Plasma Insulin
−hs-CRP
CK18 -M30, CK18 -M65
ProC3 andProC6
Plasma PCSK9
Adiponectin
Pre-Specified PGx andPrep D1(DNA)
Prep B1.5 (plasma) and B2 .5 (serum) for 
mechanistic/ disease -related bioma rkers Additional Tests for instances of suspected Hy’s Law [refer to 
Appendix 10.6]: 
ALT, AST ( repeat )
Total bilirubin (repeat)
Albumin (repeat)
Alkaline phosphatase (repeat)
Direct bilirubin
Indirect bilirubin
Creatinine kinase
GGT
PT/INR
Total bile acids
Acetaminophe n drug and/or protein adduct levels
a.Only if urine dipstick is positiv efor bloo d, pro tein, nitrites orleukocyte esterase .
b.Only in females, at PreQ ,and SCR, only .
c.AtPreQ ,SCR, and Baseline/Visit 3, only;minimum requirement for urine drug test include cocaine,
opiates/opioids, benzodiazepines and amphetamines .
d.AtPreQ, a nd SCR , only .
e.AtPreQ ,SCR, Day 1/Visit 4,and Week 6/ Visit 7 .
f.Includes triglycerides, HDL-C, direct LDL -C, and total cholesterol .
g.At Baseline/Visit 3 and onwar ds, as per SoA -Table 2.
For list of terms correspond ing to the abbreviations used her ein, refer to Appendix 10.12 .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 8910.3. Appendix 3: Adverse Events: D efinitio ns and Procedures for Rec ording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definit ion of AE
AE Definition
An AE is a ny untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study interve ntion, whe ther or not 
considered related to the study  intervention.
NOTE: An AE can therefore b eany unfavorable and unintended si gn (including an 
abnormal labor atory finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of 
study  intervention .
Events Meeting the AE Definition
Any abnormal laboratory test results (h ematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiol ogica l scans, vital sign measurements), 
including those that wor sen from baseline , consid ered clinicall y significa nt in the 
medical and scientific judgment of the inv estigator .  An y abnormal laboratory test 
results that meet an y of the conditions below mus
t be recorded as an AE:
Is associated with accompany ing s ymptoms.
Requi res additi onal diagnostic testing or medica l/surgical intervention .
Leads to a change in study  
dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the st udy, significant additional 
concomitant drug treatment, or other therap y
.
Exacerbation of a chronic or intermitten t preexisting condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed afte r study  intervention administration even 
though it may  have been presen t before t he start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -
drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of eit her s
tudy 
intervention or a concomitant medication. Overdose pe r se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicid al/self-harming intent. Such overd oses should be reported regardle ss of 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 90sequelae.
Events NOT Meeting the AE Definition
Any clinically  significant abnor mal lab oratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
inves tigator to be more severe than e xpected for the partici pant’ s condition.
The disease/disorder being studied or expected progre
ssion, sig ns, or s ymptoms of 
the disease/di sorder being studied, unless more severe than expected for the 
participant’s condi tion.
Medical or surgical procedure ( eg, endoscop y, appendec tomy): the condition that 
leads to the procedure is the AE.
Situations in which a n untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting dise ase(s) or condition(s) prese nt 
or detected at the start of the study that do not worsen .
10.3.2. Definition of SAE
If anevent is not an AE per definition above, then it cannot be an SAE even if ser ious 
conditions are met (eg, hospitalization for signs/sy mptoms o f the disease under stu dy, death 
due to progression of disease).
AnSAE is defined as a ny unto ward medic al occur rence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was a t risk of death at the time of the event. It does not refe r to an event tha t
hypothetically  might have cause d death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In gene ral, hospitalization si gnifi es that the participant has been detained (usually  
involvin g at le ast an ove rnight s tay) at the hospital or e mergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpat ient setting.   Complica tions that occur during hospitalization are AEs.   If a 
complicat ion prolongs hospitalizati on or fulfills any other serious criteria, the event is 
serious. When in do ubt as to whether “hospitalization” occurred or was necessary , the AE 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 91should be considered serious.
Hospitalization for elective treatment of a preexistin g condi tion that did not worsen from 
baseline is n ot considered an AE.
d.Results in persistent disabili ty/incapacity
The term disability  means a substantial disruption of a person’s ability
 to condu ct 
normal life functions.
This definition is not intended t o include experie nces of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  inter fere with or 
prevent every day life functions but do not constitu te a su
bstantial disrupti on.
e.Is a congenital anom aly/birth defect
f.Other situations:
Medical or scienti fic judgment should be exercised in deciding whether SAE 
reportin g is appropriate in oth er situations such as important medical events that 
may not be immediat ely life-threateni ng or result in death or hospitalization but 
may jeopardize the participant o rmay require medical or surgical i ntervention to 
prevent one of th e other outcomes listed in the above definition. These events 
should usually  be consid ered se rious.
Examples of such events include inva sive or malignant cancers, intensive treatment 
in an emergency  room or at home for alle rgic bronchospasm, blood dy scras ias or 
convulsions that do not result in hospitalization, or development of drug 
depend ency  ordrug abus e.
10.3.3. Reco rding /Reporting and Follo w-up of AE sand/or SAE s
AE and SAE Recording /Reporti ng
The table below summarizes the requirements for recording adve rse events on the CRF an d 
forreporting serious adverse events on the CT SAE Report Form to Pfi zer Safety .  These
requirements are delinea ted for 3 t ypes of events: (1) SAEs; (2) nonserious adverse events 
(AEs); and (3) expos ure to the study  intervention under study  during pregna ncy or 
breastfeeding, and occupational exposure. 
It should be n
oted th at the CT SAE Repor t Form for reporting of SAE information is not 
the 
same as the AE page of the CRF.  When the same data are coll ected, the forms must be 
comple ted in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the s ame AE ter m should be used on both the CRF and the CT SAE 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 92Report Form for reporting of SAE info rmation.
Safety Event Recorded on t he CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety W ithin 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure t o the st udy 
intervention under st udy 
during pregnancy  or 
breastfeeding, and 
occupatio nal exposureNone All (and EDP supp lemental 
form for EDP)  
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentati on (eg, hospital progress notes, laboratory  report s, and diagnostic 
reports) related to the event.
Theinvestigator will then record all relevant AE/SAE information in the CRF.
It is notaccep table for the investigator to send photocopies of the participan t’s 
medical recor ds to Pfizer Saf ety in lieu of completion of the CT SAE Report 
Form /AE/SAE CRF page.
T
here may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety . In this case, all participant identifiers, with t he 
exception of t he parti cipant n umber, will be re dacted on the copies of the medical 
records before s ubmission to Pfizer Safety .
The inv
estigator will attempt to esta blish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informatio n. Whe never poss ible, th ediagno sis 
(not the indi vidual signs/sy mptoms) will be documented as the AE/SA E.
Assessment of Intensity
The investigator will make an asse ssment of intensity  for e ach A E and SAE reported 
during the stud y and assign it to 1 of t he foll owing cate gories: 
Mild : An event that is e asily  tolerated by the participant, causing minimal 
discomfort and not interfering with every day activities.
Moderate : An event that causes su fficient discomfort and interferes with normal 
every day activiti
es.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 93Severe: An ev ent that prevents normal every dayactivities. An AE that is assessed 
as severe shoul d not be confused with an SAE. Severe is a category  utilized for
rating the intensit y of an ev ent; and both AEs and SAEs can be assessed as severe.
An ev ent is 
defined as “seriou s” when it meets at least 1 of the predefined outcomes as 
described in the defi nition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investi gator is obligated to assess the relationship between stud y inte rventio n 
and each occurre nce of each AE/SAE.
A “re asonable possibility” of a relationship convey s that there are facts, evidence, 
and/or 
arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use c linical judgment to deter mine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk fa ctors, as well as the temporal relationship of the even t to study  intervention 
administration, will be considered and investig ated.
The investiga tor will also consult th e IB and/or product information, for marketed 
produc ts, in his/her ass essment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an as sessment of causa lity.
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in th e initial report to the Sponsor. However, it is 
very i mportant that the investigator always make an assessment of caus ality 
for every e vent bef ore the initial transmiss ion of the SAE data to the Sponsor .
The investigator may change his/her opinion of caus
ality in light of follow -up 
information and send a nSAE follow-up report with the updated causality  
assessment.
The cau sality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  inte rventi oncaused the 
event, then the event will be handled as “related to study  intervention ” for repor ting 
purposes, as defined by  the Sponsor .  In addition, if the investigator determines that 
an SAE is associated with study  proced ures, the investigator m ust re cord this causal 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 94relationship in the source documents and CRF, and report such an assessm ent in the 
dedica ted sect ion of the CT SAE Report 
Form and in accordance with the SAE 
reporting requir ements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange f or the conduct of supplemental 
measurements and/or evaluations a s medic ally indic ated or a s requested by  the 
Sponsor to elucidate the nature and/or causalit y of the A Eor SAE as full y as 
possible. This may include additional labor atory  tests or investigations,
histopathological examinations, or consultation with other health
care provi ders.
Ifa participant dies durin g participation in the study or during a recognized 
follow -up period, the investigator will make attempts to locate, where applicable, 
and pro vide Pfizer Safet y with a cop y of an y postmortem findings includ ing 
his
topatholog y. 
New or updated information wi ll be recorded in the originally  completed CRF.
The i
nvestigator will submit any  update d SAE data to the Sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Saf etyviaCT SAE Re port For m
Facsimile transmission of the CT SAE Report Form is the preferred method to
transmit this information to Pfizer Safety .
In circumstances when the fac simile is not w orkin g, notification by  telephone is 
acceptable with a cop y of the CT SAE Report Form sen tby overnight mail or 
courier service.
Initial not ification via telephone does not replace the need for the inv estigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 9510.4. Appendix 4: C ontrace ptive Guid ance 
10.4.1. Male Participant Reproducti ve Inclusion Criteria
No c ontraception methods are r e
quired for male participants in this study , as the calculated 
safety margin is >100
-fold betwe en the estimated maternal exposure due to seminal transfer 
and the NOAEL for serious manifestations of develo pmental toxicity  in noncli nical studies 
with DGAT2i and ACCi.
10.4.2. Female Participant Reprod uctive Inclusion Criteria
A female participant is eligi ble to participate if she is not pregnant or breastfeeding, and at 
least 1 of the followi ng conditions applies:
Isnot a WOCBP (see definiti ons below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly  effective (with a failure
rate o f <1% per year), preferably with low user d ependency , as described below 
during the interventio nperiod and for at least 28days after the last dose of study  
intervention, which corresponds to the time needed to eliminate any  reproductive 
safet y risk of thestudy  interventi on(s). The investigator should evaluate the 
effectiveness of the contracepti
vemethod in relationship to the fi rst dose of study  
intervention.
The invest igator is responsible for review of medical history , menstrual history, and r ecent 
sexual acti vity to decrease the risk for inc lusion of a woman with an earl y undetected 
pregnancy .
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see bel ow).
Iffertility is uncl ear (eg, amenorrhea in ad olescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, addition al evaluation should be 
consi dered.
Women in the following categories are notconsidered WOCBP:
1.Premenarc hal.
2.Premenopausal female with 1 
of the following:
Documented h ysterectomy ;
Documente dbilateral salpingectomy ;

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 96Document ed bilateral oophorectom y.
Forindividuals with permane nt infertility  due to an alternate medical cause other than 
the above, (eg, mulle rian age nesis, androgen insensiti vity), investigator discretion 
should be applied to determining study  entry .
Note : Docu
mentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical record s, medi cal examin ation, o r
medical history  intervi ew. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
3. Postmenopausal female:
A postmenopausal state is defined as no menses for 12 months without an 
alternat ive med ical cause . In addition, a
High FSH level in the postmenopausal range must be used to confirm 
a
postmenopausal state in women und er 60 years of age and not using hormonal 
contraception or HRT. 
Female on HRT and whose menopausal status is in doubt will be required to 
use o ne of the non -estrogen ho rmonal highl y effective contraception methods 
if the ywish to continue their HRT during the study . Other wise, they  must
discontinue HRT to al low c onfirmation of postmenopausal status before study  
enrollmen t.
10.4.4. Cont raception Methods
Contraceptive use b y men or women should be consistent with local availability/ regulations 
regarding the use of contraceptive methods for those participating in clinic al trials.
1.Implantable progestogen -only hormone contraception as sociate d with inhibition of 
ovulation.
2.Intrauterin
e device.
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion.
5. Vasectomize d partner :
Vasectomized partner i s a highl y effective c ontra ceptive method provided that the 
partner is the sole sexual partne r of the w oman of childbearing potential an d the 
absence of sperm has been confirmed. If not, an additional highly  effective 
method of contra ception should be used. The spermatogenesi s cycle is 
approximately  90days.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 976.Combined (estrogen- and progestogen-c ontaining) hormona lcontraception associate d 
with inhibition of ovulation:
Oral;
Intravaginal;
Transdermal;
Injectable.
7.Progestoge n-onl y hormon e contraception associated with inhibition of ovulation:
Oral;
Injectable.
8.Sexual abstinence:
Sexual absti nence i s consider ed a hig hly effective method only if defined as 
refraining from heterosexual intercou r
se during the entire period of risk associated 
with the study  interve ntion. The reliabil ity of sexual abstinence needs to be 
evaluated in relation to th e durat ion of the study  and the preferred and usua l 
lifesty le of the participant.
In addition, one of the following effective barrier met hods must also be used when 
option 6or 7 are chosen ab ove:
Male orfemale condom with or without spermicide;
Cervical cap, di aphragm, orsponge with spermicide;
A combi nation of male condom with either cervical cap, diap hragm, or sponge with 
spermicide (d
ouble -barrier methods ).

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 9810.5. Appendix 5: Genetics
Use/Analys is of DNA
Genetic variation may  impact a participant’s response to stud y interven tion, 
susceptibility  to, and seve rity and progression of disease. Therefore, where l ocal 
regulations and IRB s/ECsallow , a blood sample will be collected 
for DNA anal ysis.
The sco pe of the genetic research may  be narrow (eg , 1or more can didate genes )or 
broad (e g,the entire genome ), asappropriate to the scientific question under 
invest igation.
The samples may  be analy zed as part of a multistudy  assessme nt of genetic factors
involved in the response to the study  intervention or study  interventi ons of thi s class 
to understand treatments for the disease(s) under study  or the disease(s) the mselves.
The results of genetic ana lyses may  be reported in CSR or in a separate study  
summary  or may  be used for internal decision making without being i ncluded in a 
study report .
The Sponsor will store the DNA samples in a secure storage space with adequat e 
measu res to protect confidentia lity. 
The samples will be retaine d as indicated:
Sampl es forspecif ied genetic anal ysis (see Section 8.7.1 ) will be stored for up to 
3years after regulatory  approval or other period as per loc al requirements .
Samples for bankin g will be stored ind
efinitely or for an other period as per local 
requirements.
Participant s may  with draw the ir consent for the storag e and/or use of their Banked 
Biospecimens at any  time by makin ga request to the invest igator; in this case, an y 
remaining material will be de stroy ed.  Data already  generated from the samples will 
be retained to p rotect the integri ty of existing analyses .
Banked Biospecimens will be labeled with a code.  T hekey between the code and the 
participant ’s personally  identify ing information (eg ,name , add ress) will be held at the 
study  site and will not be provid ed to t he sample 
bank .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 9910.6. Ap pendix 6: Liver Safety: Suggest ed Actions and Follow -up Assessments 
Potenti alCases ofDrug -Induced Liver I njury
Huma
ns exposed to a drug who show no sign of liver i njury (as determined by  elevations in 
transaminases) are termed “tolera tors,” whi le those who show transient liver injury , but adapt 
are termed “adaptors.”  In some par ticipan ts, transaminase elevat ions are a harbinger of a 
more serious potential outcome. Thes e participant s fail to adapt and therefore are 
"susceptible " to pr ogressive and seri ous liver injury , commonl y refer red to as DILI.  
Participant s who experience a transam
inase elevation above 3 ×ULN sh ould be monitored 
more frequently  to determine if they are an “adaptor” or are “susceptible.”
In the majority  of DILI ca ses, eleva tions in AST and/or ALT precede T Bili elevations 
(>2×ULN) b y several day s or weeks.  The in
crease in TBili ty picall y occurs while 
AST/AL T is/are still elevated above 3 ×ULN (ie, AST/AL T and TBili values will be 
elevated within the same laborat orysample ).  In r are instances, b y the tim e TBili elevations 
are detected, AS T/ALT values might have decr eased.  This occurren ceis still regarded as a 
potential DILI.  Therefore, abno rmal 
elevations in either AST OR ALT in addition to TBili 
that m eet the criteria outlined below are considered pot ential DILI (assessed per Hy ’s law 
criteria) cases and shoul d alway s be considered i mportant m edical events, even before all 
other possible ca uses of liver injury  have been excluded.
The threshold of labora tory abnormalitie s for a potential DILI case depen ds on the 
participant ’s individual baseline values and under lying conditions.  Parti cipants w ho present 
with the following laboratory  abnormal ities should be evaluated further as potential DILI 
(Hy’s law) c ases to definitiv ely dete rmine the etiology  of the abnormal laboratory  values:
Partic ipant s with AST/ALT and T Bilibaseline values wit hin the n
ormal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2×ULN with no evidence of hemoly sis and an alkali ne phosphatase value 
<2×ULN or not available.
For partici pants with baseline AST OR ALT ORTBili values ab ove the U LN, the 
following threshold values are used in th
e definition mentioned above, as needed, 
depending on which valu es are above the ULN at baseline:
Preexisting AST or ALT baseline values above the no rmal range: AST or ALT 
values >2 times the baseli nevalues AND >3 × ULN; or >8 × ULN (whichever is 
smaller) .
Preexisting values of TBili above the normal range: TBili leve l incre ased from 
baseline value b y an amount of at least 1 × ULN or if the value reac hes >3 ×ULN 
(whichever i s smaller).

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 100Rises in AST /ALT and T Bili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case whe re unce rtainty  remains as to whether it 
represents a potential Hy’s law case should b e reviewed with the Spons or.  
The participant should retu rn to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of th e abnor mal result s.  This evaluation should 
includ e laboratory  tests, detailed histor y, and ph ysical assessmen t.
In addition to repe ating mea surements of AST and AL T and TBili for suspected ca ses of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase.  Considerat ionshould 
also be given to drawi ng a separate tube of clotted bloo d and an anticoag ulated tube of blood 
for fur ther testing, as needed, for further cont emporaneous anal yses at the time of the 
recognized initial abnormalities to de termine etiology .  A deta iled history , including relevant 
information, such as review of eth anol, acetaminoph en/paracetamol (either by  itself or as a 
coformulated product in pres cription or over -the-counter medications) , recreational drug, 
supplement (herbal) use and consumption, fam ily history , sexual history , travel history , 
history  of contact with a jaundiced person, surgery , blood trans fusion, history  of liver or 
allergic dise ase, and potential occupational exposure to chemicals, should be collected.  
F
urther testing for acute hepatitis A, B, C, D, an d E infec tion and liver imaging (eg, biliary  
tract) and coll ection of serum samples for acetaminophen /paracetamol drug and/or pro tein 
adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laborator y criteria of AST/AL T and 
TBili e levation defined above should be considered potenti al DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availabili ty of all the results of the 
investigations performed to determine etiolog y of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case only after all results of 
reasonable investigations have bee n received and have exclu dedan alt ernative etiol ogy.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 10110.7. Appe ndix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as Adverse Events
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTc F to > 480 msec (absolute) or by≥60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate:
ie,rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’ durat ion.
Frequent PVCs, triplets, orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG Findings T hat May Q ualify as Serious Adverse Events
QTcFprolongation >500 msec.
New ST -Tchanges suggestive of myocardial ischemia .
New -onset l eft bundle branch block (QRS >120 ms ec).
New -onset right bundle branch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free patients in sinus rhy thm, with documented periods of 
asystole ≥3.0 seconds or any  escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node ;
In awake, sy mptom -free patients with atrial fibrillation and brad ycardia with 
1or more pauses of at least 5 seconds or longer;
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .
Ventricular r hythms >30 seconds’ duration, including idioventricu lar rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm ( HR40bpm to 

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 102<100 bpm), and monomor phic/poly morphic ventricular tach ycardia (HR >100 bpm 
(such as torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree ) heart block.
ECG Findings T hat Q ualify as Serious Adverse Events
Change in pattern suggestive of new myocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibr illation with rapid ventricular r esponse requiring cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experi ence.
The enumerated list of major events of potential clinical concer n are recommended as “ alerts ”or 
notifications from the core ECG lab oratory to the investigator and Pfizer study team ,and not to be 
considered as all inclusive of what to be reported a s AEs/SA Es.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 10310.8. Appendix 8: Strong CYP3A Inhibitors and Inducers
This li st is not considered as exhaustive. Any questions regarding use of CYP3A inhibitors 
and inducers should be directed to the Sponsor study  team.
CYP3A Inhibitors CYP3A Inducers
HIV antivirals HIV antivirals
Indinavir Nevirapine
Nelfinavir Miscellaneous
Ritonavir Barbiturates
Saquinavir Carbamazepine
Boceprevir Glucocorticoids (systemic)
Lopinavir/ritonavir Oxcarbazepine
Amprenavir Phenobarbital
Atazanavir Phenytoin
Telaprevir Rifabutin
Darunavir/ritonavir Rifampin
Fosamprenavir St.John's wort3
Tiprinavir/ritonavir Troglitazone
Antibiotics Nafcillin
Clarithromycin Avasimibe4
Troleandomy cin Enzalutamide
Telithromycin Mitotane
Anti -infective
Itraconazole
Ketoconazole
Posaconazole
Voriconazole
Miscellaneous
Nefazodone
Grapefruit juice1
Conivaptan
Mibefradil2
Idelalisib
1.Theeffect ofgrapefruit juice varies widely among brands andisconcentration -,dose-, andpreparation -
dependent. Studies have shown thatitcanbeclassified asa“strong CYP3A inhibitor” when acertain
preparati onwasused (eg,high dose, double strength) orasa“moderate CYP3A inhibitor” when another
preparation wasused (eg,lowdose, single strength).
2.Withdrawn from theUnited Statesmarket.
3.Theeffect ofSt.John’s wort varies widely andispreparation -depen dent.
4.Notamarketed drug.
Reference: U.S. Food and Drug Administration. Drug Development and Drug Interactions: 
Table ofSubstrates, Inhibitors andInducers, available at:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Dr ugInt er
actionsLabeling/ucm093664.htm .

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 10410.9. Appendix 9: Guidance to Investigators –Management of Individual Participants 
Glycemic Control –including Metformin Dose Starting at Run -In/Visit 2  
Is Participant with T2DM 
onMetformin at SCR ? 
Is TDD > 1 gm per day?No Yes
Starting at Run -In/Visit 2, participant must 
agree to drop TDD by one-third orone-
half, guided by available tablet strengthsIsFasting Plasma Glucose > 270 mg/dL [15 mmol/L ] at any visit between Week 2/Visit 5
and Week 6/Visit 7 , inclusive, as assessed via Sponsor -identified central laboratory?
No Yes
Participant to be Screen Failed 
Andmetformin dose returned to 
be same as prior to Run- In/Visit 2At Baseline/Visit 3 (orrepeat, if done ), is FPG result 
≤ 270 mg/dL (15 mmol/L)?
Yes NoNo Yes
Continue to next 
Scheduled VisitArrange for an unplanned visit 
within 5 ±2 days of receipt of 
results from scheduled visit 
and re-assess FPGIs Participant on 
Metformin? 
Increase dose to match 
TDD prior to Run -In/Visit 2Yes
No
If unplanned visit fasting result is 
>270 mg/dL [15 mmol/L ], withdraw participant from study
≤270 mg/dL  [15 mmol/L], continue to next Scheduled Visit [though, at investigator 
discretion, additional unplanned visit(s) before next Scheduled Visit permitted]  

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 10510.10. Appendix 10: Guidance to Investigators –Management of Indivi dual 
Participants w ith Elevation in Fasting Serum Triglycerides
Serum Triglyceride result at Visits startin g at Day 1/V isit 4 to Week 6/V isit 7, in clusiv e, 
as assessed  via Sponsor -identi fied central  laboratory is…
Was Scheduled Visit collection post ≥ 8-hr ov ernight fast?
Yes No
Arrange for an unpla nned visit within 5 ±2 days 
of receipt of results from scheduled visit
Collect lipid panel post ≥ 8 -hr ov ernight fast≥ 600 and< 800 mg/ dL
[≥ 6.8 and< 9.0 mmol /L]≥ 800 mg/dL
[≥ 9.0 mmol /L]
Participan t to return for next 
Scheduled Visit post ≥ 8 -hr
overnight fastWas Scheduled Visit collection post ≥ 8-hr ov ernight fast?
Yes No
Ifunplanned visit result is…
•≥ 600 and < 800 mg/ dL[≥ 6.8 and< 9.0 mmol /L]
•Particip ant to return for nex t scheduled visit post ≥ 8 -hrovernight fast
•At Investigator discretion , addition al unplanned  visit(s) before next Scheduled Visit permitted
•≥ 800 mg/dL[≥ 9.0 mmo l/L]
•Particip ant should be withdrawn from study Particip ant should be 
withdrawn from stud y

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 10610.11. Appendix 11: Guidance to Investigators – Management of Individual 
Participants With Decrease in Platelet Count
Platelet Count resu lt at Visits starting  on Day 1/V isit 4 to Week 6/Visit 7, inclusiv e, 
as assessed via Sponsor -identified central lab oratory is…
Was Sched uled Visit resu lt represen ting 
a continued decl ine relative to resu lt(s) 
from prior v isit(s)?
Yes No
Arrang e for an un planned visit within 5 ±2 days 
of receip t of resul ts from scheduled visit
Collect hematolog y panel≥ 75,000 per mm3
And < 100,000 per mm3< 75,000 per mm3
Participan t to retu rn for 
next Scheduled VisitWas Schedu led Visit result representin g 
a conti nued decli ne relative to resul t(s) 
from prior visit(s)?
Yes No
Ifunplanned visit result is…
•≥ 75,000 and< 100,000, per mm3
•Participant to return for nex t Scheduled Visit 
•At Investi gator di screti on, additional unpla nned  visit(s) before next Scheduled Visit permitted
•< 75,000 per mm3
•Withdraw participan t from study Withdraw participant from study

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 10710.12. Appendix 12: Abbreviations
The following is a list of abbreviations that may be used in the protocol.
Abbrev iation Term
%CDT percent carbohydrate deficient transferrin relative to total transferrin
A1AT Alpha -1-antitrypsin
ABCG2 constitutively expressed ATP-binding cassette transporter
Abs Absolute
ACC acetyl -CoA carboxylase
ACC i acetyl -CoA carboxylase inh ibitor (PF -05221304)
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase 
ANCOVA Analysis of Covariance 
Apo Apolipoprotein
aPTT activated partial thromboplastin t ime
AST aspartate aminotransfer ase 
ATP adenosine triphosphate
AUC 0-24 area under the concentration -time curve from time 0to 24 hours
AUC inf area under the concentration -time curv efrom time 0to infinity
AUC tau area u nder the concentration -time curve from time 0to end of dosing period
AUDIT Alcohol use disorders identification test
AV Atrioventricular
BBS Biospecimen Banking System
BCRP breast cancer resistant protein
BID bis in die (twice -a-day)
BMI body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CAPTMControlled attenuation parameter
CDT Carbohydrate deficient transferrin
CFR code of federal regulatio ns
CI Confidence Interval
CIOMS Counci lfor International Organiza tions of Medical Sciences
CK creatinin ekinase
CK18 -M30 cytokeratin -18-M30 fragment
CK18 -M65 cytokeratin -18-M65 fragment
CKD -EPI Chronic Kidney Disease Epidemiology Co llaboration equat ion
Cmax peak or maximum observe d concentration
CO 2 carbon d ioxide (bicarbonate)
CoA coenzyme A
CONSORT Consolidated Standards of Reporting Trials
CRF Case Report Form

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 108Abbrev iation Term
CRO contract resear ch organization
CSR clinical stu dy report
CT clinical t rial
Ctrough plasma concentratio n before next dose
CYP Cytochrome P-450 (3A, 2B6, 2C9, 2C19)
D/C Discontinue
DAG Diacylglycerol
dB/m decibels per meter
DCCT Diabetes Control and Complications Trial
DDI drug drug interaction
DGAT1 diacylglycerol acyltransfe rase 1
DGAT2 diacylglycerol acyl transferase 2
DGAT2i diacylglycerol acyltransferase 2 inhibitor (PF -06865571)
DILI drug-induced liver injury
DNA deoxyribonucleic acid
DNL de nov o lipogenesis
DPP-IVi dipeptidyl peptidase -IV 
DU dispensing Unit
EC ethics com mittee
ECG Electrocardiogram
eCRF electronic case report form 
ED 50 dose that produces ha lf ma ximum drug e ffect 
EDP exposure during pregnancy
EFD embry o-fetal developmental
eGFR estimated glomerular filtration rate
EMA European Medical Agency
EU European Union
EudraC T Europe an Clinical Trials Database
F/U follow-up
FFA free fatty acid
FPG fasting plasma glucose
FPI fasting plasma insulin
FSH follicle -stimulating hormone
GCP Good Clinical Practic e
GGT gamma -glutamyl transferase
GLP Good Laboratory Practice
HbA1C glycated hemoglobin
HBsAg hepatitis B surface antigen
HCC hepatocellula r carcinoma
HCV RNA hepatitis C virus genetic material (ie, Ribonucleic acid)
HCVA b hepatitis C virus antibod y
HDL -C high density lipoprotein cholesterol 
HIPPA Health Insurance Portability and Accountability Act
HIV human imm unodeficiency virus
HOMA -IR homeostatic model assessment of insulin resistance

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 109Abbrev iation Term
HR heart rat e
HRT hormone replacement therapy
hs-CRP high-sensitive C -reactive protein
HSD17b13 17-Hydroxysteroid dehydrogenase ty pe 13
IB Investigator’s Brochure
ICD informed consent document
ICH International Conference on Harmonisation
ID identification
IND investigational new dr ugapplication
INR international normalized ratio
IP investigat ional product
IPAL Integrated Path to Architectural Licensure
IRB Institutional Review Board
IRC internal review committee
IRT interactive response technology
IWR interactive web r esponse
K2EDTA dipotassium ethyle nedia minetetraacetic acid
kPa kilopascals
LDL -C low density lipopr otein -cholesterol
LFTs liver function tests
LLN lower limit of nor mal
LPLV last participant las t visit
LS least square
MATE multidrug and tox in extrusion protein
MCH mean cor puscul ar hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activ ities
MELD -Na model of end -stage liver diseas e including serum sodium (in ad dition to serum creatinine, 
bilirubin, an d INR)
MMRM mixed model repeated measure
MR magnetic resonance
MRI magnetic resonance imaging
MRI -PDFF magnetic reson ance imaging usin g proton densi ty fat fraction acquisition 
N/A not applicable
NAFLD nonalcoholic fatty liv er disease
NASH Nonalcoholic steatohepatitis
NGSP National Glycohemoglobin Standardization Program
NOAEL no observed adve rse effect level
non-HDL non-high densi ty lipoprotein cholesterol
NSAIDs non-steroidal anti -inflammatory drugs 
NTCP sodium -dependent uptake transporter
NYHA New York Heart Association
OAT organic anion transporter (P1B1, P 1B3, P2B1) 
OATP organic an ion-transporting polypeptide

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 110Abbrev iation Term
OCT2 organ ic cation transporter 2
PCSK9 proprotei n convertase subtilisin/kexin type 9
PD Pharmacodynamics
PE physical exam
P-gp P-glycoprotein
PGx Pharmac ogenom ics
PI principal investigator
PK Pharmacokinetics
PK/PD pharmacokinetic -pharmacodynamic
PNPLA3 patatin like phospholipase domain containing protein 3
PreQ prequalification visit
ProC3 N-terminal propeptide of type III procollagen
ProC6 C-terminal fragment of α3 chain of procollagen type VI  
PT prothrombin time
PVC premature ventricular contra ction
Q12H every 1 2 hours (eg, dosing)
Q8H every 8 hours
QD quaque die (once -a-day)
QRS combination of Q -, R-and S -wave on an electrocardiogram representing ventricular
depolarization
QTc QT interval correcte d for heart rate 
QTcF Fridericia’s formula , a correction formula for the QC interv al
RBC red blood cell
RNA ribonucleic acid
RR interval between 2 successive R wavesin a QRS complex
SAE serious adverse event
SAP statistical analysis plan
SCR Screen /Visit 1
SD standard deviation
SGOT serum glutamic oxalo -acetic transaminase
SGPT serum glutam ic pyruvi c transaminase
SLC10A1 solute carrier Family 10 Member 1
SLCO solute carrier organic transporter family member (1B1, 1B3, 2B1)
SoA Schedule of Activities
SOP stand ard operating pro cedure
SREBP s sterol regulatory -element binding proteins
SRSD single reference safety document
SSID service set identifier
SUSAR suspected unexpected serious adverse reaction
SWE Sheer wave elastography
t1/2 terminal half -life 
T1D type 1 diabetes
T2DM type 2 diabetes m ellitus
TBili total bilirubin
TEAE treatment -emergent a dverse event

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 111Abbrev iation Term
TI therapeutic index
TZD Thiazolidinediones
UDFF ™ ultrasound -derived fat fraction
ULN upper limit of normal
US United State s
VCTETMVibratio n-Controlled Transient Ela stography
VLDL very l ow-density lipopro tein
WBC white blood cell
WOCBP women of childbearing potential

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 11211.REFERENCES
                                                
1Yen CL , Stone S J, Koliwad S, et a l. Thematic review series: gl ycerolipids. DGAT 
enzy mes and triacy lglycerol bio synthesis. J L ipidRes2008;49(11) (Nov) :2283 -301.
2Buhman KK, Smith SJ, Stone SJ , et al. DGAT1 is not essential for intestinal
triacylglycerol absorption or chy lomicron sy nthesis. JBiol Chem
2002; 277(28) (12Jul):
25474-9.
3Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mamm alian 
diacy lglycero
l acyltransferase, and related famil y members. JBiol Chem
2001;276(42) (Oct) :38870 -6.
4Saggerson D. Malon yl-CoA, a key signa ling molecule in mammalian cells. Annu Rev
Nutr
2008;28:253-72.
5Kim CW, A ddy C,Kusunoki J, et a l.Acety l CoA carboxy lase i nhibition reduces h epatic 
steatosis but elevated pla sma trigl ycerides in mice and humans: a bedside to bench 
investigatio n. Cell Metab 2017;26( 2)(Aug) :394-406e6.
6Sany al AJ, Friedman SL , McCullough AJ, et al. Ch allenges and opportunit ies in drug 
and bio
marker devel opment for nona lcoholic steatohepatitis: findings and 
recommendations from an American Association for the St udy of Liver Diseases -U.S. 
Food and Drug Administration Joint Workshop. Hepatology  2015; 61(4)(Apr) :1392-405.
7Khan F Z, Perumpail R B, Wong R J, et al. Adva nces in hepatoc ellular carcinoma:
Nonalcoholic steatohepatitis -related hepatocellul ar carcinoma. Worl d J He patol 
2015; 7(18) (Aug):2155 -61.
8Younossi Z M, Koenig A B, Abdelatif D, et al. Global epidemiology  of nona lcoholic 
fatty liver disease –meta -analytic asses sment of preval ence, incid ence,and outcomes.
Hepatology 2016;64(1) (Jul)
:73-84.
9Lambert JE, Ramos -Roman MA, Browning JD, et al. Increased de novo lipogenesis is a 
distinct characteristic of individuals wi th nonalcoholic fatty  liver disease. 
Gastroenterolo gy 2014; 146(3) (Mar) :726-35.
10Regev A, Palmer M, Avigan M I, et al. 
Consens us:guidelines: best practices for 
detection, assessment and management of suspected acute drug- induced liver injury  
during clinical tr ials in patients with nonalcoholic stea tohepatitis. Aliment Pharmacol 
Ther 2019; 49(6)( 03):702 - 13.

PF-06865571 + PF -05221304 (DGAT2i + ACCi)
Protoco l C3711005
Final Protocol , 27March 2020
PFIZER CONFIDENTIA L
Page 113                                                                                                                                                      
11Babor TF, Higgins- Bidd le JC, Sa unders JB, et. al. AUDIT . The alcohol use disorders 
identification test. G uidelines for use in pri mary  care . WHO/MS D/MSB/01.6a. Genev a, 
Switzerland: World Health Organization; 2001: 40 pages.
12Younos si ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic 
fatty liver disease, nonalcoholic steatohepatitis, and associated f ibrosis. Hepatology
2018; 68(1) (07):349-60.
13Inker LA, Schmid CH, Tighiouart H, e t al. Estimating glomerular filtration rate from 
serum creatinine a nd cystatin C. N Engl J Med 2012; 367 (1)(Jul) :20-9.
14Wong VW , Adams LA, de Ledinghen V, et al. Noni nvasive biomarkers in NAFL D and 
NASH –current progress and future promise. Nat Rev Gastroenterol Hepatol
2018;15 (8)(08) :461- 78.
15Banholzer ML, Wandel C, Barrow P, et al. Clinical trial considerati ons on male 
contraception and collection of pregnancy  information from fem ale par tner: update. Clin 
Transl Med 2016; 5(1)(Dec) :23.
16Kim W R, Big gins SW, Kremers W K, et al. Hy ponatremia and mortalit y am ong patients 
onthe liver -transplant waiting list. N Engl J Med 2008;359(1 0)(Sep) :1081 -26.
